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Abstract 
There is a wealth of evidence to support the anti-inflammatory properties of the 
prototypical second messenger cyclic-AMP (cAMP), notably with regard to 
endothelial function. Many studies have shown that cAMP can limit vascular 
permeability by enhancing barrier function and reducing pro-inflammatory effects 
of cytokines. Although the protective effects of cAMP elevation on limiting 
endothelial dysfunction have been well documented, the exact molecular 
mechanisms remain unclear.  
Using two endothelial cell types, namely human umbilical vein endothelial cells 
(HUVECs) and a novel human endothelial angiosarcoma-derived cell line (AS-M), 
this study has further characterised the cAMP-mediated inhibitory mechanism on 
the signalling pathways of two cytokines; interleukin-6 (IL-6) and leptin. Both 
cytokines have been implicated in the regulation of the immune response and both 
have been shown to play important pathological roles in various inflammatory 
diseases. 
In preliminary studies, cAMP elevation was shown to induce suppressor of 
cytokine signalling 3 (SOCS3) in HUVECs. Further investigation of this SOCS 
protein in the context of IL-6 and leptin signalling in endothelial cells would be of 
interest in terms of possibly elucidating the molecular mechanisms underlying the 
protective effects of cAMP. Results from this study demonstrated a cAMP-
mediated inhibition of soluble IL-6Rα (sIL-6Rα)/IL-6-stimulated extracellular 
regulated mitogen-activated protein kinase 1, 2 (ERK1,2) and signal transducer 
and activator of transcription 3 (STAT3) activation in HUVECs, which was 
independent of cAMP-dependent protein kinase A (PKA). Instead, results 
demonstrated the involvement of the other major cAMP sensor; exchange protein 
activated by cAMP 1 (Epac1). Moreover, this inhibition was shown to be SOCS3-
dependent. There also appeared to be a requirement for ERK1,2 activation in the 
cAMP-mediated inhibition of sIL-6Rα/IL-6-stimulated STAT3 activation in 
HUVECs. In contrast to these findings, cAMP-mediated inhibition of leptin-
stimulated STAT3 activation in HUVECs was shown to occur via a SOCS3-
independent mechanism. The responses to cAMP elevation on sIL-6Rα/IL-6- and 
leptin-stimulated ERK1,2 activation in AS-Ms were variable, since basal levels of 
ERK1,2 activation were high. Furthermore, the responses to cAMP elevation on 
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sIL-6Rα/IL-6- and leptin-stimulated STAT3 activation in AS-Ms were either very 
modest or showed no effect, respectively. SOCS3 was not shown to be involved in 
the cAMP-mediated inhibition of sIL-6Rα/IL-6-stimulated ERK1,2 and STAT3 
activation in AS-Ms.  
In conclusion, this study further characterised the cAMP-mediated inhibitory 
mechanism in HUVECs and AS-Ms, with a particular focus on the ERK1,2 
signalling pathway of IL-6 and leptin. Despite varying results between both cell 
types, this study also identified AS-Ms as a useful and tractable cell model to study 
in the context of endothelial biology. Thus, a potentially new pathway has been 
identified which inhibits cytokine receptor activation of ERK1,2 and STAT3 in 
endothelial cells. A better understanding of this mechanism could contribute 
towards new therapeutics in the area of chronic inflammatory diseases, such as 
atheroscleriosis. 
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1.1 Endothelium Function 
The endothelium is the largest organ in the body, lining the entire vascular system, 
from the heart to the smallest capillary. It forms the crucial barrier between the 
bloodstream and underlying tissues, ultimately controlling the passage of materials 
into and out of the vessel.  
The endothelium actively regulates vascular tone, the homeostasis of which is 
maintained by the release of vasoconstrictors, such as endothelin, prostaglandins 
and reactive oxygen species (ROS), and vasodilators such as nitric oxide (NO), 
prostacyclin and endothelium-derived hyperpolarizing factor (Mombouli & 
Vanhoutte, 1999). In its healthy state, the endothelium maintains vascular tone 
and function by controlling the balance between vasodilation and vasoconstriction, 
anti-thrombosis and pro-thrombosis, anti-inflammation and pro-inflammation, cell 
growth inhibition and cell growth promotion, and also anti-oxidation and pro-
oxidation. The endothelium achieves this by expressing constitutive or induced 
molecules on its surface, such as adhesion molecules, and secreting soluble 
mediators such as vasodilators and vasoconstrictors, or cytokines and growth 
factors. One of the most important vasoactive substances is NO, which is 
synthesised by the endothelial NO synthase (eNOS). NO is not only a crucial 
mediator of endothelium-dependent vasodilation, described initially as 
endothelium-derived relaxing factor (EDRF) (Palmer et al., 1987), but also has 
important roles in inflammation and thrombosis. These include inhibition of 
leukocyte and platelet adhesion to the endothelium, inhibition of platelet 
aggregation (Alheid et al., 1987; Kubes et al., 1991; Radomski et al., 1987), and 
suppression of the expression of plasminogen activator inhibitor-1 (PAI-1), a 
prothrombotic protein in smooth muscle cells (SMC) (Bouchie et al., 1998). 
Impaired NO bioavailability is believed to play a major part in endothelial 
dysfunction (Davignon & Ganz, 2004). Endothelial dysfunction is characterised by 
impaired vasodilation and increased permeability, leukocyte adhesion and 
cytokine release. It represents an imbalance in the actions of vasoconstrictors 
versus the actions of vasodilators. Assessment of endothelial dysfunction is 
primarily based on changes in vasomotion, which is also representative of all other 
impaired functions of the endothelium (Landmesser et al., 2004). The resulting 
dysfunction is associated with many conditions, such as hypertension (Lockette et 
al., 1986; Luscher, 1990), elevated levels of low density lipoprotein and oxidised 
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lipoproteins (Gilligan et al., 1994), elevated levels of homocysteine (McDowell & 
Lang, 2000), insulin resistance and type 2 diabetes (Jansson, 2007), smoking 
(Hutchison, 1998) and obesity (Sivitz et al., 2007). 
As mentioned previously, decreased NO bioavailability may be considered a 
crucial mechanism of endothelial dysfunction. Reactive oxygen species (ROS), so-
called oxidative stress contributes greatly to endothelial dysfunction through the 
sequestration of NO. Thus, when the overall balance between oxidative stress and 
the anti-oxidative defense mechanism is upset, NO bioavailability is reduced and 
endothelium function is impaired. Mechanisms of oxidative stress leading to 
decreased NO bioavailability are discussed further in Chapter 1.1.3.  
Endothelial dysfunction is believed to underpin the development of various 
inflammatory diseases including sepsis (Aird, 2003), diabetic retinopathy (Hsueh & 
Anderson, 1992) and atherosclerosis, which is discussed hereafter in the context 
of vascular disease. 
 
1.1.1 Vascular Disease 
Vascular disease encompasses a variety of diseases including abdominal aortic 
aneurism (AAA), deep vein thrombosis (DVT), thromboangiitis obliterans (TAO) 
and peripheral arterial disease (PAD). However, it is the PAD atherosclerosis that 
represents the single, most important cause of coronary heart disease (CHD1) and 
stroke to date. CHD1 and stroke are the two main forms of cardiovascular disease 
(CVD). CVD is the major cause of death in the UK and accounts for over 208,000 
deaths each year. 48% of all deaths from CVD are caused by CHD1 and 28% from 
stroke. Despite a 30 year decline, the death rate for CHD1 in the UK is still one of 
the highest in Western Europe and costs the health care system millions of 
pounds each year (in 2003 costs accrued to around £3,500 million; 
www.heartstats.org). 
Atherosclerosis is a chronic inflammatory disease of the arteries and, depending 
on which arteries are affected, results in different clinical manifestations. For 
example, atherosclerosis in the coronary arteries can cause angina pectoris and 
myocardial infarction, while atherosclerosis in the cerebrovascular circulation may 
lead to a transient ischaemic episode or stroke.  
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1.1.2 Endothelial Dysfunction and Atherosclerosis 
There is an abundance of evidence to suggest that atherosclerosis is strongly 
linked to endothelial dysfunction. The study by Ludmer et al. (1986) was one of the 
first to show this correlation in humans. This showed that whereas there was a 
dose-dependent dilation of coronary arteries treated with acetylcholine in patients 
without coronary disease, a paradoxical vasoconstriction was observed in patients 
with mild to advanced coronary atherosclerosis, indicative of an impaired 
endothelium-dependent vasomotion (Ludmer et al., 1986). It has also been 
demonstrated that many of the risk factors that predispose to atherosclerosis have 
the potential to cause endothelial dysfunction (e.g. hypertension, 
hypercholesterolemia, diabetes mellitus, smoking and family history) (Davignon & 
Ganz, 2004; Vita et al., 1990). Thus it is not surprising that endothelial dysfunction 
has been shown to be associated with clinical events of atherosclerosis and may 
actually predict the risk of cardiac events. Several studies have shown that acute 
clinical outcomes of atherosclersosis, such as myocardial infarction and 
cardiovascular death can be predicted by endothelial dysfunction (Halcox et al., 
2002; Suwaidi et al., 2000). In these studies, intracoronary acetylcholine was 
administered to patients with mildly diseased coronary arteries or patients 
undergoing cardiac catheterisation for investigation of chest pain, and a number of 
parameters, such as intravascular ultrasound examination, coronary blood flow 
and coronary angiography were assessed to determine endothelial vasodilation. 
The results demonstrated that coronary endothelial dysfunction independently 
predicts acute cardiovascular events. Furthermore, improvement of endothelial 
vasodilation in patients surviving an acute coronary syndrome was associated with 
significantly less cardiac events (Fichtlscherer et al., 2004). These studies support 
the idea that endothelial dysfunction plays a crucial role in the progression of 
atherosclerosis. Furthermore, the findings that endothelial dysfunction in patients 
with coronary risk factors precedes angiographic or ultrasonic evidence of 
atherosclerostic plaque also suggests that it constitutes an early event in disease 
pathogenesis (Celermajer et al., 1994; Reddy et al., 1994). 
 
1.1.3 The Endothelium and Inflammation 
As mentioned previously, endothelial dysfunction is manifest as impaired 
endothelium-dependent vasomotion and reflects an impairment of important 
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endothelial functions. Of particular relevance to the present study is the 
endothelium’s anti-inflammatory role. In its normal, healthy state the endothelium 
actively regulates vascular inflammation. However, upon damage the endothelium 
assumes a pro-inflammatory phenotype. In this state, the endothelial cells become 
activated and start to exhibit oxidative stress and an increased adhesiveness to 
circulating leukocytes.  
Oxidative stress, in terms of superoxide (O2–) production, increases greatly in 
activated endothelial cells. This can be caused by a number of factors, such as 
uncoupling of eNOS, whereby O2– is generated, instead of NO. Thus, O2 reduction 
by eNOS is uncoupled from NO formation, and a functional eNOS is converted 
into a dysfunctional O2–-generating enzyme that contributes to vascular oxidative 
stress. Uncoupling has been associated with the reduced availability of the eNOS 
co-factor BH4 (Schmidt & Alp, 2007). The resultant O2– can react with NO to 
produce peroxynitrite (ONOO−), a potent oxidant, which in turn leads to uncoupling 
and enzyme dysfunction, possibly via oxidation of tetrahydrobiopterin (BH4), which 
reduces its bioavailability (Beckman et al., 1990; Laursen et al., 2001; Rubanyi & 
Vanhoutte, 1986; Schmidt & Alp, 2007). Thus, a vicious cycle is established 
whereby the vasoprotective effects of NO are precluded (Kubes et al., 1991). In 
support of this, many studies have demonstrated that BH4 can restore endothelial 
dysfunction in patients with hypercholesterolemia, diabetes or coronary heart 
disease (Heitzer et al., 2000; Maier et al., 2000; Stroes et al., 1997), implicating 
impaired eNOS function (resulting from decreased availability of BH4) in 
endothelial dysfunction (Schmidt & Alp, 2007). Furthermore, levels of an 
endothelial-derived substance, endothelin-1, are increased in response to 
oxidative stress (Kahler et al., 2000). In addition to mediating vasoconstriction, 
endothelin-1 has been shown to activate polymorphonuclear secretion and 
adhesion and macrophage activity (Zouki et al., 1999). Thus, oxidative stress 
greatly contributes towards endothelial dysfunction and this is supported by the 
findings that anti-oxidant treatment in the form of ascorbic acid can rescue 
endothelial-dependent vasodilation in patients with hypercholesterolaemia or 
coronary heart disease (Levine et al., 1996; Ting et al., 1997).  
The attachment of leukocytes to the endothelium is an essential process for the 
propagation of a normal inflammatory response in response to infection or injury. 
However when this response is exaggerated or inefficiently terminated, it can lead 
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to the development of a chronic inflammatory state. Leukocyte interaction with the 
endothelium involves a series of highly coordinated adhesive and signalling events 
mediated by specific groups of adhesion molecules, including selectins, integrins 
and cellular adhesion molecules (CAMs). Intracelluar adhesion molecule 1 (ICAM-
1), vascular adhesion molecule 1 (VCAM-1) and E-selectin are all upregulated by 
endothelial cells in response to pro-inflammatory cytokines, such as IL-1β and 
TNFα, to promote leukocyte (monocytes and neutrophils) adhesion and 
transmigration (Cotran & Pober, 1990; Hakkert et al., 1991; Luscinskas et al., 
1991; Takahashi et al., 1994). Moreover, IL-1β and TNFα stimulate the production 
of secondary cytokines, including IL-6 which is involved in activating the acute 
phase response (detailed in section 1.3.2) (Jarvisalo et al., 2006). The chemokine 
“monocyte chemoattractant protein-1” (MCP-1/CCL2) is also upregulated by IL-1β 
and TNFα in endothelial cells (Rollins et al., 1990). MCP-1 not only stimulates the 
recruitment of monocytes, but has also been shown to increase endothelial cell 
proliferation (Weber et al., 1999). Additionally, T cells are also recruited to the 
activated endothelium, where they secrete pro-inflammatory cytokines such as IL-
1β, TNFα and also IFNγ (Tesfamariam & DeFelice, 2007). Although described 
very briefly, all of these inflammatory processes greatly contribute to a chronic and 
persistent state of inflammation that manifests itself in disease, notably 
atherosclerosis. 
 
1.2 Adenosine-3',5'-cyclic monophosphate (cyclic AMP) 
Cyclic AMP (cAMP) is one of the oldest signalling molecules known. It was first 
discovered as an intracellular mediator of hormone action in 1957 (Sutherland & 
Rall, 1958). Since then, numerous studies have shown that cAMP acts as a 
second messenger for a plethora of hormones, neurotransmitters and growth 
factors to regulate a vast array of cellular processes, including proliferation, 
differentiation, secretion, apoptosis, adhesion and migration (Beavo & Brunton, 
2002). cAMP can be synthesised via G protein coupled receptor (GPCR) 
activation of adenylyl cyclases (AC), of which there are 9 membrane-bound 
isoforms (Sunahara & Taussig, 2002) and 1 soluble form, which is insensitive to 
regulation by G-protein and forskolin (a potent activator of AC, detailed in Chapter 
3) (Buck et al., 1999). Each AC molecule comprises 12 transmembrane sections 
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and 2 cytosolic domains (C1 and C2), with C1 and C2 forming the catalytic core 
(Cooper, 2003) (Figure 1.1). AC catalyses the conversion of adenosine 5’ 
triphosphate (ATP) to cAMP by formation of an intramolecular 3’–5’ 
phosphodiester bond, whereas enzymes known as cyclic nucleotide 
phosphodiesterases (PDEs) hydrolyse cAMP to adenosine 5’–monophosphate (5’-
AMP). Phosphodiesterases thereby act to degrade cAMP via hydrolysis of the 3' 
cyclic phosphate bond. PDEs may be considered a diverse set of enzymes, 
comprising 11 families of which there are 21 gene products. Alternative 
transcriptional start sites and alternative splice variants are believed to give rise to 
many more than 21 mRNA transcripts or protein products (Bender & Beavo, 
2006). The 11 families of PDEs can be divided into 3 groups, based on their 
substrate specificity; (1) cAMP-specific PDEs including PDE4, PDE7 and PDE8 (2) 
cGMP-specific PDEs including PDE5, PDE6 and PDE9 and finally (3) dual 
specificity PDEs including PDE1, PDE2, PDE3, PDE10 and PDE11 (Bender & 
Beavo, 2006). Thus cAMP levels are tightly regulated by the co-ordinated actions 
of both ACs and PDEs in the cell.  
cAMP exerts its numerous biological effects by binding and activating what was 
initially believed to be the only cAMP effector, cAMP dependent protein kinase A 
(PKA) (Walsh et al., 1968). However, other targets of cAMP have since been 
identified, namely “exchange proteins directly activated by cAMP” (Epacs) (de 
Rooij et al., 1998), cAMP-regulated ion channels (Fesenko et al., 1985) and the 
Ras or Rap guanine nucleotide exchange factor, cyclic nucleotide rasGEF 
(CNrasGEF) (Pham et al., 2000). The best characterised cAMP sensors, namely 
PKA and Epac will be discussed in more detail further on in this Chapter. For such 
a limited number of cAMP effectors, there is an extensive number of cellular 
responses. These pleiotropic effects of cAMP pose the question of how specificity 
is achieved. Interestingly, there is increasing evidence to support the notion of 
cAMP compartmentalisation within the cell. A particular focus of this work has 
been the identification of macromolecule complexes within defined regions of the 
cell, which comprise proteins of the cAMP signalling pathway. These spatially 
confined signalling complexes may only permit the selective activation of certain 
signaling pathways (discussed further in Section 1.2.2). However, this is only a 
partial explanation of how cAMP specificity may be achieved. Another 
consideration is the freely diffusible nature of cAMP in the cell. The emergence of 
8 
 
Fluorescence resonance energy transfer (FRET) approaches has enabled the 
identification of discrete pools of cAMP in the cell (Zaccolo et al., 2006). The 
restricted diffusion of cAMP to these pools is believed to be largely due to the 
actions of PDEs. PDEs have been shown to be present within multiprotein 
signaling complexes in the cell, acting to quench cAMP and controlling the 
intracellular gradients of cAMP in the cell.   
cAMP has long been known to act as an endogenous ‘off’ signal of the 
inflammatory response, preventing the effects of chronic inflammation (Moore & 
Willoughby, 1995) and a large body of research supports this notion. Some 
examples of the inhibitory effects of cAMP elevation include the suppression of 
lysosomal enzymes, ROS and platelet-activating factor (PAF) from neutrophils 
(Fonteh et al., 1993; Nielson, 1987; Weissmann et al., 1971), the reduction of 
cytokines and nitric oxide released from macrophages (Bulut et al., 1993; Renz et 
al., 1988), the inhibition of eosinophil respiratory burst activity (Dent et al., 1991) 
and the inhibition of cytotoxic T lymphocyte activation (Wisloff & Christoffersen, 
1977). Of relevance to the present study is the role that cAMP plays in modulating 
inflammation in the context of endothelial cell function. Studies have shown that 
cAMP can limit vascular permeability by enhancing barrier function, and reduce 
pro-inflammatory effects of cytokines (Blease et al., 1998; Cullere et al., 2005; 
Fukuhara et al., 2005; Morandini et al., 1996; Pober et al., 1993). For example, 
TNFα-stimulated expression of E-selectin and VCAM-1 has been shown to be 
inhibited by cAMP elevation in human lung microvascular endothelial cells 
(HLMECs) and HUVECs (Blease et al., 1998; Morandini et al., 1996; Pober et al., 
1993). Additionally, inhibition of neutrophil adherence to TNFα-stimulated 
HLMECs in response to cAMP elevation has been observed (Blease et al., 1998).  
 
1.2.1 PKA  
PKA is a ubiquitous cellular kinase that phosphorylates serine and threonine 
residues in response to cAMP. It is the most well studied cAMP effector and was 
initially described during a number of studies in the 1950s and ‘60s carried out by 
Edwin G. Krebs et al. looking at the glycogenolytic enzyme glycogen 
phosphorylase and how it was regulated in skeletal muscle (Krebs et al., 1959; 
Krebs et al., 1966). These experiments suggested the involvement of a cAMP-
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induced kinase enzyme, but it was not until later experiments conducted by Walsh 
et al. (1968) and Reimann et al. (1971) that this cAMP-induced kinase enzyme 
was identified as cAMP-dependent protein kinase (Reimann et al., 1971; Walsh et 
al., 1968), now called PKA.  
 
1.2.2 PKA Structure and Regulation 
PKA comprises 2 catalytic (C) subunits and 2 regulatory subunits (R), which form 
a heterotetramer (Taylor et al., 1990). In mammals, 3 genes for the catalytic 
subunit exist (Cα, Cβ and Cγ) and 4 genes for the regulatory subunit (RIα, RIβ, 
RIIα and RIIβ). cAMP binds to two binding sites on each R subunit, which relieves 
the contact with the C subunits, causing the release of the active C subunits. Thus, 
unstimulated PKA is held in an inactive state via conformational constraints 
imposed by the R subunits, until cAMP binds and liberates the C subunits (Granot 
et al., 1980). The free catalytic subunits are then able to phosphorylate serine and 
threonine residues in adjacent PKA substrates, for example C-Raf/Raf1, which is 
phosphorylated at specific serine residues (Dhillon et al., 2002b). Thus, until cAMP 
is elevated in the cell, the regulatory subunits inhibit PKA activity. In addition to 
this, the regulatory subunits also bind to scaffolding proteins known as A-Kinase 
Anchoring Proteins (AKAPs), which anchor the PKA holoenzyme to specific 
subcellular structures (Colledge & Scott, 1999; Michel & Scott, 2002). This AKAP-
regulatory subunit interaction controls intracellular localisation of PKA and thus 
regulates PKA-mediated biological effects. For example, the muscle-specific A-
kinase anchoring protein (mAKAP) has been proposed to anchor PKA to a cellular 
localisation, wherein PDE4D3 serves as an adapter protein for Epac1 and ERK5, 
which together generates a cAMP-responsive signalling complex, present in 
cardiomyocytes. This complex integrates 2 cAMP-mediated pathways, whereby 
PKA and Epac can become activated via ERK5 phosphorylation of PDE4D3, 
which suppresses phosphodiesterase activity leading to increased cAMP. 
Activated PKA can then phosphorylate PDE4D3, which increases its affinity for 
cAMP and decreases localised cAMP levels and activated Epac1 can inhibit 
ERK5, thus preventing continued inactivation of PDE4D3. Hence, a feedback loop 
is generated, which causes cAMP levels to fall when they become elevated. 
(Dodge-Kafka et al., 2005). This study partly contributes towards the 
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understanding of the present thesis’ results and will be discussed further in the 
Results chapters. 
Further to these regulatory effects of the PKA regulatory subunits, another level of 
regulation can be exerted via endogenous PKA inhibitors termed “protein kinase 
inhibitor” (PKI) peptides. Walsh and his colleagues discovered PKI soon after the 
discovery of PKA in 1971 (Walsh et al., 1971). There are 3 isoforms termed PKIα, 
PKIβ and PKIγ (Beale et al., 1977; Collins & Uhler, 1997; Olsen & Uhler, 1991), all 
of which act to inhibit the phosphorylation of PKA substrates by competitively 
binding to the substrate binding site of the free C subunit following dissociation 
from the R subunits. Thus, PKI inhibition only occurs in the presence of cAMP, 
after the regulatory and catalytic subunits have been separated (Ashby & Walsh, 
1972; Ashby & Walsh, 1973). As well as acting as a potent competitive inhibitor of 
PKA, PKI has also been shown to mediate the export of free catalytic subunits of 
PKA from the nucleus to the cytoplasm (Fantozzi et al., 1994), wherein these 
catalytic subunits can reassociate with the regulatory subunits to re-form the PKA 
holoenzyme and thus restore cAMP regulation (Dalton & Dewey, 2006). This is 
possible because PKI has a nuclear export signal, which causes the ATP-
dependent export of the PKI-bound catalytic subunit out of the nucleus and into 
the cytoplasm (Wen et al., 1994). Of interest, endothelial cells from pulmonary 
artery, foreskin microvascular and brain microvascular sources have all been 
shown to express the PKIα and PKIγ isoforms (Lum et al., 2002). Furthermore, 
overexpression of PKI in human microvascular endothelial cells has been shown 
to abolish cAMP-mediated inhibition of endothelial permeability, implicating PKA in 
regulating endothelial barrier function (Lum et al., 1999). 
 
1.2.3 Epac 
Epac was discovered in 1998 by 2 independent groups, as a Rap1 guanine-
nucleotide-exchange factor directly activated by cyclic AMP (de Rooij et al., 1998; 
Kawasaki et al., 1998). Rap1 belongs to the Ras superfamily of small GTPases, 
comprising more than 150 members. This family is sub-divided into 5 main groups, 
based on sequence and functional similarities; (1) Ras (2) Rho (3) Rab (4) Arf and 
(5) Ran. The Ras sub-family consists of 36 members, including R-Ras, Ral and 
Rap proteins (Wennerberg et al., 2005). All members of the Ras superfamily 
function as molecular switches, cycling between inactive GDP-bound forms and 
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active GTP-bound forms. This cycle is regulated by guanine nucleotide exchange 
factors (GEFs) and a combination of GTPase activating proteins (GAPs) and 
intrinsic GTPase activity. GEFs dissociate the bound GDP to allow the association 
of the more abundant GTP, thus activating the G protein, whereas the intrinsic 
GTPase activity, together with GAPs catalyse GTP hydrolysis and subsequently 
inactivate the protein (Boriack-Sjodin et al., 1998). The GTPase Rap1 was first 
identified as an antagonist of Ras, whereby overexpression of Rap1 was shown to 
suppress the transformation of cells with an oncogenic K-Ras mutation (Kitayama 
et al., 1989). Since then, Rap1 and its regulation by Epac has been the focus of 
much research. More than 30 GEFs capable of activating Ras members have 
been identified and many of these GEFs activate Rap (Quilliam et al., 2002). 
Epac1 and Epac2 represent a novel class of GEFs, since these are the only Rap1 
GEFs activated directly by cAMP. This was an important discovery in terms of 
helping to explain PKA-independent effects of cAMP documented in numerous 
studies (Gonzalez-Robayna et al., 2000; Kashima et al., 2001; Laroche-Joubert et 
al., 2002; Rangarajan et al., 2003; Schmidt et al., 2001).  
 
1.2.4 Epac Structure and Regulation 
Epac 1 and 2 are structurally very similar, with each protein containing; (1) a 
cAMP-binding domain, which is similar to that found in the regulatory domain of 
PKA, so-called B-site (2) a CDC25 homology domain, which exhibits GEF activity 
for Rap proteins, (3) a Ras association (RA) domain, which facilitates binding to 
Ras, (4) a Ras exchanger motif (REM), which is involved in interaction with the 
GEF domain and finally (6) a Disheveled/Egl-10/pleckstrin (DEP) domain, which is 
required for membrane association (Bos, 2006) (Figure 1.2). However, differences 
between both proteins do exist; for example, although both Epacs have been 
shown to possess a putative RA domain, only Epac2 has been shown to bind H-, 
K- and N-RasGTP via this domain (Li et al., 2006). This interaction has been 
shown to promote the translocation of Epac2 from the cytosol to the plasma 
membrane, causing the subsequent activation of a pool of membrane-localised 
Rap1 (Li et al., 2006). Thus, it appears that only Epac2 has a functional RA 
domain (Epac1 lacks key residues involved in Ras association; (Wohlgemuth et 
al., 2005). Furthermore, Epac2 differs from Epac1 by having an additional cAMP 
binding domain, the so-called A-site, which has a lower affinity for cAMP (87µM) 
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than the B-site cAMP-binding domains of Epac1 and Epac2 (4 and 1.2 µM, 
respectively) (de Rooij et al., 2000). The function of this second cAMP binding 
domain has yet to be determined (Rehmann et al., 2003a). Additionally, the DEP 
domain of Epac1 has been shown to target Epac1 to the plasma membrane (de 
Rooij et al., 2000), whereas the function of the DEP domain of Epac2 appears to 
be less clear, since membrane association of Epac2 has only been observed 
when Epac2 is over-expressed (Li et al., 2006). In keeping with localization 
differences between both Epac1 and Epac2, Epac1 has also been shown to 
possess a mitochondrial localisation signal at its N terminus (Qiao et al., 2002) 
which is absent from Epac2. This may explain the lack of punctuate staining of 
Epac2 in cells (Li et al., 2006). The localization of Epac1 appears to be dependent 
on the cell cycle, showing membrane and mitochondria localization during 
interphase in COS-7 cells (Qiao et al., 2002). 
Despite their differences, both Epac1 and Epac2 are capable of activating Rap1 
and Rap2 in response to cAMP (de Rooij et al., 2000). Binding of Rap to Epac is 
believed to occur following a conformational change induced by cAMP binding, 
which relieves the auto-inhibition imposed by the N-terminal regulatory region. 
This has been proposed based on the crystal structure of Epac2 in the absence of 
cAMP (Rehmann et al., 2006). Thus, the closed structure of Epac2 displays a 
covering of the regulatory region over the predicted binding site, which appears to 
sterically hinder access of Rap. cAMP binding is believed to disrupt this inhibition, 
although the structure of Epac in the presence of cAMP has yet to be determined.  
 
1.2.5 Roles of Epac in Endothelial Biology 
Of relevance to endothelial biology, endothelial cells only appear to express Epac1 
(Fang & Olah, 2007). Studies in this area have revealed Epac1 to be important in 
the modulation of endothelial barrier function. Rap1 has been shown to have many 
downstream effectors, including scaffolding proteins, such as AF6 (Boettner et al., 
2003), RapL (Katagiri et al., 2003) and Riam (Lafuente et al., 2004). These 
scaffolding proteins have been implicated in cell adhesion and cell-cell junction 
formation and hence, a role for Epac in these processes has been thoroughly 
investigated. One of the first studies to demonstrate a role for Epac in cell 
adhesion was conducted by Rangarajan et al. (2003) showing that integrin-
mediated cell adhesion was enhanced via an Epac-Rap1 pathway following cAMP 
13 
 
elevation (Rangarajan et al., 2003). However, this study was carried out in an 
ovarian carcinoma cell line. To assess the role of Epac in endothelial biology, 
various studies have been conducted in endothelial cells, wherein endothelial 
barrier function is crucial for the maintenance of a healthy endothelium. A defining 
feature of endothelial dysfunction is increased vascular permeability, leading to 
inflammatory cell infiltration and chronic inflammation. Several studies have 
demonstrated an Epac1-mediated enhancement of endothelial barrier function. 
More specifically, Epac1-Rap1 mediated increases in vascular endothelial (VE) 
cadherin-dependent cell adhesion and cortical actin have been observed 
(Fukuhara et al., 2005; Kooistra et al., 2005). Structurally, the endothelial cell 
barrier is made up of adherens junctions (AJ) and tight junctions. VE-cadherin 
constitutes the AJ and mediates calcium-dependent intercellular adhesions, which 
is strengthened by the association of VE-cadherin with the actin cytoskeleton. 
Thus, Epac1 has been implicated in this process, demonstrating for the first time a 
PKA-independent signalling pathway in endothelial cells, which regulates vascular 
permeability. Although Rap1 has been implicated in this pathway, it has also been 
reported that Epac1 can bind and activate R-Ras, which has also been implicated 
in integrin-mediated cell adhesion (Lopez De Jesus et al., 2006).  
 
1.3 Cytokines 
Cytokines are small soluble regulatory proteins that function as intercellular 
messengers, predominantly in the immune system. The vast majority of cytokines 
are referred to as “interleukins”, a name that traditionally implied that they were 
secreted by and acted upon leukocytes. Chemokines are another group of 
cytokines, defined by the role they play in chemotaxis. However, cytokines can be 
secreted by numerous cell types and exert a plethora of physiological effects, such 
as the development of cellular and humoral immune responses, induction of the 
immune response, control of cellular proliferation and regulation of 
haematopoiesis. 
Classification of cytokines can be based on a number of parameters, including, 
structural differences (Heinrich et al., 1998). The “four α-helix bundle” family 
comprise cytokines with a four α-helix bundle structure consisting of 2 pairs of anti-
parallel α-helices. These cytokines can be further sub-divided into short chain, 
long chain and eight α-helices groups (Bravo & Heath, 2000). The short chain 
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group comprise cytokines with α-helices of 8-10 residues in length, such as IL-2, 
IL-3 and IL-4, whilst the long chain group comprise cytokines with α-helices of 10-
20 residues in length, such as growth hormone (GH), erythropoietin (EPO), 
granulocyte colony-stimulating factor (GCSF) and the gp130 cytokines. The third 
group include cytokines, such as IL-5 and interferon-γ, which have a duplication of 
the 4-helix bundle and thus, a total of 8 α-helices.  
Cytokine receptors can again be classified according to structure and on this basis 
may belong to any one of five receptor families; (1) Immunoglobulin superfamily, 
(2) Class I family, (3) Class II family, (4) TNF superfamily and lastly (5) Chemokine 
receptor family. The class I receptor family comprise most of the receptors that 
function in the immune and haematopoetic systems and possess a characteristic 
cytokine receptor homology domain (CHD2), which is situated in the extracellular 
domain. The CHD2 comprises 7 β-strands that are arranged as anti-parallel β-
sandwiches, connected by a proline-rich sequence. The defining feature of this 
structure is the WSXWS box, (Trp-Ser-Xaa-Trp-Ser, where X is a nonconserved 
residue), present in the C-terminal end and a conservation of cysteine residues 
(Bazan, 1990).  
 
1.3.1 Interleukin-6 (IL-6) 
IL-6 belongs to the IL-6 family of haematopoietic cytokines, a sub-family of the four 
α-helix bundle cytokines; the long chain group, comprising IL-6, IL-11, oncostatin 
M (OSM), leukaemia inhibitory factor (LIF), cardiotrophin 1 (CT-1), ciliary 
neurotrophic factor (CNTF), and cardiotrophin-like cytokine (CLC). IL-6 has a wide 
variety of biological effects and this is in part reflected in its nomenclature. For 
example, IL-6 was cloned in 1986 (Hirano et al., 1986) and called B cell 
stimulatory factor-2 (BSF-2), because of the crucial role it played in the 
differentiation of B cells to immunoglobulin-producing cells (Muraguchi et al., 
1981). However, other groups cloned the same protein under the name of 
interferon β2 protein (IFNβ2) because it was shown to induce interferon (IFN) 
activity (Zilberstein et al., 1986). Later, hybridoma growth factor (HGF) (Van 
Damme et al., 1987) was found to be the same protein, so-called because this 
group found that it induced myeloma and plasmacytoma growth, and also induced 
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acute phase reactants in hepatocytes. When these proteins were discovered to be 
identical the names were unified as IL-6 (Naka et al., 2002). 
In general, the IL-6 family of cytokines have been demonstrated to play important 
roles in haematopoiesis, embryonic development, fertility, liver and neuronal 
regeneration and, of particular relevance to the present study, inflammation and 
the immune response (Naka et al., 2002). Notably, dysregulation of IL-6 signalling 
has been shown to be heavily implicated in the development of various chronic 
inflammatory diseases, including rheumatoid arthritis, Castleman’s diease, juvenile 
idiopathic arthritis and Crohn’s disease (Nishimoto & Kishimoto, 2004). 
 
1.3.2 Roles of IL-6 
IL-6 is well known for the role it plays in the acute phase response, whereby it 
potently induces the production of acute phase proteins (Gauldie et al., 1987). 
Examples of acute phase proteins include, C-reactive protein (CRP), fibrinogen, 
serum amyloid protein and various complement components. The concentration of 
these proteins increase (positive acute-phase proteins) or decrease (negative 
acute-phase proteins) by a minimum of 25-fold, the threshold for classification as 
an acute phase protein, to as much as 1000-fold, as in the case of CRP, in the 
setting of acute inflammation (Gabay & Kushner, 1999). These fold differences in 
acute phase proteins have been documented during conditions, such as infection, 
trauma, surgery, burns, tissue infarction etc. and appear to serve beneficial 
effects, by initiating, sustaining or modulating the inflammatory process (Gabay & 
Kushner, 1999). IL-6 is considered to be the chief stimulator of the production of 
most acute phase proteins (Gauldie et al., 1987). The involvement of IL-6 in 
mediating the acute phase response is demonstrated in studies of IL-6 knock-out 
mice, whereby this response is severely impaired following tissue damage or 
infection. Furthermore, these mice display impaired T-cell dependent antibody 
responses when challenged with virus (Kopf et al., 1994).  
Epidemiological studies have shown that, in addition to C-reactive protein (CRP), 
IL-6 plasma levels are strong independent predictors of risk of future 
cardiovascular events (Rattazzi et al., 2003), suggesting an involvement of IL-6 in 
cardiovascular disease. In more detail, these studies, which included the WHS and 
WHI (healthy women), PHS (healthy men), and the Iowa65+ Rural Heath (elderly) 
studies, showed that those subjects in the top quantile of baseline IL-6 levels had 
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an almost 2 fold greater risk of death and CVD events when compared to those in 
the lower quantile (Rattazzi et al., 2003). Indeed endothelial dysfunction has been 
shown to correlate with CRP levels (Fichtlscherer et al., 2000). Furthermore, a 
study conducted recently found that patients who were in a stable phase following 
myocardial infarction displayed a negative correlation between endothelium-
dependent vasodilation and IL-6 levels (Erzen et al., 2007). 
It is interesting to note that IL-6 has been shown to possess anti- as well as pro-
inflammatory properties, which appear to depend on the duration of the 
inflammatory response. For example, during acute responses, IL-6 has been 
shown to reduce the levels of pro-inflammatory cytokines (Xing et al., 1998). 
However, during states of chronic inflammation, IL-6 becomes pro-inflammatory, 
involved in the transition from neutrophil to monocyte recruitment in areas of 
inflammation, a defining feature of the transition from acute to chronic 
inflammatory states (Hurst et al., 2001; Kaplanski et al., 2003). This may be in part 
due to increased shedding of the secretory form of the IL-6 receptor, namely sIL-
6Rα from neutrophils at sites of acute inflammation, since sIL-6Rα is required for 
trans-signalling, a mechanism described in section 1.3.3. For example, IL-6 and 
sIL-6Rα have been shown to induce endothelial cells to secrete IL-8 and MCP-1 
and upregulate adhesion molecules (Romano et al., 1997), establishing an 
autocrine loop for MCP-1 which favours monocyte recruitment and the transition 
from acute to chronic inflammation (Marin et al., 2001). In contrast, there is a 
reduction in neutrophil recruitment and an increase in neutrophil phagocytosis, 
during which levels of TNFα and MCP-1 are upregulated (Gabay, 2006). sIL-6Rα 
appears to be important in this transition and has been shown to induce the 
expression of E-selectin, ICAM-1, VCAM-1, IL-8 and IL-6 in human umbilical vein 
endothelial cells (HUVECs). sIL-6Rα is therefore capable of activating EC 
inflammation via endothelial-derived IL-6, which can itself be upregulated by IL-6 
and sIL-6Rα (Modur et al., 1997). Thus, IL-6 appears to modulate the immune 
response by dictating the recruitment and activation of different leukocyte classes 
and inducing different cytokines (Jones et al., 2005).  
As mentioned previously, IL-6 is heavily implicated in the development of chronic 
inflammatory diseases, such as RA, juvenile idiopathic arthritis, Castleman’s 
disease and Crohn’s disease (Nishimoto & Kishimoto, 2004). For example, in 
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disease models of arthritis, anti-IL-6R antibody has been shown to reduce the 
development of arthritis (Takagi et al., 1998) and interestingly, blockade of sIL-6Rα 
by a soluble form of the IL-6 receptor (gp130) reduces the severity of arthritis, 
implicating  sIL-6Rα in the development of RA (Nowell et al., 2003). Indeed, a 
humanised anti-IL-6R monoclonal antibody has been used in the treatment of RA 
with strong therapeutic effects (Nakahara & Nishimoto, 2006). It has also been 
used in Crohn’s disease (Ito et al., 2004) and Castleman's disease (Nakahara and 
Nishimoto, 2006). 
 
1.3.3 IL-6-activated Signalling Cascades 
All members of the IL-6 family signal via receptor complexes containing the 
glycoprotein gp130, belonging to the class 1 cytokine receptor family. IL-6, IL-11 
and CNTF cannot bind gp130 directly. They first need to bind to their respective 
membrane-bound α-receptor subunits; IL-6Rα, IL-11Rα and CNTFRα (Davis et 
al., 1991; Hilton et al., 1994; Yamasaki et al., 1988). Regarding IL-6, endothelial 
cells do not express IL-6Rα. However, soluble forms of the receptor (sIL-6Rα) 
exist and these can bind IL-6 to generate a so-called trans-signalling sIL-6Rα/IL-6 
complex that is capable of efficiently activating gp130. sIL-6Rα can be produced 
by limited proteolysis (shedding) of membrane-bound receptors from, for example, 
neutrophils recruited to sites of vascular injury (Marin et al., 2002). Additionally, 
sIL-6Rα can be generated by translation from an alternatively spliced sIL-6Rα 
transcript (Muller-Newen et al., 1996). The remaining IL-6-type cytokines bind 
directly with their respective signal transducing receptors; LIF, CNTF, CT-1 and 
CLC bind and signal via heterodimers of gp130 and LIFR, while OSM signals via 
heterodimers of gp130-LIFR and/or gp130-OSMR (Figure 1.3). 
The extracellular domain of all members of the class 1 receptor cytokine family 
have the characteristic motif CHD2 mentioned earlier (Bazan, 1990) and different 
numbers of fibronectin type III (F-III) domains. The CHD2 of gp130 has been 
shown to interact with distinct areas on the surface of the IL-6 cytokines. One such 
site, which is common to all the IL-6 cytokines and binds CHD2 is site II. In addition 
to site II, another site termed site III interacts with the second signalling receptor 
via the Ig-like domains of either a second gp130 or LIFR or OSMR. Therefore, 
even when signalling via gp130 homodimers, 2 different sites and 2 different 
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epitopes on gp130 are required for ligand recognition (Kurth et al., 1999). If an α-
receptor is involved in signalling, as is the case with IL-6, site I on IL-6 binds with 
the CHD2 on sIL-6Rα (Figure 1.4). 
 
- The Janus Kinases (JAKs)  
Most cytokine receptors have no intrinsic tyrosine kinase activity and therefore rely 
on signalling via associated tyrosine kinases. Numerous studies have shown that 
the JAK family are the predominant kinases utilised by cytokine receptors for this 
purpose (Muller et al., 1993; Witthuhn et al., 1993). However, another class of 
tyrosine kinases called the Src family kinases (SFK) have also been shown to be 
activated by cytokine receptors. Indeed, studies have shown that co-operation 
between both SFKs and JAKs are required for optimal signal transduction (Ingley 
& Klinken, 2006). In mammals, the JAK family has 4 members; JAK1, JAK2, JAK3 
and TYK2. JAK1, JAK2 and TYK2 are widely expressed, whereas JAK3 is 
restricted to the haematopoietic immune system (Musso et al., 1995). Importantly, 
JAK3 deficiency is the basis of human autosomal recessive “severe combined 
immunodeficiency” (SCID) (Macchi et al., 1995).  
Structurally JAKs comprise 7 conserved domains, termed The JAK homology (JH) 
domains 1-7, numbered from the carboxyl to the amino terminus (Figure 1.5 a.). 
The hallmark of the JAKs is the presence of JH1, which is a functional tyrosine 
kinase domain, and JH2, which is a catalytically inactive pseudo-kinase domain; 
the presence of these domains give rise to the kinase’s name (the “two-faced” 
Roman god Janus). Despite lacking tyrosine kinase activity, JH2 is proposed to 
have regulatory functions. For example, deletion of this domain has been shown to 
increase JAK2 and JAK3 phosphorylation, as well as signal transducer and 
activator of transcription (STAT) activation. The JH2 domain is believed to 
negatively regulate the kinase domain via an intramolecular interaction between 
JH1 and JH2, which effectively suppresses basal kinase activity. Upon ligand 
binding, conformational changes relieve this interaction and allows activation of 
JH1 (Saharinen et al., 2000; Saharinen & Silvennoinen, 2002). JH3-JH5 domains 
have homology with SH2 domains, implying interactions with other signalling 
components via phosphorylated tyrosine residues. However, partners for these 
domains have yet to be identified (Ingley & Klinken, 2006). Lastly, JH6-JH7 
domains constitute a Band 4.1, ezrin, radaxin, moesin (FERM) domain, which has 
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been implicated in interactions with cytokine receptors (Huang et al., 2001), and 
the JH1 domain to increase activity (Zhou et al., 2001).  
The membrane-proximal regions of gp130 predominantly bind JAK1, supported by 
the findings that in cells lacking JAK1, IL-6 signalling is impaired (Guschin et al., 
1995). These regions contain conserved motifs called box1 and box2 and both are 
necessary for efficient JAK binding. Deletions or mutations to box1 result in 
impaired binding of JAKs to gp130 (Haan et al., 2000; Tanner et al., 1995) and 
deletion of box2 only leads to JAK association when the kinase is over-expressed 
(Tanner et al., 1995). It has therefore been proposed that box2 increases the 
affinity of JAK binding (Heinrich et al., 2003). In addition to box1 and box2, an 
interbox1-2 region on gp130 is also involved in JAK binding and again, in studies 
where this region has been mutated, abrogated JAK signalling has been observed 
(Haan et al., 2000). 
Ligand binding causes a conformational change within the gp130 homodimer, 
which allows JAK transphosphorylation and activation. Following JAK activation, 
specific tyrosine residues on the receptor become phosphorylated by the activated 
JAKs. The structural basis of the JAK-receptor interaction and the mechanism by 
which the receptor re-orientates to receive the phosphorylation is currently very 
poorly understood. Nevertheless, after the receptor has become phosphorylated at 
specific tyrosine residues, SH2-domain containing proteins are recruited to the 
receptor and activate downstream signalling. Two major intracellular pathways 
activated by gp130 are the signal transducer and activator of transcription (STAT) 
pathway and the extracellular signal-regulated kinase 1/2 (ERK1/2) pathway. 
 
- The STAT Pathway  
The STAT family of transcription factors were first described by Darnell et al. 
(1994) in the early 90s as ligand-induced transcription factors in cells treated with 
interferon (IFN) (Darnell et al., 1994; Fu et al., 1992). To date, the STAT family 
comprises seven mammalian members; STAT1, STAT2, STAT3, STAT4, STAT5a, 
STAT5b and STAT6. Additionally, alternative splicing of STAT1, 3, 4, 5a and 5b 
yields isoforms with truncated C-terminal domains, for example the STAT3β 
isoform lacks the 55 C-terminal amino acids of STAT3α, but gains a unique 7 
amino acids (Schaefer et al., 1995). The β isoforms have been reported to act as 
dominant negative regulators of transcription when overexpressed (Caldenhoven 
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et al., 1996). Moreover, these isoforms have been shown to differ in their 
transcriptional activities, for example isoform-specific deletions of STAT3β and 
STAT3α have shown that STAT3β activates a distinct subset of STAT3 genes in 
response to IL-6 and may not act as a dominant negative in vivo (Maritano et al., 
2004). 
STATs are activated by a wide range of cytokines, as well as growth factors and 
hormones (Lim & Cao, 2006). Depending on the STAT member involved, a range 
of ligands which are sometimes overlapping can activate STAT1, STAT3, STAT5a 
and STAT5b, whereas only a few cytokines are capable of activating STAT2, 
STAT4 and STAT6 (Lim & Cao, 2006). For example, STAT3 can be activated by 
cytokines and growth factors, including the IL-6 family members and EGF, and is 
implicated in mitogenesis, survival and anti-apoptosis (Bromberg, 2001). STAT6, 
on the other hand is predominantly activated by IL-4 and is involved in T helper 2 
(Th2) development (Shimoda et al., 1996).  
Structurally, STATs comprise several distinct functional domains, including an N-
terminal domain, a coiled-coil domain, a DNA binding domain, a linker domain, a 
SH2 domain and a C-terminal transactivation domain (Figure 1.5 b.). The N-
terminal domain is involved in dimerisation and tetramerisation, and the 
recruitment of phophatases for some STATs (Meyer et al., 2004; Ota et al., 2004; 
Vinkemeier et al., 1998). The coiled-coil domain is implicated in protein-protein 
interactions. For example, c-Jun has been shown to interact with this domain in 
STAT3, whereby STAT3 and c-Jun cooperation is required for maximal IL-6-
dependent acute-phase response gene activation driven by the 2-macroglobulin 
enhancer (Zhang et al., 1999b). This domain has also been shown to be involved 
in receptor binding, whereby mutations within it impair STAT3 recruitment to 
gp130 (Zhang et al., 2000). The DNA-binding domain is highly conserved amongst 
all the STATs and, as well as binding DNA, it also controls nuclear translocation. It 
has been proposed to achieve this by maintaining the necessary conformation for 
importin binding (Ma & Cao, 2006). Importins are required for cytokine-induced 
nuclear import of STATs, whereas nuclear export involves a “chromosome region 
maintenance 1” (CRM1)/ exportin1-dependent process (Meyer & Vinkemeier, 
2004). The linker domain is implicated in transcriptional activation, since studies 
using point mutations within this region of STAT1 abolished transcriptional 
responses to IFN-γ (Yang et al., 1999). Additionally, this domain also participates 
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in protein-protein interactions, demonstrated by STAT3 interaction with “genes 
associated with retinoid–IFN-induced mortality-19” (GRIM-19), a death regulatory 
gene product. GRIM-19 association with STAT3 has been shown to block STAT3 
transcriptional activity (Liu et al., 1998). The most conserved domain within the 
STATs is the SH2 domain. This domain is essential for binding to receptors via 
specific phospho-Tyr residues (Hemmann et al., 1996), and can also mediate 
dimerisation (Shuai et al., 1994). Lastly, the C-terminal transactivation domain and 
the conserved tyrosine and serine residues facilitate the activation, dimerisation 
and transcriptional activation of STATs (Darnell et al., 1994; Shuai et al., 1993). 
The transactivation domain mediates protein-protein interactions including 
interactions with the “cAMP response element binding protein” (CREB)-binding 
protein (CBP) to regulate gene transcription (Gingras et al., 1999; Zhang et al., 
1996). 
All IL-6 type cytokines are capable of activating STAT1 and STAT3 via gp130. 
However, STAT3 activation has been observed at a greater extent than STAT1 
activation (Heinrich et al., 1998). STAT recruitment to activated IL-6 type receptors 
is mediated by the STAT SH2 domain and requires the phosphorylation of certain 
tyrosine residues. In particular, STAT3 binds four phospho (p)YXXQ motifs of 
gp130 (Y767RHQ, Y814FKQ, Y905LPQ and Y915MPQ) (Stahl et al., 1995), whereas 
STAT1 is more restricted and binds two (p)YXPQ motifs in gp130 (Y905LPQ and 
Y915MPQ) (Gerhartz et al., 1996). Once recruited, STATs become phosphorylated 
by JAKs on a single tyrosine residue; Y701 in STAT1 and Y705 in STAT3 (Kaptein et 
al., 1996; Shuai et al., 1993). In addition, STAT serine phosphorylation by MAP 
kinases has also been observed at S727 in both STAT1 and STAT3 (Wen et al., 
1995). The relevance of this is still not completely understood, but it has been 
proposed that serine phosphorylation is required for maximal transcriptional 
activity, since a mutated Ser727 to Ala in STAT3 results in reduced transcriptional 
activity (Shen et al., 2004). Following phosphorylation, activated STATs form 
homo- and/or hetero-dimer complexes, consisting of STAT1-STAT1, STAT1-
STAT3 or STAT3-STAT3 dimers, which translocate to the nucleus to bind 
response elements of IL-6 inducible genes. STATs bind to essentially 2 types of 
response elements; (1) interferon stimulated response element (ISRE) and (2) 
gamma-activated site (GAS). The ISRE appears to be restricted to IFN signalling 
(Fu et al., 1990), whereas the GAS, including  sis-inducible element (SIE), acute 
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phase response element (APRE) and other GAS-like sequences are present in 
promoters such as c-fos and acute phase proteins and are targets of STATs. 
Target genes downstream of STAT3 include acute phase genes, such as 
fibrinogen (Wegenka et al., 1993), cell cycle regulators such as cyclin D1, and 
anti-apoptotic genes such as Bcl-XL (Bromberg et al., 1999).  
 
- ERK1/2 Pathway 
ERK1 and ERK2 are ubiquitously expressed, proline-directed serine and threonine 
protein kinases, discovered in the early 90s (Boulton & Cobb, 1991) and belong to 
the mitogen-activated protein kinase (MAPK) family. ERK1 and ERK2 constitute 
one of three sub-families of MAPK, together with the c-Jun N-terminal kinase 
subfamily (JNK1, JNK2 and JNK3) and the p38-MAP kinase subfamily (α, β, γ and 
δ). Additionally, ERK3 - ERK8 have also been identified, but their regulation and 
roles are much less understood (Bogoyevitch & Court, 2004). ERK1 and ERK2 are 
generally considered one entity (ERK1/2), since they are 83% identical, with the 
differences shown to be outside the kinase region (Boulton et al., 1991). ERK1/2 is 
expressed in all tissues and may be activated by a wide range of stimuli, including, 
growth actors, serum, cytokines, hormones and osmotic stress (Chen et al., 2001). 
ERK1/2 is implicated in many cellular processes, including cell proliferation, 
survival and differentiation (Kolch, 2005).  
Conventionally, ERK1/2 is activated as the final step in a Raf-MEK-ERK kinase 
cascade (Figure 1.6). The small G protein Ras is an upstream activator of Raf, and 
recruits Raf to the plasma membrane. Notably, mutations in Ras genes are found 
in 30% of all human cancers (Bos, 1989). Raf activation involves phosphorylation 
at specific Ser, Tyr and Thr residues, which differ between the 3 Raf isoforms; A-
Raf, B-Raf and Raf-1/C-Raf. For example, phosphorylation of both Ser338 and 
Tyr341 appears to be crucial for Raf-1 activation, since mutation of both residues 
(Ser338/Tyr341 to Ala) has been shown to abrogate Raf-1 activity (Mason et al., 
1999). Furthermore, phosphorylation of Thr491 and Ser494 has been shown to be 
necessary, but not sufficient for Raf-1 activation. These sites co-operate with 
Ser338 and Tyr341 to activate Raf-1 (Chong et al., 2001). Alternatively, Ser259 on 
Raf-1 has been identified as an inhibitory phosphorylation site, whereby this site is 
phosphorylated in resting cells and requires dephosphorylation to activate Raf-1 or 
conversely may be hyperphosphorylated by PKA to inhibit Raf-1 activity (Dhillon et 
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al., 2002a; Dhillon et al., 2002b). Thus, activation of Raf-1 involves complex 
changes in phosphorylation, which are still not fully understood. This complicated 
activation of Raf-1 also applies to A-Raf. However, B-Raf activation appears to be 
simpler and this is reflected in the findings that B-Raf activates MEK and ERK 
more potently than Raf-1 or A-Raf (Galabova-Kovacs et al., 2006; Pritchard et al., 
1995). B-Raf has the highest basal activity and has been found to be mutated in 
many cancers (Repasky et al., 2004). 
Despite these differences, all 3 Raf isoforms are capable of activating MAP/ERK 
kinases 1/2 (MEK1/2), except for A-Raf, which cannot activate MEK2 (Beeram et 
al., 2005). MEK1/2 becomes phosphorylated on serine residues 217 and 221 
within the activation loop, which is a region within protein kinases that modulate 
kinase activity (Alessi et al., 1994; Canagarajah et al., 1997). MEK1/2 are dual-
specificity kinases that phosphorylate ERK1/2 on Thr (Thr202/185 on ERK1/2 
respectively) and Tyr residues (Tyr204/187 on ERK1/2 respectively) (Canagarajah 
et al., 1997; Owens & Keyse, 2007) in a “TEY” motif within the activation loop. The 
“TEY” motif is a tripeptide motif including Thr(T)-Glu(E)-Tyr(Y), which depicts the 
phosphorylation sites of ERK1/2, separated by a single amino acid (Glu). The 
amino acid between the two phosphorylation sites defines the different groups of 
MAPK, for example, the aforementioned Glu is the amino acid found in the ERK1, 
2 and 5 tripeptide motif, whereas JNKs (JNK1-3) exhibit a Pro (Thr-Pro-Tyr) and 
p38 MAPKs (α-δ) a Gly (Thr-Gly-Tyr) (Widmann et al., 1999). Raf isoforms are the 
best characterised MEK1/2 activators, however other activators exist, including 
tumour progression locus 2 (Tpl2) (Salmeron et al., 1996). 
Structurally, the MAPKs comprise 2 domains; an N-terminal domain which 
consists of β-sheets and 2 helices, so-called αC and αL16, and the C-terminal 
domain which is predominantly helical, with 4 short β-strands containing the 
residues involved in catalysis (Turjanski et al., 2007). The catalytic site is localised 
at the junction between these two domains. MAPKs can be distinguished from 
other protein kinases by the presence of a 50 residue MAPK insertion in the C-
terminal, with an extension of this domain which spans the entire protein. All 
MAPKs are structurally very similar, which poses the question of how specificity of 
signalling between the different MAPKs is achieved. Differences in the docking 
motif binding sites that are located outside the catalytic domain of MAPKs, which 
dictate substrate specificity could account for this. Furthermore, conformational 
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changes have been observed in MAPKs upon binding to upstream activators, 
scaffolds and downstream targets, which can also contribute towards MAPK 
specificity (Zhou et al., 2006).       
SHP2 (SH2-domain-containing cytoplasmic protein tyrosine phosphatase) is a 
ubiquitously expressed and highly conserved enzyme. Like its name suggests, 
SHP2 comprises two N-terminal SH2 domains and a C-terminal protein tyrosine 
phosphatase domain and will be detailed in section 1.4.4.1. It is recruited to 
pTyr759 on gp130 following IL-6 type receptor dimerisation and is subsequently 
phosphorylated by JAKs. The phosphorylation of SHP2 provides docking sites for 
the adapter protein Grb2 (growth factor receptor binding protein 2), which is 
constitutively associated with the GDP/GTP Ras exchange factor, “Son of 
sevenless” (Sos). It has been proposed that the C-terminal domain residues 
Tyr542 and Tyr580 within SHP2 interacts with the Grb2-Sos complex (Heinrich et 
al., 2003). Sos recruitment to the receptor complex allows for the activation of Ras, 
which in turn leads to the activation of the Ras-Raf-MEK-ERK cascade. The 
activation of ERK1/2 results in the preferential phosphorylation of substrates with 
the consensus sequence, Pro-Xaa-Ser/Thr-Pro (Gonzalez et al., 1991) and more 
than 150 substrates have been identified (Table 1). In summary, a diagram of the 
IL-6-activated STAT and ERK1,2 signalling cascades, as described above, is 
shown in Figure 1.7.  
Alternatively, phosphorylated SHP2 has also been shown to associate with the 
scaffolding proteins Gab1/2 and the p85 subunit of phosphatidylinositol-3-kinase 
(PI3K), forming a tertiary complex. This complex can go on to activate the Akt 
pathway and might also feed back into the Ras/ERK cascade (Ernst & Jenkins, 
2004).  
 
1.3.4 Leptin 
Discovered in 1994 by positional cloning, leptin is the product of the obese (ob) 
gene (Zhang et al., 1994). Sequence analysis of leptin showed no strong 
similarities with any other proteins, however analysis of the tertiary structure using 
X-ray crystallography, revealed leptin to be a four-helix bundle cytokine, similar to 
that of the long chain helical family comprising, amongst others, IL-6 (Zhang et al., 
1997). However, further to this, NMR studies designated leptin a member of the 
short helix subfamily of cytokines, since the length of the helices were found to be 
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very similar to those of interleukin-2 (IL-2), interleukin-4 (IL-4) and macrophage-
colony stimulating factor (M-CSF), all members of the same short helix family 
(Kline et al., 1997). The receptor, which is encoded by the diabetes (db) gene, is 
termed OB-R and belongs to the same class of receptors as IL-6, namely the class 
I cytokine receptor family (Tartaglia et al., 1995). Thus, while the OB-R and 
receptors of the class 1 cytokine family, such as gp130, LIFR and G-CSFR share 
very similar sequences and are classed together on this basis, they do not appear 
to share the same similarities with respect to their ligands.  Despite this, the 
findings that leptin and OB-R have structural and sequence similarities with other 
cytokine/cytokine receptor families has greatly aided research into leptin signalling, 
especially since its discovery has lagged behind that of IL-6, which was discovered 
in 1986 (Kishimoto, 2006).   
Leptin comes from the greek “leptos” meaning thin. As its name suggests, leptin is 
predominantly known for its role in the regulation of food intake and energy 
balance. This is clearly demonstrated in the mouse model of leptin deficiency 
(ob/ob mice), which suffers from early onset morbid obesity (Zhang et al., 1994). 
Associated diseases with this model include insulin resistance, diabetes mellitus 
and infertility (Zhang et al., 1994). Thus, leptin’s effects are not simply restricted to 
body weight and this is further reinforced by the almost universal expression 
pattern of the leptin receptor in the body. Like IL-6, leptin may therefore be 
considered a pleiotropic molecule with a range of biological effects. 
 
1.3.5 Leptin Receptors 
Leptin acts via transmembrane receptors of which there are at least 6 isoforms; 
OB-Ra – OB-Rf, encoded by a single gene (Lee et al., 1996). All of these splice 
variants share the same extracellular domain of over 800 amino acids, a 
transmembrane domain of 34 amino acids (except for OB-Re) and a variable 
intracellular domain (Figure 1.8) (Beltowski, 2006; Fruhbeck, 2006). The OB-R has 
2 CHD2s and four fibronectin type III domains (Hegyi et al., 2004). Based on the 
different intracellular domains, the OB-R isoforms are classed into (1) short forms 
(2) long forms and (3) secreted forms. The secreted form of OB-R is OB-Re and is 
produced by ectoderm shedding of membrane-bound OB-R or alternative splicing 
(Ge et al., 2002). OB-Re contains only the extracellular domain of OB-R and 
appears to act as a buffering system for free leptin, since the expression pattern of 
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OB-Re is quite extensive, with levels of OB-Re comparable to those of leptin 
(Lollmann et al., 1997). The short forms of OB-R (OB-Ra, OB-Rc, OB-Rd and OB-
Rf), all have the same first 29 intracellular amino acids as the long form, OB-Rb, 
but only OB-Rb, which has a cytoplasmic domain of 301 amino acids (1162 amino 
acids full length) has full signalling capability (detailed in signalling section). 
Indeed, mice deficient in the OB-Rb receptor (db/db) display a phenotype 
characterised by obesity, diabetes mellitus and infertility which is exactly the same 
phenotype as that of the ob/ob mice and mice lacking all the OB-R isoforms 
(db3J/db3J) (Kowalski et al., 2001). Furthermore, this phenotype can be rescued by 
neuron-specific OB-Rb transgenes (de Luca et al., 2005; Kowalski et al., 2001). 
This demonstrates the importance of the OB-Rb isoform in leptin signalling and 
highlights the less understood roles of the short forms of OB-R, despite their 
distinct tissue distribution (Lee et al., 1996). The short forms of OB-R have 
however, been implicated in the transport of leptin across the blood-brain barrier 
(Hileman et al., 2000), which is supported by the high expression of these short 
forms in the choroid plexus (Tartaglia, 1997). OB-Rb is predominantly expressed 
in the hypothalamus (Schwartz et al., 1996), but has been found in many tissues, 
notably in endothelial cells (Sierra-Honigmann et al., 1998). A large body of 
research suggests that OB-Rb is crucial for mediating leptin effects and these 
effects have been demonstrated to be extremely diverse.  
 
1.3.6 Roles of Leptin 
Leptin is mainly produced by white adipocytes. The concentration of circulating 
leptin has been documented to be relative to body mass index (BMI) and total 
body fat (Fruhbeck, 2006) and serves to communicate with the CNS to regulate 
food intake and energy expenditure (Friedman & Halaas, 1998). This role of leptin 
is heavily supported by the intensely studied mouse models of leptin and leptin 
receptor deficiency (ob/ob and db/db), since both models display increased food 
intake, coupled with decreased energy expenditure. This results in a phenotype 
resembling morbid human obesity, whereby each mouse model weighs three 
times more than their normal littermates. Furthermore, treatment of ob/ob mice 
with exogenous leptin was shown to reverse these effects (Ahima et al., 1996). On 
this basis, leptin was initially considered to be a wonder drug for the treatment of 
obesity. However, it was soon shown that obese individuals actually have elevated 
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levels of leptin in their bloodstream, due to their increased fat mass, which do not 
appear to mediate weight loss (Maffei et al., 1995). Moreover, leptin administration 
to these individuals was shown to have minimal effects (Heymsfield et al., 1999). 
This phenomenon gave rise to the concept of leptin resistance occurring at, at 
least two levels: (1) the level of the blood brain barrier at which the transport 
system may have become saturated or (2) the level of OB-Rb activation or 
signalling, whereby the transduction of the leptin signal has become impaired.  
Leptin has traditionally been exclusively associated with these central effects on 
energy homeostasis and body weight. However, like many cytokines, research into 
leptin has uncovered a wide range of biological activities mediated by this 
adipokine, whereby involvement in diverse systems, such as the endocrine, 
immune, reproductive, wound healing, respiratory and the CVS have been 
observed (Beltowski, 2006; Fruhbeck, 2006; Munzberg et al., 2005; Peelman et 
al., 2004). Of relevance to the present study are leptin’s peripheral effects on the 
immune system and the involvement of leptin in the pathogenesis of diseases, 
particularly those of the CVS. 
It is well known that obesity is a key risk factor for cardiovascular disease (Van 
Gaal et al., 2006) along with insulin resistance, type 2 diabetes, hypertension and 
dyslipidemia (Roth, 1997). Hyperleptinaemia may be considered another risk and 
has been shown to contribute to cardiovascular disease as detailed hereafter. 
Interestingly, research has shown a link between hyperleptinaemia and endothelial 
dysfunction, whereby high concentrations of leptin (resembling the concentrations 
observed in morbid obesity) administered to dogs and rats were shown to 
attenuate vasodilation of coronary arterioles in response to acetylcholine (Knudson 
et al., 2005). However, studies are conflicting in this area and whether leptin plays 
a role in endothelial function in humans is currently unknown.    
Indeed, it has been proposed that leptin mediates atherogenesis in obese 
individuals. This is based on the assumption that leptin resistance is selective i.e. 
only the body weight effects of leptin are impaired in leptin resistance, while other 
effects are maintained (Beltowski, 2006; Ozata et al., 1999). The concept of 
selective resistance was suggested by a study using ob/ob mice and Agouti yellow 
obese (Ay) mice, which are mice that have an overexpression of an agouti peptide 
that blocks melanocortin receptors, leading to obesity. Ay mice exhibit 
hyperleptinaemia and a higher arterial pressure than their lean littermates. 
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Interestingly, Ay mice have a higher arterial pressure than ob/ob mice, despite 
having milder obesity than ob/ob mice. Thus, it appears that peripheral effects of 
hyperleptinemia are preserved, whereas central affects are resistant. 
Administration of exogenous leptin to ob/ob mice results in weight loss, however 
the peripheral effects of leptin administration increase arterial pressure (Correia et 
al., 2002; Mark et al., 1999). This concept of selective resistance is supported by 
the findings that ob/ob mice on an atherogenic diet are protected from 
atherosclerosis, despite displaying obesity, diabetes, and hyperlipidemia (Schafer 
et al., 2004). Furthermore, administration of exogenous leptin to these ob/ob mice 
revert from an anti-atherogenic to a pro-atherogenic phenotype and in WT mice 
exacerbates atherosclerosis, but has no effect in db/db mice (Schafer et al., 2004). 
Leptin has also been shown to promote atherosclerosis and thrombus formation in 
atherosclerosis-prone apoE-deficient mice despite a reduction in adipose tissue 
mass and fasting insulin levels (Bodary et al., 2005). The expression of leptin 
receptors on various cell types involved in cardiovascular disease, such as 
monocytes/macrophages (Zarkesh-Esfahani et al., 2001) and, importantly, 
vascular endothelial cells (Bouloumie et al., 1998) only strengthens the link 
between leptin and cardiovascular disease.  
In vitro studies have shown that leptin potentiates inflammatory and immune 
responses by increasing pro-inflammatory cytokines, including TNFα, IL-6 and IL-
12 and increasing the phagocytic activity of macrophages (Loffreda et al., 1998). 
Leptin also induces ROS generation and increases expression of MCP-1 in bovine 
aortic endothelial cells (BAEC) (Yamagishi et al., 2001). In addition, leptin has 
been shown to promote angiogenesis (Park et al., 2001; Sierra-Honigmann et al., 
1998) which has been demonstrated to contribute towards unstable plaque 
growth. 
In humans, the ob gene mutations are fortunately rare and, in the few reported 
cases, the phenotype highly resembles that of the ob/ob mouse, with individuals 
displaying the characteristic morbid obesity trait (Montague et al., 1997). Of 
interest, this phenotype has also been associated with low T cell counts and an 
increased incidence of infectious disease and mortality (Ozata et al., 1999). 
Further to this, (Ciccone et al., 2001)have shown an association between plasma 
leptin levels and insulin resistance and inflammation, each of which are risk factors 
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for cardiovascular disease (Wannamethee et al., 2007). Moreover, in a study 
conducted by Wolk et al. (2004), levels of plasma leptin were demonstrated to 
predict future cardiovascular events such as cardiac death, myocardial infarction 
(MI), cerebrovascular accident, or re-vascularization in patients with 
angiographically confirmed atherosclerosis (Wolk et al., 2004). With relation to 
atherosclerosis, a correlation between the intima-media thickness (IMT) of the 
common carotid artery, which is an early marker of atherosclerosis, and plasma 
leptin concentrations has been demonstrated (Ciccone et al., 2001). OB-Rb 
expression has been shown in human atherosclerotic plaques (Park et al., 2001) 
and together with C-reactive protein (CRP), IL-1 and IL-6, leptin has been shown 
to act as an acute-phase reactant, being produced at high levels during 
inflammation, sepsis and fever (La Cava & Matarese, 2004). 
 
1.3.7 Leptin-activated Signalling Cascades 
Leptin signals via OB-R homodimers and mainly activates the JAK/STAT pathway 
(Vaisse et al., 1996) in a very similar way to the IL-6-type cytokine receptors (refer 
to IL-6 section). In the first instance, leptin binds and causes a conformational 
change in the OB-Rb homodimer, which enables the transphosphorylation of the 
OB-Rb-associated JAKs, specifically JAK2 (Kloek et al., 2002). JAK2 associates 
with the OB-Rb via a conserved box1 region (Bahrenberg et al., 2002; Kloek et al., 
2002), in comparison to gp130 that has been shown to require both box1 and box2 
regions for optimal JAK binding. Since, OB-Rb possesses specific tyrosine 
residues on its intracellular domain, it is the only isoform with full signalling 
capability (Hegyi et al., 2004). Transphosphorylation and activation of JAK2 
following leptin binding leads to phosphorylation of specific tyrosine residues on 
OB-Rb, providing docking sites for downstream signalling molecules. OB-Rb has 3 
conserved tyrosine residues on the intracellular domain; Tyr985, Tyr1077, and 
Tyr1138 (Tartaglia, 1997). Both Tyr985 and Tyr1138 are phosphorylated upon 
leptin binding, but Tyr1138 is not (Banks et al., 2000). 
 
STAT Pathway  
P-Tyr1138 on OB-Rb, serves as a docking site for STATs, since replacement of 
this residue with serine impairs STAT signalling and results in an obese, 
hyperphagic phenotype in mice (Bates et al., 2003). STAT1, STAT3 and STAT5 
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have all been demonstrated to bind OB-Rb (Hekerman et al., 2005). Despite 
earlier reports suggesting that Tyr1077 does not participate in leptin signalling due 
to lack of tyrosine phosphorylation, a study has since shown by the use of point 
mutations in OB-Rb, that Tyr1077 or Tyr1138 is required for leptin-induced tyrosyl 
phosphorylation of STAT5, and Tyr1138 is essential for activation of STAT1 and 
STAT3 (Hekerman et al., 2005). Thus, OB-Rb is capable of activating a broader 
range of STAT proteins than gp130. In vivo studies, however have demonstrated 
that signalling of leptin occurs mainly through STAT3 (Bates & Myers, 2004). 
Following STAT activation via associated JAKs, homo- and/or hetero-dimerisation 
complexes are formed, which translocate to the nucleus to bind and activate target 
gene transcription. 
 
ERK1/2 Pathway 
SHP2 is recruited to pTyr985 on OB-Rb (Banks et al., 2000; Bjorbaek et al., 2001), 
becomes Tyr phosphorylated by JAK2 and recruits the adapter protein Grb2 
(Banks et al., 2000), which then mediates activation of the Ras-Raf-MAPK 
cascade (mentioned earlier in section 1.3.3) via the Ras GEF Sos. In addition, 
ERK activation has also been observed in the absence of OB-Rb phosphorylation. 
In this pathway, the short isoform OB-Ra and the OB-Rb lacking all Tyr residues 
are both able to activate ERK via direct signalling from JAK2 to the ERK pathway. 
Thus, two pathways of ERK activation are proposed, whereby one pathway 
requires OB-Rb phosphorylation of Tyr985 and the other pathway does not. 
However, both pathways require the phosphatase activity of SHP2, since 
catalytically inactive SHP2 completely inhibits ERK activation. The substrates of 
SHP2, which mediate ERK activation by leptin have still be identified. Further to 
this, ERK phosphorylation via Tyr985 of OB-Rb requires Tyr phosphorylation of 
SHP2 (Bjorbaek et al., 2001). Refer to Figure 1.9 for a diagram of the leptin-
activated STAT and ERK1,2 signalling cascade.  
 
1.4 Regulation of Cytokine Signalling 
Cytokine signalling is typically transient, suggesting the involvement of negative 
regulatory steps aimed at terminating this response. Indeed, controlling these 
responses is crucial for avoiding detrimental inflammatory outcomes, including the 
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development of diseases such as atherosclerosis, RA, Crohn’s disease and 
Castleman’s disease (Nishimoto & Kishimoto, 2004). 
There are many mechanisms with which to negatively control cytokine signalling; 
these include receptor internalisation, ubiquitin-mediated proteasomal 
degradation, protein inhibitors and activators of STATs (PIAS), protein tyrosine 
phosphatases (PTPs) and suppressors of cytokine signalling (SOCS). These 
endogenous inhibitory mechanisms will be described, with an emphasis on the 
SOCS proteins as inhibitory regulators of IL-6 and leptin signalling.  
 
1.4.1 Receptor Internalisation 
Endocytosis of receptors via clathrin-coated vesicles into early endosomes, 
termed “clathrin-mediated endocytosis” (CME), has three potential consequences; 
(1) receptors can return to the plasma membrane from where they came 
(recycling), (2) receptors can be transported to a different domain of the plasma 
membrane (transcytosis) or (3) receptors can progress to lysosomes, where they 
are degraded. It is important to note here that receptor endocytosis is no longer 
solely considered a mechanism for the termination of signalling. Rather, it has also 
been shown to contribute to cell signalling, whereby signalling processes can 
occur in endosomes (Miaczynska et al., 2004; Polo & Di Fiore, 2006). 
Endocytosis relies on the expression of endocytosis motifs on membrane proteins 
and their interaction with adapters present in clathrin-coated pits, such as the AP-2 
adapter complexes. The most well-studied of these membrane protein motifs 
include the di-leucine and tyrosine-based motifs (Bonifacino & Traub, 2003). An 
example of this can be observed in gp130, whereby studies using mutant gp130s 
with different truncations in the intracellular domain identified a sequence of 10 
amino acids (TQPLLDSEER) containing a di-leucine internalisation motif, which 
was shown to be crucial for receptor- mediated endocytosis of the IL-6 receptor 
complex (Dittrich et al., 1994). However, in addition to these peptide motifs, 
proteins can be ubiquitinated on cytosolic lysine residues and this can also serve 
as a signal for endosomal sorting (Bonifacino & Traub, 2003). Unlike cytosolic or 
nuclear proteins that can be polyubiquitinated and degraded via the proteasome 
(mentioned later), membrane proteins tend to be modified by mono- or di-ubiquitin 
conjugates (Belouzard & Rouille, 2006). Certainly, this has been the case with the 
OB-Ra. The OB-Ra cytoplasmic tail contains no tyrosine or di-leucine-based 
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endocytosis motifs, but instead possesses two lysine residues which are each 
ubiquitinated and these act as internalization motifs for clathrin-dependent 
endocytosis of the receptor (Belouzard & Rouille, 2006).  
It is interesting to note that only 5-25% of OB-R isoforms have been located at the 
cell surface under basal conditions, with the remaining proportion localised to 
intracellular pools (Barr et al., 1999; Fruhbeck, 2006). Indeed, the fate of OB-Ra 
and OB-Rb following internalisation is their eventual degradation in lysosomes and 
this appears to be mediated by a ligand-independent constitutive endocytosis in 
some studies (HeLa cells) (Belouzard et al., 2004) and a ligand-dependent 
endocytosis of the two OB-R isoforms in other studies (CHO cells) (Uotani et al., 
1999). OB-Rb, in particular, has been shown to be undergo internalisation to the 
greatest extent when compared to the other OB-R isoforms, (Barr et al., 1999), 
and this may be a contributory factor to leptin resistance (Fruhbeck, 2006). With 
regards to gp130, endocytosis has been shown to occur constitutively, 
independent of IL-6/IL-6R stimulation (Thiel et al., 1998). 
The mechanisms involved in these intracellular trafficking processes have yet to 
be fully established. Studies of class 1 cytokine receptor routing are limited, but 
from the existing studies, all follow the endosomal/lysosomal pathway including 
the growth hormone receptor (GHR), leptin receptor (LR), prolactin receptor 
(PRLR), IL-9R and gp130 (Belouzard et al., 2004; Dittrich et al., 1994; Irandoust et 
al., 2007; Thiel et al., 1998; Uotani et al., 1999), with the exception of the 
thrombopoietin receptor (TPOR), which is recycled back to the plasma membrane 
(Royer et al., 2005). The lysosomal routing of the G-CSFR from early to late 
endosomes and lysosomes is of interest, since this process is believed to be 
mediated by the suppressor of cytokine signalling 3 (SOCS3) protein via 
ubiquitination of G-CSFR (Irandoust et al., 2007). SOCS3 will be discussed in 
more detail in section 1.6.5 and represents another inhibitory mechanism of 
cytokine signalling. Thus, the lysosomal routing of G-CSFR depicts a novel 
mechanism of inhibition, involving two pathways, i.e. the endosomal/lysosomal 
pathway and SOCS3.  
Further to CME, clathrin-independent mechanisms of endocytosis also exist, such 
as raft/caveolae-mediated endocytosis (RCE), which is a much less studied 
endocytotic mechanism than the former. It is of interest because caveolae are 
especially abundant in specific cell types like endothelial cells (Couet et al., 2001). 
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Caveolae can be described as small, omega-shaped domains enriched in 
cholesterol, sphingolipids and caveolin proteins. Such domains have been 
implicated in cell signalling processes as well as endocytosis (Couet et al., 2001). 
Notably, studies have demonstrated the involvement of these lipid rafts in IL-6-
mediated STAT activation, whereby disruption of the rafts by methyl-β-
cyclodextrin, which removes cholesterol from the membrane, inhibits STAT 
signalling (Sehgal et al., 2002). Caveolin-1 has also been shown to modulate 
insulin signalling, EGF signalling and, importantly, cAMP signalling (Abulrob et al., 
2004; Nystrom et al., 1999; Razani et al., 1999).  
Thus, CME and RCE can either dictate receptor fate or modulate cell signalling 
pathways. Which of these endocytic pathways are used and under what conditions 
is a question that still remains to be answered. The choice of pathways could 
potentially be influenced by the type of stimulus; for example IL-6 treatment has 
been shown to increase trafficking of TGF-β1 receptors to non-lipid raft-associated 
pools and this leads to enhanced TGF-β1-Smad signalling (Zhang et al., 2005). 
Alternatively, it could be the ligand concentration, since the EGFR has been 
shown to be internalised almost exclusively via the CME pathway at low doses of 
EGF, and the RCE pathway at high doses of EGF (Sigismund et al., 2005).  
Overall, endocytic pathways appear to play a very complex role in the integration 
and attenuation of signals and could potentially have effects on IL-6- or leptin-
mediated signalling cascades in endothelial cells.  
 
1.4.2 PIAS 
Mammalian “protein inhibitor of activated STAT” (PIAS) proteins, comprise PIAS1, 
PIAS3, PIASx (PIAS2) and PIASγ (PIAS4), each existing as 2 isoforms, except for 
PIAS1. As their name suggests, PIAS proteins were originally identified as 
negative regulators of STAT proteins, (Chung et al., 1997; Liu et al., 1998). 
Despite their nomenclature, it has now emerged that PIAS proteins are capable of 
positively or negatively regulating a broad range of proteins. Examples of the 
proteins that can be regulated by PIAS proteins, which are involved in immune 
regulation, are shown in (Table 2). 
Every member of the PIAS family has been shown to regulate STAT signalling 
(Shuai & Liu, 2005). Notably, PIAS1 and PIAS3 have been shown to interact with 
STAT1 and STAT3 respectively (Chung et al., 1997; Liu et al., 1998). PIAS-STAT 
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interactions are cytokine-dependent and result in inhibition of STAT-mediated 
transcription. Transcriptional inhibition can result from PIAS proteins blocking the 
DNA-binding activity of transcription factors. For example,  PIAS1 and PIAS3 have 
both been shown to inhibit the DNA-binding activity of STAT1 and STAT3 
respectively (Chung et al., 1997; Liu et al., 1998). The mechanism by which this 
occurs however is still unclear. Alternatively, PIAS proteins can also recruit co-
regulators, such as histone deacetylases (HDACs), which repress transcription. 
For example, PIASx inhibits IL-12-mediated STAT4 activation via recruitment of 
HDACs (Arora et al., 2003). Interestingly, PIAS proteins have also been shown to 
act as E3 ligases for “small ubiquitin-related modifier” (SUMO) (Kotaja et al., 
2002). SUMO is known as an ubiquitin-like protein (ULP) because of its similarity 
with ubiquitin (described in the next section). Sumoylation involves the conjugation 
of SUMO to protein substrates: for example, sumoylation of STAT1 by PIASx-
alpha via Lys703 has been observed. However the functional consequences of 
this modification have yet to be determined, since it does not appear to alter 
transcriptional activation (Rogers et al., 2003). Thus, the role of PIAS-mediated 
sumoylation in the context of STAT signalling is unclear. However, in general, 
sumoylation has been implicated in many cellular processes including, the 
modulation of transcription factors, the targeting of proteins to the nucleus, protein-
protein interactions and protein stability (Johnson, 2004).    
 
1.4.3 Ubiquitin-mediated Proteasomal Degradation 
Protein degradation in mammalian cells is predominantly mediated by the 
ubiquitin-proteasome system (UPS) (von Mikecz, 2006), and is crucial in many 
cellular events, including antigen presentation (Kloetzel, 2001), cell cycle 
progression (Koepp et al., 1999) and removal of misfolded proteins (Hilt & Wolf, 
1996). Ubiquitination primarily involves targeting proteins for degradation via the 
26S proteasome, but has also been implicated in endocytosis (Reggiori & Pelham, 
2001; Strous et al., 1996) and cell signalling (Khush et al., 2002; Ting & Endy, 
2002). 
The process of ubiquitination involves a series of enzymatic steps, beginning with 
the activation of ubiquitin (Ub) via formation of a thioester bond between an 
ubiquitin (Ub)-activating enzyme (E1) and the carboxyl group of Gly76 on Ub. The 
activated Ub is then transferred to an Ub-conjugating enzyme (E2), before transfer 
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from E2 to the substrate lysine residue by E3 ubiquitin ligase. Thus, 3 enzymes 
are involved in the ubiquitination of substrates, which ultimately results in the 
formation of an iso-peptide linkage between Lys residues on the substrate and 
Gly76 on Ub. Although 3 enzymes are involved in this process, only the E3 
dictates specificity for the target protein and acts to ubiquitinate the substrate by 
either accepting the Ub from E2 and transferring it to the substrate or by bringing 
the substrate into close proximity with the E2 ligase-activated Ub complex (Pickart, 
2001; Walters et al., 2004). Substrates can either be monoubiquitinated or 
polyubiquitinated at one or multiple sites. Polyubiquitin chains are formed by the 
addition of more Ub moieties to existing Ub via linkage between specific Lys 
residues in Ub and the C-terminal residue Gly76. These linkages to Lys residues 
appear to dictate the fate of the protein substrate. For example, linkage at Lys48 
typically targets substrates to the 26S proteasome (Thrower et al., 2000). In 
contrast, linkage at Lys63 has been implicated in nonproteolytic signalling, for 
example activation of IκB kinase (IKK) in the NF-kappaB signalling pathway (Deng 
et al., 2000). 
Two major types of E3 ubiquitin ligases exist, defined by the presence of either a 
“homologous to E6-associated protein C terminus” (HECT) domain or a “really 
interesting new gene” (RING) fold. Recently, a new class of E3 ligase has been 
described, which contains a Lin11/Isl-1/Mec-3 (LIM) domain. The function of the 
LIM domain, which is present in many proteins remains largely unknown, although 
involvement in protein-protein interactions has been suggested (Dawid et al., 
1998). Importantly, a LIM domain protein known as STAT-interacting LIM protein 
(SLIM) has been shown to act as a ubiquitin E3 ligase and targets Tyr-
phosphorylated STAT1 and STAT4 for proteasomal-mediated degradation. 
Overexpression of SLIM results in impaired STAT1 and STAT4 activity due to 
decreased STAT protein levels. Furthermore, deficiency of SLIM in T cells leads to 
increased levels of phosphorylated and total STAT4, and increased amounts of 
IFNγ when stimulated with IL-12, in keeping with the major role of IL-4 signalling in 
the differentiation of IFNγ-secreting Th1 cells (Tanaka et al., 2005).  
 
1.4.4 PTPs – a focus on SHP2 
Protein phosphatases reverse the effects of protein kinases by catalysing the 
removal of phosphoryl groups. In terms of signal transduction, dephosphorylation 
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of proteins can alternatively initiate, sustain or terminate signals (Andersen et al., 
2001). Protein tyrosine phosphatases (PTPs) comprise a large family of proteins, 
which are characterised by a unique signature motif. Residues in this motif form 
the phosphate-binding loop and two residues in particular, namely Cys and Arg, 
are critical for the catalytic activity of PTPs (Andersen et al., 2001; Tiganis & 
Bennett, 2007). PTPs can be grouped into two general families; (1) the tyrosine-
specific PTPs, which can dephosphorylate substrate proteins on tyrosine; these 
can be further sub-divided into transmembrane, receptor-like PTPs and non-
transmembrane PTPs, and (2) the dual-specificity phosphatases (DSPs), which 
can dephosphorylate protein substrates on tyrosine, serine and threonine residues 
(Tiganis & Bennett, 2007). Our understanding of PTPs is greatly lagging behind 
that of PTKs, which is partly due to the discovery of PTKs a decade before PTPs. 
PTPs exhibit a high degree of specificity for their substrates. This is achieved by 
the PTP catalytic domain, which recognises the specific phosphorylated residues 
and the flanking amino acids within the substrate, and the non-catalytic N- and C- 
terminal domains, which target the PTP to particular intracellular compartments for 
substrate recognition (Andersen et al., 2001). PTP specificity can be demonstrated 
by the subfamily of DSPs, termed the mitogen-activated protein kinase 
phosphatases (MKPs), which dephosphorylate MAPKs on tyrosine and threonine 
residues. Of the 10 members that make up this family, some can specifically target 
one class of MAPK (e.g. DUSP6/MKP-3 which specifically dephosphorylates ERK) 
while others can target more than one class of MAPK (e.g. DUSP1/MKP-1 which 
dephosphorylates ERK, JNK and p38 MAP kinases) (Owens & Keyse, 2007).  
The prototypical PTP is PTP1B which was discovered in 1988 (Charbonneau et 
al., 1988). It has been shown to have numerous substrates, but the most 
extensively studied of these include the insulin receptor (IR) and JAK2 (Tiganis & 
Bennett, 2007). A lot of this information has come from the study of PTP1B-
deficient mice, which exhibit enhanced insulin sensitivity, which is associated with 
increased tyrosine phosphorylation of the insulin receptor in muscle and liver. 
Furthermore, these mice are resistant to diet-induced obesity (Elchebly et al., 
1999). Further studies have revealed the involvement of leptin signalling in the 
above phenotype and have demonstrated PTP1B inhibition of leptin signalling via 
dephosphorylation of JAK2 (Cheng et al., 2002). 
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T-cell-specific protein tyrosine phosphatase (TCPTP), including its nuclear isoform 
TC45, has several proposed substrates, including the IR, EGFR (Tiganis & 
Bennett, 2007), JAK1, JAK3 (Simoncic et al., 2002) STAT1 (ten Hoeve et al., 
2002) and STAT3 (Yamamoto et al., 2002). Of interest, Yamamoto et al. (2002) 
demonstrated TC45-mediated suppression of STAT3 activation in response to IL-6 
in 293T cells, implicating the nuclear isoform of TCPTP in the negative regulation 
of IL-6 signalling. This negative regulation is supported by studies of TCPTP-
deficient mice. These mice display a complex phenotype in comparison to PTP1B-
deficient mice, wherein the mice are viable but exhibit haemopoietic defects, 
resulting in splenomegaly, lymphadenopathy and thymic atrophy. As a result, the 
mice die at 3-5 weeks. Specifically, homozygous mice display defects in bone 
marrow, B cell lymphopoiesis, and erythropoiesis, as well as impaired T and B cell 
functions. Taken together, the abnormalities displayed in TCPTP-deficient mice 
strongly suggest a crucial role of TCPTP in hematopoiesis and immune function 
(You-Ten et al., 1997). 
 
1.4.4.1 SHP-2  
The SH2-domain containing protein tyrosine phosphatases (SHPs) are a subfamily 
of non-transmembrane PTPs comprising two vertebrate SHPs, SHP1 and SHP2. 
SHP1 expression is restricted to cells of the haematopoietic system, whereas 
SHP2 is ubiquitously expressed. Both proteins contain two N-terminal SH2 
domains (N-SH2 and C-SH2) and a C-terminal catalytic phosphatase domain. As 
such, SHP1 and SHP2 have the unique ability to function as phosphatases, 
dephosphorylating signalling components and down-regulating signal transduction, 
whilst also serving as adapter molecules via their SH2 domains, recruiting further 
adapter molecules to transducer downstream signalling (Heinrich et al., 2003; Neel 
et al., 2003; Salmond & Alexander, 2006). SHP1 and SHP2 appear to have non-
redundant roles, since deletion of either protein in mice results in death at 2-3 
weeks due to severe inflammation, so-called the “motheaten” phenotype because 
of the patchy hair loss caused by sterile dermal abscesses (SHP1), (Neel et al., 
2003) or embryonic lethality due to defective gastrulation or mesodermal 
differentiation (SHP2) (Neel et al., 2003). Thus, one SHP does not compensate for 
the other in these phenotypes. The differences between SHP1 and SHP2 effects 
appear to be due to the differences in SH2 domain-mediated protein interactions, 
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as well as differences in the PTP domains of both proteins (Salmond & Alexander, 
2006). 
Of particular relevance to the present study is the finding that SHP2 binds to 
Tyr759 on gp130 and Tyr985 on OB-Rb (Carpenter et al., 1998; Stahl et al., 1995). 
The dual function of SHP2 as a phosphatase and an SH2 domain-containing 
protein poses the question; does SHP2 serve as a positive or negative regulator of 
IL-6 or leptin signalling?  
 
1.4.4.2 Positive Effects of SHP2 on the ERK Pathway 
The finding that ERK activation is inhibited in mice with a mutation of Tyr759 to 
Phe (gp130F759/F759) or cells transfected with a mutated Tyr759 gp130 construct, 
establishes a positive regulatory role of SHP2 on the ERK pathway (Kim & 
Baumann, 1999; Ohtani et al., 2000). Furthermore, catalytically inactive dominant-
negative SHP2 mutants have been shown to block leptin-mediated ERK 
phosphorylation and ERK-dependent gene transcription from the egr-1 promoter, 
suggesting a positive role of SHP2 in leptin signalling (Bjorbaek et al., 2001). 
Indeed, previous studies on growth factor signalling, including EGF, insulin and 
platelet-derived growth factor (PDGF) signalling have each demonstrated a 
positive regulatory role of SHP2 on ERK signalling and gene expression (Bennett 
et al., 1994; Bennett et al., 1996; Yamauchi et al., 1995).  
 
1.4.4.3 Positive and Negative Effects of SHP2 on the STAT Pathway 
In contrast to these positive effects, gp130F759/F759 mice and cells transfected with 
a Tyr759→Phe mutated gp130 construct have demonstrated impaired SHP2 
activation, prolonged STAT3 and STAT1 activation and enhanced acute-phase 
protein gene induction, suggesting a negative role of SHP2 on the STAT pathway 
(Ohtani et al., 2000; Schaper et al., 1998). In further support of this negative 
regulatory role, the gp130F759/F759 mouse phenotype displays splenomegaly, 
lymphadenopathy and an enhanced acute phase reaction (Ohtani et al., 2000). 
However, these results are complicated by the findings that suppressor of cytokine 
signalling 3 (SOCS3), another inhibitory mechanism of cytokine signalling detailed 
in the next section, binds to the same site as SHP2 on gp130 and OB-Rb (De 
Souza et al., 2002) and could therefore contribute towards these negative effects. 
To address this issue, studies have employed catalytically inactive dominant 
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negative SHP2 mutants in gp130 signalling. Expression of these mutants have 
resulted in increased gp130, JAK and STAT3 phosphorylation as well as gene 
induction (Lehmann et al., 2003; Symes et al., 1997), which confirms the 
involvement of SHP2 in the negative regulation of the STAT pathway via gp130.  
These negative effects of SHP2 on gp130 signalling do not appear to be observed 
for OB-Rb signalling, since mutation of Tyr985 of OB-Rb has no effect on STAT 
activation (Li & Friedman, 1999). Also, using dominant negative SHP2 strategies 
(COS-1 cells), SHP2 was shown not to have an effect on STAT3 phosphorylation 
or STAT3-mediated gene transcription from the SOCS3 promoter (Bjorbaek et al., 
2001). However, these studies demonstrated no effect of SHP2 on STAT 
activation and STAT-dependent promoter activity following 15 minutes and 6 hours 
of leptin treatment respectively. Further research by this group has demonstrated 
that following 24 hours of leptin treatment, STAT-mediated transcription was 
enhanced in cells expressing mutated Tyr985Phe OB-Rb (Bjorbaek et al., 2001) 
and suggested that the induction of SOCS3 by leptin over prolonged leptin 
treatment could account for the enhanced STAT3 response, implicating SOCS3 
involvement and not SHP2. In addition, over these extended periods of leptin 
treatment, SHP2 could possibly act as an indirect positive regulator of the STAT 
pathway, preventing SOCS3 binding to the OB-Rb at Tyr985 (Bjorbaek et al., 
2001).     
 
1.4.4.4 Possible Mechanisms of SHP2’s Actions on ERK and STAT Signalling 
Thus, in general, a positive role of SHP2 in cytokine-induced ERK activation and a 
negative or positive role of SHP2 in cytokine-induced STAT activation have been 
proposed. How SHP2 mediates this positive effect on ERK activation and the 
contribution of SHP2 to the negative regulation of STAT signalling, in relation to 
SOCS3, are still areas under investigation. To address the first point, SHP2 
appears to exert a positive effect on ERK signalling by acting as an adapter 
protein, wherein SHP2 becomes recruited to phosphotyrosine residues on 
activated receptors and following activation, associates with the adapter protein 
Grb2, which is bound to the Ras GDP-GTP exchange factor Sos. This Grb2/Sos 
complex can then go on to activate the Ras-ERK pathway (as discussed earlier in 
the signalling sections). This has been demonstrated for growth factor receptor 
signalling, including FGFR, and OB-Rb (Banks et al., 2000; Bennett et al., 1994; Li 
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et al., 1994; Myers, 2004). With regards to gp130 signalling, it has been proposed 
that the SHP2-Grb2 mode of ERK activation could be adopted (Heinrich et al., 
2003). However, in addition to this, Grb2-associated binder-1 (Gab1) has been 
shown to become tyrosine phosphorylated in response to IL-6 and associates with 
SHP2 and PI3K to activate ERK (Takahashi-Tezuka et al., 1998). Alternatively, 
SHP2 can act as a Tyr phosphatase, dephosphorylating particular substrates, 
which are negatively regulated by tyrosine phosphorylation. For example, SHP2 
has been shown to dephosphorylate tyrosine residues on EGFR required for 
RasGAP recruitment to the EGFR, thereby inhibiting phosphorylation dependent 
translocation of RasGAP to the plasma membrane and maintaining Ras and 
hence ERK activation (Agazie & Hayman, 2003).  
A model of SHP2 phosphatase activity exists, whereby the binding of SHP2 to 
phosphotyrosine residues has been shown to activate its phosphatase activity 
(Barford & Neel, 1998). This can occur in two ways, (1) the SH2 domains can bind 
to pTyr motifs on activated receptors, such as pTyr759 on gp130, which leads to 
unfolding of the protein and subsequent phosphatase activation or (2) the SH2 
domains can bind to pTyr542 and 580 on the C-terminal tail of SHP2 itself and 
cause conformational changes leading to activation. If pTyr binding does not 
occur, SHP2 remains in an inactive state, whereby the N terminal SH2 (N-SH2) 
domain appears to sterically hinder the access of phosphotyrosine substrates to 
the PTP domain, as demonstrated by its crystal structure (Hof et al., 1998). 
Therefore, the N-SH2 domain of SHP2 can either bind and inhibit the 
phosphatase, or bind to phosphotyrosines to activate the enzyme (Figure 1.10). 
Interestingly, in the human autosomal dominant disorder Noonan syndrome (NS), 
approximately 50% of all cases are caused by mutations in the SHP2 gene, 
PTPN11, and specifically in portions of the amino N-SH2 domain. These mutations 
lock SHP2 in its active conformation and subsequently cause excessive SHP2 
activity (Tartaglia et al., 2001). NS is characterised by short stature, cardiac 
defects, facial dysmorphia and an increased risk of developing leukaemia 
(Salmond & Alexander, 2006). Of relevance, this syndrome displays aberrant 
regulation of the Ras/ERK pathway (Bentires-Alj et al., 2006). Thus, NS 
demonstrates an involvement of SHP2 on ERK activation in humans. However, 
further research is required to better understand the exact mechanisms involved. 
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Likewise, the mechanisms by which SHP2 negatively or positively regulates STAT 
activation are not well understood and the relative contribution of both SHP2 and 
SOCS on gp130 or OB-Rb signalling is still unclear. There are reports showing 
that SHP2 can act directly as a STAT phosphatase (STAT5a) (Chen et al., 2003; 
Yu et al., 2000) and indeed STAT3/SHP2 complexes have been detected (Gunaje 
& Bhat, 2001). A large body of evidence supporting a negative role of SHP2 in 
gp130-mediated STAT activation exists, whereas conversely, SHP2 has been 
shown to have no effects on OB-Rb-mediated STAT3 phosphorylation (Bjorbaek 
et al., 2001). The possibility that SHP2 acts as an indirect positive regulator of 
STAT3, impeding SOCS3 recruitment at the Tyr985 site, has been described 
(Bjorbaek et al., 2001). Clearly, the involvement of SHP2 in gp130 and OB-Rb 
signalling requires further study. 
 
1.4.5 SOCS Family of Proteins 
There are eight members of the suppressor of cytokine signalling (SOCS) family of 
proteins to date; CIS (cytokine-inducible SH2 domain-containing protein) and 
SOCS1 through to SOCS7. SOCS1 was the first member to be discovered in 1997 
by three independent groups (Endo et al., 1997; Naka et al., 1997; Starr et al., 
1997). Using the predicted amino acid sequence of SOCS1 as a probe, database 
searches identified 20 proteins with shared sequence homology within the C-
terminal SOCS box region. Based on the presence of a central SH2 domain, the 
SOCS proteins were subdivided into a group of their own. The remaining proteins 
were divided into the following groups; WD-40-repeat proteins with a SOCS box 
(WSB proteins), ankyrin repeat proteins with a SOCS box (ASB proteins), sprouty 
(SPRY) domain-containing SOCS box proteins (SSB proteins) and GTPase 
domain-containing proteins (RAR and RAR-like proteins) (Krebs & Hilton, 2001). In 
addition to a central SH2 domain, all members of the SOCS family contain an 
amino-terminal of variable length (50-380 amino acids) and a conserved 40 amino 
acid carboxyl terminal SOCS box (Alexander, 2002; Yoshimura et al., 2007). 
Three systems of nomenclature exist for the SOCS proteins, but the SOCS 
nomenclature is the most widely accepted. Further analysis of the primary amino 
acid sequences of all SOCS members revealed paired associations according to 
sequence similarity. Thus, CIS and SOCS2, SOCS1 and SOCS3, SOCS4 and 
SOCS5, and SOSC6 and SOCS7 form related pairs. CIS, SOCS1, SOCS2 and 
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SOCS3 are quite well characterised, while the remaining members are poorly 
understood in comparison. Since SOCS1 and SOCS3 are well studied, homology-
paired and have been shown to potently inhibit IL-6/leptin signalling, focus will be 
placed on these SOCS members and on SOCS3 in particular. 
 
1.4.5.1 SOCS Proteins as Inhibitors of Cytokine Signalling 
SOCS proteins function as classical negative feedback inhibitors of cytokine 
signalling, since most SOCS proteins are themselves induced by cytokines. 
Cytokines shown to induce SOCS include the gp130 signalling cytokines, IL-2, IL-
3, IL-4, IL-10, IFN-γ, G-CSF and leptin. (Alexander, 2002; Yoshimura et al., 2007). 
Other inducers of SOCS proteins comprise Toll-like receptor (TLR) agonists (e.g. 
LPS, CpG-DNA), GH, prolactin, statins and importantly, cAMP (Dalpke et al., 
2001; Gasperini et al., 2002; Lang et al., 2003; Yoshimura et al., 2007). The SOCS 
proteins can inhibit signalling by multiple mechanisms according to the SOCS 
member and signalling pathway involved. Currently, there are 3 known 
mechanisms by which SOCS proteins can downregulate cytokine signalling 
(Figure 1.11): 
1. SOCS proteins can bind specific pTyr residues via their SH2 domain. 
SOCS3 binds to the pTyr motif 759 (pTyr759/mouse homologue pTyr785) on 
gp130 (Nicholson et al., 2000) and pTyr985/Tyr1077 on the leptin receptor 
(Eyckerman et al., 2000) and physically occupies the same sites as other SH2 
domain-containing signalling components, such as SHP2, thereby competing with 
and subsequently inhibiting other signalling pathways (De Souza et al., 2002; 
Heinrich et al., 2003). Peptide studies have shown that the binding specificity of 
SOCS3 is very similar to that of SHP2, with optimal SOCS3 and SHP2 
phosphopeptide ligands containing overlapping consensus sequences (De Souza 
et al., 2002). The same group showed that SOCS3 binds to the gp130 receptor 
with much higher affinity than the leptin receptor (De Souza et al., 2002). However, 
the findings that SOCS3 can bind two sites on the leptin receptor may compensate 
for the low affinity each site exhibits for SOCS3, for example two SOCS3 
molecules are capable of binding the leptin receptor simultaneously, whereas only 
one SOCS3 molecule can bind gp130 at any one time (De Souza et al., 2002). 
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2. The kinase inhibitory region (KIR) of SOCS1 and SOCS3, located 
downstream of the SH2 domain, is capable of interacting with the substrate 
binding site of the kinase domain in JAK2, acting as a pseudosubstrate and thus 
inhibiting the catalytic activity of JAK2 and activation of signalling from the 
associated receptor (Sasaki et al., 1999; Yasukawa et al., 1999). Specifically, 
Tyr31 of SOCS3 and Tyr65 of SOCS1 have been identified as the residues 
responsible for the pseudosubstrate inhibition of JAK2 (Bergamin et al., 2006). 
Interestingly, structural data relating to this interaction has revealed that it is 
implausible for Tyr31 or Tyr65 to reach the active kinase domain of JAK2 whilst 
bound via the SH2 domain i.e. in cis (Bergamin et al., 2006). This does not rule out 
the possibility that the SOCS proteins could bind to one JAK via their SH2 domain 
and inhibit another JAK via pseudosubstrate inhibition i.e. in trans, or the 
possibility that binding of the SOCS SH2 domain to the specific phosphotyrosine 
residues as outlined above positions the KIR for binding to the kinase domain of 
associated JAK2. This appears to be a more likely scenario than the former trans 
concept, since the crystal structure of the SOCS3/gp130 and various structural 
data favour the physiological target of SOCS3 SH2 domain to be pTyr757/759 of 
mouse/human gp130 and not the activation loop of JAK2 (Bergamin et al., 2006). 
3. The SOCS box present within all SOCS members can recruit elongins B 
and C, which together with cullin 5 and RING-box 2 (Rbx2) form an E3 ubiquitin-
ligase complex. This complex associates with enzymes E1, a ubiquitin-activating 
enzyme and E2, a ubiquitin-conjugating enzyme, to mediate Lys48 
polyubiquitination and subsequent proteasomal degradation of signalling 
components bound to the SOCS proteins via their SH2 domains (Kamura et al., 
2004; Ungureanu et al., 2002; Zhang et al., 1999a). A possible ubiquitination site, 
Lys-6 is also present at the N-terminus of SOCS3. A truncated isoform of SOCS3 
lacking this site has a much longer half-life than the wild-type SOCS3, suggesting 
that Lys-6 plays an important role in proteasomal degradation. Moreover, this 
demonstrates that SOCS3 expression can be regulated at a post translational 
level (Sasaki et al., 2003).  
Ubiquitin-mediated degradation has been proposed to be quite a generic 
mechanism of degradation, since SOCS proteins can potentially target the whole 
receptor-cytokine complex including the JAKs, plus the SOCS proteins themselves 
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for proteasomal degradation by the proteasome. It poses the question of how 
SOCS proteins selectively block JAK signalling at one type of receptor and leave 
other receptors using the same JAKs? This could possibly be explained by using 
the former concept mentioned in 2 above i.e. that SOCS SH2 domains could be 
preferentially binding the specific phosphotyrosine residues on activated receptors 
rather than JAKs, thereby causing degradation of associated JAKs as well as the 
receptor-cytokine complex, and achieving specifity at the receptor level. Indeed, it 
has been shown that mutation of Tyr757 to Phe on murine gp130 is sufficient to 
cause enhanced IL-6-inducible gene expression (Anhuf et al., 2000). Furthermore, 
bone marrow-derived macrophages (BMDM) isolated from mice with a mutation of 
Tyr757 to Phe in gp130 is sufficient to switch the IL-6 mediated response to an ‘IL-
10-like’ anti-inflammatory response, in terms of inhibiting LPS-induced induction of 
pro-inflammatory cytokines (El Kasmi et al., 2006). Previous studies have linked 
the absence of SOCS3 with the establishment of the anti-inflammatory response 
following IL-6 treatment (Yasukawa et al., 2003) as will be discussed later, so the 
former data suggests that mutation of only the specific phosphotyrosine that binds 
SOCS3 is sufficient to cause cytokine receptors to become refractory to SOCS 
inhibition, despite the presence of JAKs. Specific phosphotyrosine binding of 
SOCS members therefore appears to be the main mode of SOCS3 association 
with the receptor and not JAK association via the SH2 domain. This is in contrast 
to SOCS1, since studies have shown that the phenotype of SOCS1- deficient mice 
can only be partially rescued in mice with SOCS1 lacking the SOCS box, but 
retaining the SH2 domain. This shows that both the SOCS box and SH2 domain 
are required for the inhibitory effects on IFN-γ signalling (Zhang et al., 2001). 
In contrast to the above findings of SOCS interaction with elongins B and C, 
leading to proteasomal degradation, some studies have found that interaction with 
the elongin BC complex can stabilise SOCS3 (Haan et al., 2003) and SOCS1 
(Kamura et al., 1998). Haan et al. (2003) showed that tyrosine phosphorylation of 
SOCS3 disrupted elongin interaction, which accelerated SOCS3 degradation. This 
may suggest that tyrosine phosphorylation of SOCS3 is a prerequisite to 
proteasomal degradation. Indeed, Haan et al. (2003) suggested that the elongin 
BC interaction with SOCS3 may function to associate SOCS3 with a latent 
ubiquitination complex that only becomes active when SOCS3 is phosphorylated. 
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SOCS phosphorylation causes the dissociation of elongin C and the bringing 
together of the ubiquitination machinery into close proximity with SOCS3, 
subsequently triggering its degradation (Haan et al., 2003). This concept therefore 
combines the both views of elongin BC interaction and proteasomal degradation.  
 
1.4.5.2 SOCS Proteins as Regulators of Other Signalling Pathways 
In addition to the involvement of SOCS proteins in cytokine signalling, SOCS1 and 
SOCS3 have been shown to bind both EGF and FGF receptors (EGFR, FGFR) 
and affect downstream signalling events, in both positive and negative ways (Ben-
Zvi et al., 2006; Xia et al., 2002). With regards to EGF signalling, SOCS1 and 3 
have been shown to facilitate EGFR proteasomal degradation in HEK293 cells 
(Xia et al., 2002), while SOCS1 has been shown to inhibit STAT1 phosphoryation, 
but elevate ERK phosphorylation in response to FGF treatment in rat 
chondrosarcoma (RCS) cells (Ben-Zvi et al., 2006). Furthermore, SOCS1 and 
SOCS3 have been demonstrated to associate with insulin receptor substrate 1 
(IRS1) and IRS2 following insulin stimulation and interact with the elongin BC 
ubiquitin-ligase complex to promote Lys48 polyubiquitination and degradation (Rui 
et al., 2002). 
As mentioned earlier, SOCS3 offers another level of regulation by being able to 
become tyrosine phosphorylated itself on residues 204 and 221 located in the 
SOCS box by IL-2, erythropoietin (EPO), epidermal growth factor (EGF) and 
platelet-derived growth factor (PDGF) (Cacalano et al., 2001). The phosphorylated 
tyrosine residue 221 has also been shown to associate with and inhibit RasGAP. 
Using a murine B cell line, it was found that WT SOCS3 could inhibit IL-2-
mediated STAT5 phosphorylation, but maintain IL-2-mediated ERK 
phosphorylation, whereas a Tyr204/221Phe mutant SOCS3 still inhibited STAT5 
phosphorylation, but in contrast to the WT, abolished ERK phosphorylation, 
suggesting a phosphorylation-dependent maintenance of ERK signalling. 
(Cacalano et al., 2001). This inhibitory effect of the mutant was also observed 
following EPO and PDGF treatment. Thus, phosphorylation of Tyr204 and Tyr221 
of SOCS3 following growth factor stimulation leads to pTyr221 interaction with the 
SH2 domain of RasGAP, which subsequently sustains the activation of Ras and 
ERK. The duration of ERK signalling has been shown to be important for 
determining biological outcome, for example sustained activation of ERK has been 
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shown to be required for the control of G1 progression by regulating cyclin D1 
activation (Weber et al., 1997). SOCS3 therefore appears to have pathway-
specific effects as well as receptor-specific effects, and appears to show positive 
regulation as well as its well-known negative regulation, adding further 
complexities to its actions.  
Another level of complexity demonstrated by SOCS proteins is their ability to 
interact with other SOCS family members (Piessevaux et al., 2006; Tannahill et 
al., 2005). For example, although SOCS2 plays a major role in the negative 
regulation of GH signalling (Greenhalgh et al., 2005), it has also been shown to 
enhance GH signalling. This is believed to be caused by the binding of SOCS2 to 
other SOCS members and modulating their activity via the elongin BC complex, 
with subsequent proteasomal degradation (Piessevaux et al., 2006; Tannahill et 
al., 2005). This SOCS2-mediated inhibitory effect on other SOCS members has 
been observed on SOCS1- and SOCS3-dependent inhibition of growth hormone 
(GH) signalling, thus potentiating GH signalling (Piessevaux et al., 2006). SOCS2 
has also been shown to enhance IL-2 and IL-3 signalling (Tannahill et al., 2005) by 
accelerating proteasome-dependent degradation of SOCS3. Similar effects again 
have been shown on signalling via the IFN type 1 and leptin receptors (Piessevaux 
et al., 2006). These observations imply that SOCS2 is counteracting the effects of 
other SOCS proteins, rather like a secondary negative feedback mechanism, to 
limit the effects of excessive levels of SOCS proteins. This assumption is 
supported by the findings that SOCS2 induction usually occurs a long time after 
cytokine stimulation and is prolonged, whereas SOCS1 and SOCS3 expression is 
typically quite rapid and transient (Adams et al., 1998; Pezet et al., 1999). 
Although quite poorly understood, SOCS6 and SOCS7 have also been shown to 
bind other SOCS members and similar effects to SOCS2 have been observed for 
SOCS6 (Piessevaux et al., 2006). Again, this data suggests that SOCS proteins 
can act as positive and negative regulators of signalling pathways and could 
explain some reported anomalies, such as the enhanced insulin signalling 
observed in transgenic mice overexpressing SOCS6 (Li et al., 2004) or the 
gigantism observed in transgenic mice overexpressing SOCS2 (Greenhalgh et al., 
2002). 
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1.4.5.3 Functional Roles of SOCS Proteins 
The functions of SOCS proteins have largely been elucidated by the generation of 
mice engineered to lack particular SOCS genes. These studies have greatly 
enhanced our understanding of the roles SOCS proteins play, particularly with 
regards to the immune response, and have also identified key definitive roles of 
individual SOCS members, such as the non-redundant role SOCS1 appears to 
play in IFNγ signaling (Alexander et al., 1999; Marine et al., 1999) (Table 3). 
However, this is not always the case and knock-out models can encounter 
problems. Due to placental insufficiency, SOCS3-null mice die at mid-gestation 
(Roberts et al., 2001; Takahashi et al., 2003). To overcome this, other ways of 
investigating SOCS3 deficiency have been explored. A genetic cross study 
conducted by Robb et al. (2005) showed that mice on a leukaemia-inhibitory factor 
(LIF)/SOCS3-null background were rescued from embryonic lethality due to 
placental failure, and the mice appeared normal at birth (Robb et al., 2005). It is 
believed that the deletion of SOCS3 leads to dyregulated LIF signalling through 
the LIFRα-chain, which alters trophoblast differentiation and causes placental 
defects (Boyle & Robb, 2008). In support of this is the finding that the number of 
trophoblast giant cells are reduced in LIFRα-null mice, compared with an 
abnormally high number of trophoblast giant cells in SOCS3-null mice (Takahashi 
et al., 2003). Although embryonic lethality is rescued, a high neonatal mortality 
rate is observed in SOC3-/-LIF-/- mice and adult mice develop a fatal inflammatory 
disease, which is very similar to that seen in mice with a conditional deletion of 
SOCS3 in hematopoietic cells (Croker et al., 2004). LIF-/- mice, on the other hand 
have a normal lifespan and do not exhibit any major hematopoietic abnormalities. 
This suggests that SOCS3 plays a vital role in the negative regulation of the 
inflammatory response. 
Another way to overcome SOCS3 embryonic lethality is the generation of 
conditional knock-outs, using the Cre recombinase and loxP system. In this way, 
the modified target gene can be ablated in adulthood, thus avoiding the placental 
insufficiency as observed with SOCS3 knock-outs. Furthermore, this ablation of 
the gene can be targeted to any tissue at any defined time. This is a powerful tool 
for the examination of genes that appear to be crucial during embryonic 
development, but may play important roles in particular adult tissues (Sauer, 
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1998). Applying this system with irradiated mice reconstituted with SOCS3-/- fetal 
liver cells, the SOCS3 gene has been specifically deleted in the liver and in 
macrophages. The absence of SOCS3 results in prolonged STAT3 and STAT1 
activation following IL-6 treatment, but normal activation of STAT1 in response to 
IFNγ and normal activation of STAT3 in response to IL-10 (Croker et al., 2003; 
Lang et al., 2003). SOCS3 deficiency also upregulates several IFNγ-responsive 
genes following IL-6 treatment, which is not observed upon IL-6 stimulation of cells 
with functional SOCS3 alleles. This suggests that STAT1 provokes a dominant 
IFNγ-like gene expression profile owing to excessive STAT1 phosphorylation and 
activation. Furthermore, a mutation in gp130 (Tyr759Phe) in mice, which impedes 
SOCS3 and/or SHP2 recruitment, was shown to result in a phenotype displaying 
rheumatoid arthritis (RA)-like joint disease, a condition known to be associated 
with dysregulation of IL-6 signalling (Atsumi et al., 2002). Collectively, these 
studies show that SOCS3 is the main physiological regulator of IL-6 signalling and 
that SOCS3 can regulate the specificity of the cytokine response as well as the 
duration of the signal (Croker et al., 2003; Lang et al., 2003).  
Interestingly, in the absence of SOCS3 in mouse macrophages, IL-6 has been 
shown to induce an ‘IL-10-like’ anti-inflammatory response, as demonstrated by a 
reduction in LPS-induced production of TNFα and IL-12, by IL-6 in SOCS3 
deficient cells. (Yasukawa et al., 2003). This is interesting because there is 
currently no explanation as to why these two cytokines have such diverse effects. 
Both cytokines use identical JAK-STAT members and yet have very distinct gene 
expression patterns (Figure 1.12) (Murray, 2007). IL-10 has been shown to be 
anti-inflammatory in macrophages and dendritic cells, activating a different set of 
genes from IL-6, but both cytokines also activate a common pool of genes, 
including SOCS3 (Murray, 2007). Yasukawa et al. (2003) proposed that the 
difference in gene expression may be due to the intensity of the STAT3 signal. 
However, Murray (2006) has identified flaws in this concept, for example the 
strength of the signal does not account for the commonality of genes activated by 
the two cytokines. One obvious difference between the two cytokines is the 
involvement of SOCS3 as an inhibitory step in IL-6 signalling, but not in IL-10 
signalling. Studies have shown that if modified receptors are used, which are 
either naturally insensitive to SOCS3 (e.g. IL-22R) or engineered to be insensitive 
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(e.g. IL-6, leptin receptors), but activate STAT3, an anti-inflammatory response is 
triggered (El Kasmi et al., 2006). Thus, based on SOCS3 involvement, a 
hypothesis has been proposed describing the activation of a generic pool of 
STAT3 by the IL-10R, which is not subjected to any inhibition by SOCS3. The IL-
6R, on the other hand activates a different pool of STAT3, which is specifically 
inhibited by SOCS3, possibly via post-translational modification by kinases or 
phosphatases etc. These different pools of STAT3 may therefore go on to activate 
very different sets of genes. This is just one idea put forward by Murray (2007) and 
highlights the gaps in our understanding of the various modes of action of SOCS3 
on signalling pathways and hence the importance of further studies.   
With regards to leptin signaling, mice with a neural-specific deletion of SOCS3 
have been generated using the Cre-loxP system. Similar to the IL-6 data 
presented above, SOCS3 deletion results in prolonged activation of STAT3 in 
response to leptin. Moreover, SOCS3 deficient mice exhibited a greater body 
weight loss when compared to their wild-type littermates. These knock-out mice 
were also resistant to high fat diet-induced weight gain and hyperleptinaemia, and 
retained insulin sensitivity. This study showed that SOCS3 is a key regulator of 
leptin signalling and hence plays an important role in diet-induced leptin and 
insulin resistance (Mori et al., 2004). A number of studies support this link between 
SOCS3 and leptin resistance, whereby leptin-mediated induction of SOCS3 has 
been associated with the attenuation of OB-Rb signalling (Bjorbaek et al., 1998). 
Chronic stimulation of OB-Rb has been shown to result in the desensitisation of 
OB-Rb signalling, whereby the receptor becomes refractory to re-stimulation. 
Mutation of the STAT3 binding site on OB-Rb (Tyr1138Ser), which mediates 
STAT3-induced SOCS3 induction, alleviates this feedback inhibition. Moreover, 
RNA interference-mediated knock-down of SHP2 had no effect on the attenuation 
of OB-Rb signalling, suggesting a role for SOCS3 in the feedback inhibition of OB-
Rb signalling and not SHP2 (Dunn et al., 2005).  
 
1.5 Aim  
The anti-inflammatory effects of cAMP have been well documented, notably with 
regards to endothelial barrier function. However, the exact molecular mechanisms 
underlying these effects are still unclear. To investigate this further in the context 
of endothelial inflammation, the signalling pathways of IL-6 and leptin will be 
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examined in response to cAMP elevation in two endothelial cell types; human 
umbilical vein endothelial cells (HUVECs) and a novel human endothelial 
angiosarcoma-derived cell line (AS-M). Focus will be placed on SOCS3 as a 
potential mediator of the possible inhibitory effects, since previous experiments in 
the Palmer lab have demonstrated SOCS3 induction in response to cAMP 
elevation. Refer to Figure 1.13 for a diagram of the working hypothesis. In 
addition, this study also aims to further characterise AS-Ms in the context of both 
cytokine and cAMP signalling, since there are currently very limited studies on AS-
Ms in the public domain. This endothelial cell line represents a less costly cell 
system when compared to HUVECs and could prove to be a tractable endothelial 
model for future research in endothelial biology.  
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Figure 1.1 The structure of AC  
 
AC comprises 12 transmembrane (TM) domains, which can be divided into TM1 
and TM2 and 2 cytoplasmic domains labelled C1 (in blue) and C2 (in red). The C1 
and C2 domains can be further divided into C1a and C2a, which are highly 
conserved, forming the catalytic core and the less conserved C1b and C2b 
domains. 
(Taken from Cooper et al., 2003) 
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Figure 1.2 Schematic Representations of the Domain Structure of Epac1 and 
Epac2 
 
CDC25HD – CDC25 homology domain with GEF activity, RA - Ras association 
domain, REM – Ras exchanger motif, B-site – cAMP binding domain, DEP – 
disheveled Egl-10 pleckstrin domain, A-site – cAMP binding domain. 
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Figure 1.3 IL-6-type Receptor Complexes 
 
All members of the IL-6-type cytokines signal via gp130, some via homodimers of 
gp130 like IL-6/IL-Rα, the majority via heterodimers of gp130 and LIFR, like LIF 
and lastly via heterodimers of gp130 and LIFR or OSM-R, like OSM 
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Figure 1.4 Structure of IL-6  
 
IL-6 comprises 4 long α-helices, denoted A, B, C and D and receptor binding sites 
I, II and III shown by circles.  
(Taken from (Heinrich et al., 2003).  
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Figure 1.5a & b Schematic Representations of the JAK Homolgy (JH) and 
STAT Domains 
 
The JH domanins are numbered 1-7, from the carboxyl to the amino terminus. 
These constitute the kinase, pseudo-kinase, SH2 and FERM domains. The STAT 
domains include the N-terminal dimerisation domain, the coiled-coil domain, the 
DNA binding domain, the linker domain, the SH2 domain and the C-terminal 
conserved tyrosine residues and transactivation domain. 
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Figure 1.6 Evolutionary Conserved Raf-MEK-ERK Pathway  
 
Conventionally, the serine/threonine kinase Raf (MAPKK), of which there are 3 
isoforms; A-Raf, B-Raf and Raf-1, is activated by Ras GTPases, which are 
themselves activated by most cell-surface receptors. All 3 isoforms of Raf are 
capable of activating MEK (MAPKK) by phosphorylation of 2 serines in the 
activation loop. MEK is a dual-specificity kinase, which activats ERK (MAPK) by 
phosphorylating threonine and tyrosine residues in a TEY motif, present in the 
activation loop. Both MEK and ERK have two isoforms, which are mostly co-
regulated. 
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Table 1 ERK 1,2 Substrates 
 
More than 150 ERK1/2 substrates have been identified. These substrates can be 
classified into transcription factors, protein kinases and phosphatases, cytoskeletal 
proteins, signalling proteins, apoptotic proteins and proteinases, and other types of 
proteins. (Table taken from (Lu & Xu, 2006). 
Transcription 
factors 
Kinases and 
phosphatases 
Cytoskeletal 
proteins 
Signalling 
proteins 
Apoptotic 
proteins & 
proteinases 
Other proteins 
AML1 (RUNX1) DAPK Annexin XI EGFR Bad Amphiphysin 1 
Androgen receptor ERK1/2 Caldesmon ENaCβ/γ Bim-EL CPSII/CAD 
ATF2 FAK1 Calnexin Fe65 Calpain CR16 
BCL6 GRK2 CENP-E FRS2 Caspase 9 GRASP55 
BMAL1 Inhibitor-2 Connexin-43 Gab1 EDD GRASP65 
CBP Lck Cortactin Gab2 IEX1 HABP1 
C/EBPβ MAPKAP3 Crystallin GAIP MCL-1 Histone H 
CRY1/2 MAPKAP5 DOC1R Grb10 TIS2 HnRNP-K 
E47 MEK1/2 Dystrophin IRS1 TNFR CD120a KIP 
Elk1 MKP1/2 Lamin B2 LAT  MBP 
ER81 MKP7 MAP1 LIFR  PHAS-I 
ERF MLCK MAP2 MARCKS  CPLA2 
Estrogen receptor MNK1/2 MAP4 Naf1α  Rb 
c-Fos MSK1/2 MISS PDE4  SAP90/PSD95 
Fra1 PAK1 NF-H PLCβ  Spinophilin 
GATA1/2 PTP2C NF-M PLCγ  Topoisomerase 
II 
HIF1α Raf1 Paxillin Potassium 
channel Kv 4.2 
 Tpr 
HSF1 B-Raf Stathmin KSR1  TTP (Nup47) 
ICER RSK1-4 SW1/SNF Rab4  Tyrosine 
hydroxylase 
c-Jun S6K Synapsin 1 SH2-B  Vif 
Microphthalmia Syk Tau ShcA  Vpx 
c-Myc  Vinexin β Sos1   
N-Myc   Spin90   
Net (Sap2)   TSC2   
NFATc4      
NF-IL6      
NGFI-B/TR3/Nur77      
Pax6      
PPARγ      
P53      
Progesterone 
receptor 
     
RNA Pol. II      
PUNX2      
Sap1      
Smad1      
Smad2/3      
SP1      
SRC1      
SREBP1/2      
STAT1/3      
STAT5a      
TALI1/SCL      
TFII-I      
TFIIIB      
TGIF      
TIF1A      
UBF      
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Figure 1.7 IL-6-activated STAT and ERK1,2 Signalling Cascade 
 
IL-6 signals via gp130 homodimers. IL-6 cannot bind and activate gp130 directly, it 
first needs to bind an IL-6 receptor α-subunit (IL-6Rα). ECs do not express IL-6Rα, 
but soluble forms of the receptor, termed soluble IL-6Rα (sIL-6Rα) are shed from 
adjacent leukocytes at sites of inflammation. The sIL-6Rα/IL-6 trans-signalling 
complex binds and activates gp130, which causes conformational changes in the 
gp130 homodimer. JAK1, which is bound to gp130 via conserved box1 and box2 
regions, becomes phosphorylated as a result of these conformational changes. 
JAK1 phosphorylation and activation leads to the phosphorylation of specific Tyr 
residues, which provide docking sites for SH2 domain-containing proteins for 
downstream signalling. Two major pathways activated by gp130 are the STAT 
pathway and the ERK pathway. PTyr759 serves as a docking site for SHP2, which 
becomes phosphorylated via JAK1 and leads to the activation of the ERK 
pathway. PTyr767, 814, 905 and 915 are all docking sites for STAT3, whereas 
pTyr905 and 915 can also recruit STAT1. STAT3 appears to be the predominant 
STAT activated during IL-6 signalling. Following STAT phosphorylation via JAK1, 
homo-and/or heterodimerisation complexes are formed. 
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Figure 1.8 Leptin Receptors 
 
A diagram of the 6 leptin isoforms, OB-Ra - f, showing the cytokine homology 
domains (CHD2), the fibronectin type III domains (F-III), the box1, 2 motifs and the 
phospho-Tyr residues of OB-Rb. 
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Figure 1.9 Leptin-activated STAT and ERK1,2 Signalling Cascade 
 
Leptin signals via OB-R homodimers. Leptin can bind to one of six isoforms of OB-
R, however, only OB-Rb has full signalling capability, due to the presence of key 
phosphoTyr residues on its intracellular domain (Y985, Y1077 and Y1138). Leptin 
binding causes conformational changes in the OB-R homodimer, which allow 
JAK2 transphosphorylation. JAK2 is associated with the conserved box1 region on 
OB-R. JAK2 phosphorylation and activation leads to the phosphorylation of 
specific Tyr residues, which provide docking sites for SH2 domain-containing 
proteins for downstream signalling. Two major pathways activated by OB-Rb are 
the STAT pathway and the ERK pathway. PTyr985 serves as a docking site for 
SHP2, which becomes phosphorylated via JAK2 and leads to the activation of the 
ERK pathway. In addition, ERK activation has also been demonstrated in the 
absence of OB-Rb phosphorylation, yet requires JAK2 activation. With regards to 
STAT activation, pTyr1077 provides a docking site for STAT5, whereas pTyr1138 
recruits STAT1, STAT3 and STAT5. However, STAT3 appears to be the 
predominant STAT activated during leptin signalling. Following STAT 
phosphorylation via JAK2, homo-and/or heterodimerisation complexes are formed. 
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Table 2 PIAS Regulated Proteins 
 
PIAS proteins have been shown to regulate more than 60 proteins, with most of 
these constituting transcription factors. The proteins in the table are the main 
proteins shown to interact with PIAS proteins in immune regulation. 
(Taken from Shuai & Liu, 2005) 
 
Interacting Protein PIAS 
Inteferon Pathways 
 
STAT1 PIAS1, PIASγ, PIAS3, PIASx-α 
STAT3 PIAS3 
STAT4 PIASx 
STAT5 PIAS3 
GFI1 PIAS3 
ATBF1 PIAS3 
IRF1 PIAS3 
IRF3, -7 PIASγ 
NF ­ κB Pathways 
 
NF - κB p65 PIAS1, PIAS3 
TRIF PIASγ 
SMAD Pathways  
SMAD3 PIAS3, PIASγ 
SMAD4 PIAS1, PIASx-β 
Oncoproteins and Tumour 
Suppressor Proteins 
 
p53 PIAS1, PIASx-β 
p73 PIAS1, PIASx 
JUN PIAS1, PIASx 
MYB PIASγ 
MDM2 PIAS1, PIASx-β 
PLAG1 PIAS1, PIASγ 
LEF1 PIASγ 
Viral Proteins  
IE2 PIAS1 
RTA PIAS1 
E1 PIAS1, PIASx 
NP PIAS1, PIASx-β 
Others  
C/EBP-ε PIAS1, PIASx 
SATB2 PIAS1 
MITF PIAS3 
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Figure 1.10 Schematic Representation of the Model of SHP2 Phosphatase  
Activation  
 
In the inactive state, the SH2 domain of SHP2 appears to sterically hinder the 
access of phosphoTyr substrates to the protein Tyr phosphatase (PTP) domain 
and inhibit phosphatase activity. Activation of the phosphatase occurs in 2 ways; 
(1) the SH2 domains can bind to phosphoTyr motifs on activated receptors, which 
leads to unfolding of the protein and subsequent phosphatase activation or (2) the 
SH2 domains can bind to the phosphoTyr residues 542 and 580 on the C-terminal 
tail of SHP2 itself and cause conformational changes, which leads to activation.  
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SH2 SH2
Y580
Y542
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Y580 Y542Y580
Y542
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Y
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Figure 1.11 The Three Main Mechanisms Utilised by SOCS Proteins to 
Downregulate Cytokine Signalling 
 
(1) Binding of SOCS proteins to specific phosphotyrosine residues on receptors 
and physically blocking occupation of docking sites of other SH2 domain-
containing signalling proteins, such as SHP2. 
(2) The kinase inhibitory region (KIR) of SOCS1 and SOCS3 binding to the kinase 
domain of JAK and inhibiting JAK activation. 
(3) The SOCS box of SOCS proteins recruiting the ubiquitin-ligase machinery and 
promoting the proteosomal degradation of signalling proteins bound to SOCS via 
their SH2 domains.   
The orange oval represents SH2 domain-containing signalling proteins.  
(Adapted from Howard & Flier, 2006) 
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Table 3 SOCS Knockout in Mice  
 
The major consequences of SOCS knockout in vivo, with tissue-specific knock-
outs described in the text (Section 1.4.5.3).  
 
 
Gene Knockout mice 
CIS Has no detectable abnormal 
phenotype (Marine et al. 1999). 
SOCS1 Neonatal lethality, due to 
dysregulation of IFNγ signalling. 
(Marine et al., 1999). Additionally, 
fatty degeneration in liver, 
hematopoietic infiltration of multiple 
organs and lymphoid deficiencies 
(Starr et al., 1998). 
SOCS2 Gigantism and dysregulation of GH 
signalling (Metcalf et al., 2000). 
SOCS3 Embryonic lethality due to placental 
defects (Marine et al., 1999, Roberts 
et al., 2001, Takahashi et al., 2003). 
SOCS6 Mild growth retardation (Krebs et al., 
2002). 
SOCS7 Enhanced insulin sensitivity and 
increased growth of pancreatic islets 
(Banks et al., 2005).  
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Figure 1.12 IL-6 and IL-10 Signalling 
 
IL-6 and IL-10 signal via identical JAK-STAT members, but activate different sets 
of genes; IL-10 activates a subset of anti-inflammatory genes, whereas IL-6 
activates a sub-set of IL-6 regulated genes. SOCS3 is representative of a 
‘common’ subset of genes activated by both cytokines. 
(Taken from Murray et al., 2007) 
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Figure 1.13 Diagram of the Working Hypothesis 
cAMP-elevating stimuli, such as β-adrenergic catecholamines, histamine, 
prostaglandins and adenosine bind to their respective G protein coupled receptors 
(GPCRs) to activate the adenylyl cyclase signalling pathway, resulting in increased 
intracellular cAMP levels. cAMP then activates Epac, a cAMP-activated guanine 
nucleotide exchange factor for the small GTPases Rap1 and Rap2. Active 
Rap1GTP goes on to trigger SOCS3 induction, possibly via the C/EBP family of 
transcription factors. SOCS3 accumulation subsequently leads to the inhibition of 
sIL-6Rα/IL-6-and leptin-stimulated ERK1,2 and STAT3 activation. 
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2.1 Materials 
 
Abcam plc., Cambridge, UK 
SOCS3 Ab        (cat. no. ab16030) 
Phospho-CREB (Ser133) Ab     (cat. no. ab3419) 
Sp1 Ab       (cat. no. ab13370) 
 
Autogen Bioclear UK Ltd., Calne, UK 
SOCS3 si-RNA (h)      (cat. no. sc-41000) 
Control siRNA-A      (cat. no. sc-37007) 
 
Biolog Life Science Institute, Bremen, Germany 
8-(4-Chlorophenylthio)-2’-O-methyl-cAMP   (cat. no. C 041) 
 
Cell Signaling Technology (New England BioLabs UK Ltd.) Herts, UK 
Phospho-p44/42 MAPK (Thr202/Tyr204) mouse mAb  (cat. no. 9106) 
Phospho-STAT3 (Tyr705) mouse mAb    (cat. no. 9138) 
p44/42 MAPK Ab       (cat. no. 9102) 
STAT3 Ab        (cat. no. 9132) 
 
Dharmacon RNA Technologies, Lafayette, CO 
Epac1-targeted siRNA     (cat. No. M-007676-00) 
 
GE Healthcare UK Ltd., Buckinghamshire, UK 
Rainbow molecular weight marker    (cat. no. RPN 756) 
 
Inverclyde Biologicals, Bellshill, UK 
Protan nitrocellulose transfer membrane   (cat. no. 10401396) 
 
Invitrogen Ltd., Paisley, UK 
Opti-MEM®, reduced serum medium   (cat. no. 31985-047) 
Oligofectamine reagent     (cat. no. 12252-011) 
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Lonza Wokingham Ltd., Berkshire, UK 
Dulbecco's Phosphate Buffered Saline (DPBS)  (cat. no. BE17-512F) 
EGM bulletkit       (cat. no. CC-3162) 
Pooled HUVEC cryopreserved in EGM    (cat. no. CC-2519) 
 
Merck Biosciences, Nottingham, UK 
MG-132        (cat. no. 474790) 
Forskolin        (cat. no. 344270) 
Rolipram       (cat. no. 557330) 
H89        (cat. no. 371963) 
U0126       (cat. no. 662005) 
Phorbol-12-myristate-13-acetate (PMA)   (cat. no. 524400) 
 
Perkin Elmer Life and Analytical Sciences, Monza, Italy 
Enhanced chemiluminescence (ECL) reagents   (cat. no. NEL 104) 
 
Pierce (Perbio Science UK Ltd.) Northumberland, UK 
Restore western blot stripping buffer    (cat. no. 21059) 
 
Promega, Southampton, UK 
Wizard plus miniprep DNA purification system  (cat. no. A7100) 
Passive lysis 5x buffer      (cat. no. E1941) 
 
Qiagen Ltd., Crawley, UK 
Endofree plasmid maxi kit      (cat. no. 12362) 
 
R & D Systems Europe Ltd., Abingdon, UK 
Recombinant human leptin (OB)     (cat. no. 398-LP) 
Recombinant human IL-6      (cat. no. 206-IL) 
Recombinant human sIL-6Rα     (cat. no. 227-SR) 
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Roche Diagnostics Ltd., Burgess Hill, UK 
Fugene® 6 transfection reagent    (cat. no. 11815091001) 
Agarose       (cat. no. 1388991) 
 
Santa Cruz Biotechnology Inc., Heidelberg, Germany 
SOCS3 (m-20) goat polyclonal Ab    (cat. no. sc-7009) 
SOCS3 siRNA (h)      (cat. no. sc-41000) 
Control siRNA-A      (cat. no. sc-37007) 
 
Sigma-RBI, Dorset, UK  
Anti-α-tubulin mAb       (cat. no. T9026) 
Sterile filtered cell culture water     (cat. no. W3500) 
Trypsin – EDTA       (cat. no. T4299) 
Tween – 20        (cat. no. P5927) 
30% (w/v) acrylamide/0.8% (w/v) bis-acrylamide  (cat. no. A3699) 
L-glutamine        (cat. no. G7513) 
Penicillin-streptomycin     (cat. no. P0781) 
Anti-mouse IgG (peroxidase-conjugated)  (cat. no. A4416) 
Anti-rabbit IgG (peroxidase-conjugated)   (cat. no. A6154) 
Soybean trypsin inhibitor     (cat. no. T9003) 
Benzamidine       (cat. no.12072) 
Bovine serum albumin     (cat. no. A7030) 
Bromophenol blue      (cat. no. B7021) 
Ampicillin       (cat. no. A9393) 
N, N, N’,N’-tetramethylethylenediamine (TEMED) (cat. no. T9281) 
Phenylmethylsulphonyl fluoride (PMSF)   (cat. no. P7626) 
Medium 199       (cat. no. M7528) 
Nonidet P-40       (cat. no. N6507) 
Tissue culture bovine serum albumin   (cat. no. A1595) 
 
Wild-type (SOCS3+/+) and SOCS3-/- murine embryonic fibroblasts (MEFs) 
(Kawaguchi et al., 2004) were generously provided by Prof. Akihiko Yoshimura 
(Kyushu University, Japan). 
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Monoclonal anti-Epac1 antibody 5D3 (Price et al., 2004) was generously supplied 
by Prof. Johannes Bos (University Medical Center, Utrecht, Netherlands). 
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2.2 Methods 
 
2.2.1 Cell Culture 
HUVECs and AS-Ms were maintained at 37°C in a humidified atmosphere 
containing 5% (v/v) CO2 in EGM-2 supplemented with 2% (v/v) foetal bovine 
serum (FBS), plus hydrocortisone, hFGF, VEGF, R3-IGF, ascorbic acid, hEGF, 
GA-1000 (Gentamicin, Amphotericin-B) and heparin, as recommended by the 
supplier (Lonza), which will hereafter be referred to as EGM. MEFs were cultured 
in Dulbecco’s Modified Eagle’s Medium supplemented with 10% (v/v) FBS, 2mM 
L-glutamine, 100U/ml penicillin and 100µg/ml streptomycin, which will hereafter be 
referred to as DMEM. Cells were grown until 70% confluence before being 
passaged and seeded into plates or dishes for experimentation or flasks for further 
propagation. Passaging the cells involved washing the cells once with tissue grade 
PBS and adding 2ml of endothelial trypsin (HUVECs and AS-Ms) and 2ml of 
trypsin (MEFs) to each flask. Cells were left for a few minutes at 37°C to allow 
detachment from the flask. Fresh DMEM was added to the MEF cell mixture and 
gently pipetted to resuspend the cells. The HUVEC/AS-M cell mixture was added 
to a 50ml tube containing EGM to neutralise the trypsin and spun down at 200 g 
for 5 minutes. The cell pellet was then resuspended in fresh medium. HUVECs 
and AS-Ms were counted using a haemocytometer and seeded at the following 
densities; 3-4x105 cells per well of a 6 well plate, 12x105 cells per 10cm2 dish.  
 
2.2.2 Transfection of cells using Oligofectamine 
Based on 1 well of a 6 well plate, 3μl Oligofectamine was added to 12μl Optimem 
and incubated for 10 minutes at room temperature. Oligonucleotides were 
resuspended to give the relevant stock concentrations (10μM SOCS3 siRNA, 
20μM Epac1 siRNA). The appropriate volumes of these oligonucleotides were 
then used for experimentation (based on prior optimisation experiments) and 
made up to a final volume of 185μl with Optimem. Following 10 minutes, the 
Oligofectamine mix was added to the oligonucleotides and incubated for a further 
20 minutes at room temperature. During this time, the cells were washed twice 
with Optimem and 1ml Optimem per well was added to the cells. 200μl of 
transfection mix per well was added dropwise to the cells, which were then placed 
back in the incubator for 5 hours. Following 5 hours, 1ml EGM was added to each 
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well and the cells left overnight at 37°C. This procedure was repeated the next day 
and the experimental conditions were applied on the third day. 
 
2.2.3 Transfection of cells using Fugene 
Based on 1 well of a 6 well plate, 0.5-1μg of endotoxin-free DNA was added to 
200μl serum-free medium (Optimem) and mixed. 10μl Fugene was added to the 
DNA suspension and mixed again. The transfection mix was then incubated for 15 
minutes at room temperature before being added dropwise over the cells of each 
well. The cells were incubated overnight at 37°C and the following day the medium 
was replaced with fresh EGM. 
 
2.2.4 Preparation of Cell Extracts for Immunoblotting 
Following treatment of cells with the relevant stimuli, cells were transferred to ice. 
The medium was removed and cells were washed twice with ice cold PBS. Cells 
were then scraped down into 50µl RIPA lysis buffer (50mM HEPES pH7.5, 150mM 
NaCl, 1% (w/v) Triton X-100, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS, 
0.01M sodium phosphate, 5mM EDTA, 0.1mM PMSF, 1μg/ml soybean trypsin 
inhibitor, 1μg/ml benzamidine) and transferred to ice cold micro-centrifuge tubes. 
The tubes were incubated on ice for 20 minutes to allow the proteins to solubilise 
before centrifugation at 20,000 g for 5 minutes at 4°C. The supernatant was 
transferred to fresh micro-centrifuge tubes for determination of protein 
concentration and analysis by SDS-PAGE and immunoblotting. 
 
2.2.5 Bicinchoninic acid (BCA) Assay to Determine Protein Concentration 
Bovine serum albumin (BSA) standards, ranging from concentrations of 0-2 mg/ml 
were added in duplicate to a 96 well plate in volumes of 10μl per well. The same 
volume of each cell lysate sample of unknown concentration was added to the 
plate in duplicate. 200μl of BCA solution (1% (w/v) 4, 4 dicarboxy-2, 2 biquinoline 
disodium salt, 2% (w/v) sodium carbonate, 0.16% (w/v) sodium potassium tartrate, 
0.4% (w/v) sodium hydroxide, 0.95% (w/v) sodium bicarbonate pH 11.25, 0.08% 
(w/v) copper (II) sulphate) was added to each well and incubated at room 
temperature for 10 minutes. Following incubation, protein concentration was 
determined by measuring the absorbance of samples at 492nm (A492) using a 
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MRX-TCII plate reader (Dynex Technologies). The absorbance values of the 
standards were used to construct a best-fit straight-line plot, from which the values 
of the unknown protein samples could be determined. 
 
2.2.6 Bradford Assay to Determine Protein Concentration 
Bovine serum albumin (BSA) standards, ranging from concentrations of 0-2 mg/ml 
were added in duplicate to a 96 well plate in volumes of 10μl per well. The same 
volume of each cell lysate sample of unknown concentration was added to the 
plate in duplicate. 50μl of Bradford’s reagent, which had previously been diluted 
1:4 with distilled deionised water, was added to each well and the samples 
incubated at room temperature for 5 minutes. Following incubation, protein 
concentration was determined by measuring the absorbance of samples at 630nm 
(A630) using a MRX-TCII plate reader (Dynex Technologies). The absorbance 
values of the standards were used to construct a best-fit straight-line plot, from 
which the values of the unknown protein samples could be determined. 
 
2.2.7 SDS-PAGE and Immunoblotting  
Each sample was equalised for protein concentration and volume, and 2 x SDS-
PAGE sample buffer (50mM Tris pH 6.8 at room temperature, 10% (v/v) glycerol, 
12% (w/v) SDS, 10mM dithiothreitol, 0.0001% (w/v) bromophenol blue) was 
added. Samples were then subjected to fractionation by SDS-PAGE using a 10% 
or 12% acrylamide resolving gel (10%/12% (w/v) acrylamide, 0.3% (w/v) 
bisacrylamide, 0.4M Tris (pH8.8), 0.1% (w/v) SDS, 0.01% (w/v) ammonium 
persulphate and 0.001% (v/v) TEMED) and a 3% acrylamide stacking gel (3% 
(v/v) acrylamide, 0.1% (v/v) bisacrylamide, 0.1M Tris (pH6.8), 0.1% (w/v) SDS, 
0.001% (w/v) ammonium persulphate and 0.001% (v/v) TEMED). Electrophoresis 
of samples was performed in the presence of pre-stained protein makers 
(Rainbow Markers 14.3 – 220kDa) using Biorad Mini-Protean III gel 
electrophoresis systems and running buffer (24.7mM Tris, 0.19M glycine, 0.1% 
(w/v) SDS) at 150V. The electrophoresis of samples and markers was stopped 
when the bromophenol blue dye front reached the bottom of the gel. Fractionated 
proteins were then electrophoretically transferred to a nitrocellulose membrane at 
400mA for 45 minutes in transfer buffer (24.7mM Tris, 0.19M glycine, and 20% 
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(v/v) methanol). Following transfer the membranes were washed in Tris Buffered 
Saline-Tween (TBST) (20mM Tris, pH7.5, 150mM NaCl, 0.1% (v/v) Tween 20) 
once and transferred to blocking solution (5% (w/v) skimmed milk in TBST) for a 1 
hour incubation with shaking at room temperature. Membranes were then 
incubated with primary antibody diluted in 5% BSA (w/v) in TBST overnight at 4°C 
on a rotating platform. The next day, the membranes were washed three times (10 
minutes/wash) in TBST and incubated with the appropriate HRP-conjugated 
secondary antibody diluted in blocking solution (5% (w/v) skimmed milk in TBST) 
for 1 hour on a rotating platform at room temperature. The membranes were 
washed a further three times in TBST and finally incubated with ECL reagents as 
per the manufacturer’s instructions. Immunoreactive proteins were visualised 
using X-ray film and the optical density of the bands was measured using the 
TotalLab 2003.02 software. Briefly, TotalLab analysis involved a step-wise manual 
approach to allow lane creation (using a semi-automated approach to define the 
number of lanes), background substraction (using the Rolling Ball method) and 
band detection (using 3 parameters; minimum slope, noise reduction and 
percentage maximum peak). Normalisation was performed as appropriate for each 
set of data and the values expressed as a proportion of the selected band.   
 
2.2.8 Preparation of Antibiotic Agar Plates  
LB agar (1% (w/v) bactotryptone, 0.5% (w/v) yeast extract, 1% (w/v) sodium 
chloride, 1.5% (w/v) agar), which had been autoclaved and left to cool before 
addition of 50μg/ml ampicillin was poured into 10cm Petri plates. These plates 
were left overnight at room temperature to solidify. The next day, plates were 
transferred to 4°C for storage.   
 
2.2.9 Plasmid DNA Preparation 
A stab from a glycerol stock was inoculated with 10ml of LB broth (1% (w/v) 
bactotryptone, 0.5% (w/v) yeast extract, 1% (w/v) sodium chloride), supplemented 
with 50μg/ml ampicillin. This was then placed in a shaking incubator overnight at 
37°C. The next day, plasmid DNA was extracted from the culture by using the 
Promega™ Wizard Plus SV mimiprep purification kit as per the manufacturer’s 
instructions. Alternatively, the culture was transferred to 250ml of LB broth, 
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supplemented with 50μg/ml ampicillin and placed back in the shaking incubator 
overnight at 37°C. The next day, plasmid DNA was extracted from the culture 
using the Qiagen endofree plasmid maxi kit as per the manufacturer’s instructions.  
 
2.2.10 Transformation of Competent XL1 Blue E.coli cells 
One vial of XL1 Blue cells was defrosted on ice, before transferring 80µl to a pre-
chilled micro-centrifuge tube. Approximately 30-40ng of plasmid DNA was added 
to the tube and left on ice for 20 minutes. The tube was then incubated at 42°C for 
2 minutes and placed back on ice. 1ml of LB broth was added to the tube and 
incubated for a further 30 minutes at 37°C. Following incubation, 100µl of the 
transformation mix was plated out onto agar plates containing 50μg/ml ampicillin 
and incubated overnight at 37°C. 
 
2.2.11 Reporter Gene Assay 
HUVECs and AS-Ms were seeded into 6 well plates at densities of 3 x 105 
cells/well and 3.5 x 105 cells/well respectively. Cells were left for 24 hours prior to 
replacing the medium with fresh EGM. 1 hour after the medium change, cells were 
transfected with a trans-activator plasmid (Gal4-Elk-1) at 1µg/well, a Firefly 
luciferase reporter plasmid (Gal4-luc) at 1µg/well and a normalisation Renilla 
luciferase plasmid (pRL-CMV) at 0.5µg/well using Fugene reagent as described in 
section 2.2.3. The cells were then incubated overnight at 37°C, prior to another 
medium change with fresh EGM. The cells were left for a further 24 hours before 
treatment with or without leptin (125ng/ml), sIL-6Rα/IL-6 (25ng/ml/5ng/ml) or PMA 
(1µM) for 6 hours. Following treatment, cells were lysed in 50µl passive lysis buffer 
and stored at -80°C. Firefly and Renilla luciferase buffers were prepared fresh for 
each experiment; Firefly luciferase buffer pH8 (25mM Gly-gly, 15mM KXPO4 pH8, 
4mM EGTA, 2mM ATP, 1mM DTT, 15mM MgSO4, 0.1mM CoA enzyme and 
0.075mM luciferin), Renilla luciferase buffer pH5 (1100mM NaCl, 2.2mM 
Na2EDTA, 220mM KXPO4 pH5, 0.44mg/ml BSA, 1.3mM NaN3 and 0.0143mM 
coelentrazine). 30µl of each cell lysate was transferred to a white-walled 96 well 
plate. The plate was then placed into the Luminoskan Acsent luminometer and 
100µl of each of the luciferase buffers was automatically added to each well and 
luminescence was measured. 
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2.2.12 Nuclear Extraction 
12x105 HUVECs or AS-Ms were seeded into 10cm2 dishes. 24 hrs after seeding, 
cells were washed twice in PBS and serum starved for 4 hrs. Following 4 hrs, cells 
were treated with or without leptin (125ng/ml) or sIL-6Rα/IL-6 (25ng/ml/5ng/ml) for 
30 minutes or PMA (1µM) for 5 minutes. Cells were transferred onto ice and 
washed twice with cold PBS before adding 1ml PBS to each dish. The cells were 
scraped down and transferred to ice cold micro-centrifuge tubes for centrifugation 
at 5000 g for 5 minutes at 4°C. The cell pellet was resuspended in 400μl of ice 
cold buffer A (10mM HEPES (pH 7.9), 10mM KCl, 0.1mM EDTA, 0.1mM EGTA, 
1mM DTT), supplemented with protease inhibitors on the day (0.1mM PMSF, 
10μg/μl soybean trypsin inhibitor and 10μg/μl benzamidine) and left on ice for 10 
minutes to allow the cells to “swell”. 25μl of 10% (v/v) NP40 was then added to 
each sample to lyse the cells. Each sample was centrifuged again at 13,000 g at 
4°C for a few seconds to pellet the nuclear fraction. The supernatant containing 
the cytosolic fraction was removed and transferred to fresh micro-centrifuge tubes 
for storage at -80°C. 
The remaining pellet was washed three times in buffer A with brief centrifugation 
(20,000 g for 10 seconds) to remove any residual cytosolic supernatant and then 
resuspended in buffer B (20mM HEPES (pH 7.9), 450mM NaCl, 1mM EDTA, 1mM 
EGTA, 1mM DTT) supplemented with protease inhibitors on the day (0.1mM 
PMSF, 10μg/μl soybean trypsin inhibitor and 10μg/μl benzamidine). Each sample 
was incubated on ice for 15 minutes with brief vortexing every 5 minutes and then 
centrifuged at 13,000 g for 5 minutes at 4°C. The supernatant containing the 
nuclear fraction was transferred to fresh micro-centrifuge tubes and stored at -
80°C. Protein concentrations were measured using Bradford’s assay and samples 
analysed by SDS-PAGE and immunoblotting.  
 
2.2.13 Statistical Analysis 
All statistical analyses were performed using Student’s two-tailed unpaired t-test 
as described in Excel 2007 software. 
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Establishing the cell systems, including the tools and 
conditions to use for the further examination of the working 
hypothesis 
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3. 1 Introduction 
The endothelium is no longer considered an inert layer of cells lining the 
vasculature, but crucially an active layer of cells with many regulatory roles. A 
healthy endothelium presents a non-adhesive and anti-thrombotic surface, which 
maintains vascular tone. Impaired vasodilation is considered the hallmark of 
endothelial dysfunction and reflects impairment of other endothelium functions, 
such as the endothelium’s anti-inflammatory properties (Davignon & Ganz, 2004; 
Landmesser et al., 2004). When damaged, the endothelium assumes a highly 
inflammatory phenotype that leads to localised inflammation and the development 
of inflammatory disease states, including sepsis (Aird, 2003), diabetic retinopathy 
(Hsueh & Anderson, 1992) and atherosclerosis (Ludmer et al., 1986).  
IL-6 and leptin both signal via the same class of receptors, namely the class I 
cytokine family of receptors and both have been shown to be potent pro-
inflammatory cytokines in various cells, such as HUVECs, bovine aortic 
endothelial cells (BAEC) and mouse macrophages (Loffreda et al., 1998; Romano 
et al., 1997; Yamagishi et al., 2001). They can act as acute-phase reactants, 
produced at high levels during inflammation, sepsis and fever (La Cava & 
Matarese, 2004). Importantly, both cytokines have been shown to modulate EC 
function, for example, by upregulating adhesion molecules such as VCAM-1 and 
ICAM-1, increasing MCP-1 and endothelin-1 expression, and inducing oxidative 
stress (Modur et al., 1997; Quehenberger et al., 2002; Romano et al., 1997; 
Yamagishi et al., 2001). Additionally, both have been implicated in the 
development of inflammatory diseases, such as RA and atherosclerosis (Bodary et 
al., 2005; Nishimoto & Kishimoto, 2004).  
The prototypical second messenger cAMP may be considered a crucial 
immunomodulator. Of relevance to the present study is the role that cAMP plays in 
the modulation of important endothelial functions. Many studies have shown that 
cAMP can limit vascular permeability by enhancing barrier function and reducing 
pro-inflammatory effects of cytokines. For example, TNFα-, PMA- or LPS-
stimulated expression of E-selectin has been shown to be inhibited by cAMP 
elevation in HUVECs and human lung microvascular endothelial cells (HLMECs) 
(Blease et al., 1998; Morandini et al., 1996; Pober et al., 1993). Additionally, 
inhibition of neutrophil adherence to TNFα-stimulated HLMECs in response to 
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cAMP elevation has been observed (Blease et al., 1998). Further studies have 
shown that cAMP elevation decreases vascular permeability in HUVECs, and 
increases cortical actin. Thrombin-enhanced permeability has also been observed 
to be reduced by cAMP treatment in HUVECs (Cullere et al., 2005). Another study 
demonstrated decreased vascular permeability and enhanced vascular endothelial 
(VE) cadherin-mediated adhesion in HUVECs following cAMP elevation (Fukuhara 
et al., 2005). It is important to note that the latter two studies proposed that the 
signalling pathway responsible for the observed effects was independent of PKA, 
namely the cAMP/Epac/Rap1 pathway, which is discussed in more detail in 
Chapter 4. Thus, a number of studies support the notion that cAMP reduces 
vascular permeability, and hence maintains barrier function. Although the 
protective effects of cAMP have been well documented, the molecular 
mechanisms involved remain incompletely defined.  
The SOCS family of proteins represent possible mediators of the anti-inflammatory 
effects of cAMP. SOCS3 is one of the better studied members of the family and 
has been shown to be a potent inhibitor of the IL-6 and leptin signalling pathways 
(Bjorbaek et al., 1998; Croker et al., 2003; Lang et al., 2003; Mori et al., 2004). 
Importantly, previous work in this laboratory has shown that elevation of cAMP 
induces a time-dependent accumulation of SOCS3 protein in HUVECs (Sands et 
al., 2006). Thus, the further investigation of this SOCS protein in the context of IL-
6 and leptin signalling in endothelial cells would be of interest in terms of possibly 
elucidating the molecular mechanisms underlying the protective effects of cAMP. 
For this research, two endothelial cell types were utilised; human umbilical vein 
endothelial cells (HUVECs) and an angiosarcoma-derived cell line (AS-M). 
HUVECs have previously been used in the Palmer lab to generate publications in 
the same area of work as the current study (Sands & Palmer, 2005; Sands et al., 
2006). HUVECs have also been widely used in the literature in the context of this 
research area. Thus, for consistency and as an excellent point of reference from 
previous and ongoing research, HUVECs provide a useful and tractable 
endothelial cell model to study. The second cell type AS-M is a novel endothelial 
cell line, which has been established from a cutaneous angisarcoma on the scalp, 
a rare malignant neoplasm originating in the endothelium (Krump-Konvalinkova et 
al., 2003). AS-Ms display a number of endothelial characteristics, for example, the 
expression of proteins known to be present predominantly in endothelial cells such 
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as vWF and CD31 and the induction of adhesion molecules ICAM-1, VCAM-1 and 
E-selectin when challenged with bacterial LPS. Furthermore, they demonstrate 
active uptake of acetylated LDL (acLDL), which is regarded as a typical endothelial 
reaction (Krump-Konvalinkova et al., 2003; Voyta et al., 1984). These 
characteristics are all comparable to those of primary isolated HUVECs. Since the 
establishment of this cell line, the cells have undergone at least 100 population 
doublings. This is an obvious advantage over primary endothelial cells, since all 
primary cells have a limited lifespan. Extended cultivation of endothelial cultures 
typically results in phenotypical cell changes. During the course of the present 
study, HUVECs were passaged to a maximum of 4 passages. AS-Ms in 
comparison underwent many more passages, representing a more tractable 
endothelial cell type which may be used for the generation of stable knock-
ins/outs. For example, one study has used AS-Ms to knock-down the G-protein-
coupled sphingosine 1-phosphate receptor (S1P1) by RNA interference. Long 
term silencing has enabled this group to demonstrate for the first time the 
involvement of S1P in key functions of endothelial cells (Krump-Konvalinkova et 
al., 2005).  
Using these two cell types, the objective of this results chapter was to initially 
establish the cell systems, which will form the basis for further examination of the 
working hypothesis (Section 1.6 of the Introduction). In addition, research carried 
out on the immortal cell line, AS-M will characterise this cell line in the context of 
both cytokine (IL-6 and leptin) and cAMP signalling, since there are currently very 
limited studies on AS-Ms in the public domain. This would be beneficial for two 
reasons. Firstly, AS-Ms represent a more tractable cell system when compared to 
HUVECs because of the potential for stable knock in/outs. Secondly, AS-Ms are 
less costly than HUVECs. Results from this chapter will ultimately characterise this 
cell line, and establish the tools and conditions to use in both cell types for further 
experimentation. 
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3.2 Results 
IL-6 and leptin signal via gp130 and OB-R homodimers respectively. IL-6 first 
binds to a soluble form of the receptor, sIL-6α to generate a trans-signalling 
complex that is capable of efficiently activating gp130, whereas leptin can bind 
directly to one of six isoforms of OB-R. However, only OB-Rb has full signalling 
capability, due to the presence of key phosphoTyr residues on its intracellular 
domain (Fruhbeck, 2006; Heinrich et al., 1998). IL-6 and leptin have both been 
shown to activate the ERK1,2 and STAT3 pathways (Fruhbeck, 2006; Heinrich et 
al., 1998). To compare pathway activation by both cytokines in HUVECs and AS-
Ms in the present study and to identify a suitable timepoint to use in subsequent 
experiments, HUVECs and AS-Ms were treated with IL-6/sIL-6α or leptin over a 
timecourse from 0 to 60 minutes, and phosphorylation of ERK1,2 and STAT3 was 
assessed by immunoblotting.  
In HUVECs, ERK1,2 phophorylation levels (Thr202 and Tyr204 of Erk1, Thr185 
and Tyr187 of Erk2) in response to IL-6/sIL-6α peaked after 15 minutes of 
stimulation (12±3 fold increase over vehicle, p<0.05 n=3 versus vehicle-treated 
control) and declined to 40±7% (n=3) of peak levels at 60 minutes. The protein 
kinase (PKC) activator phorbol 12-myristate 13-acetate (PMA) was included as a 
positive control for ERK1,2 activation in this experiment and subsequent 
experiments, since PMA has been shown by others to be an efficacious activator 
of ERK1,2 in these cells (Sexl et al., 1997) (Figure 3.1). STAT3 phosphorylation at 
Tyr705 in response to IL-6/sIL-6α treatment displayed a similar temporal pattern of 
phosphorylation as ERK1,2 in these cells, peaking at 15 minutes (54±17 fold 
increase over vehicle, p<0.05 n=3 versus vehicle-treated control) and declining to 
41±11% (n=3) of peak levels at 60 minutes (Figure 3.2). In contrast to IL-6 
treatment in these cells, leptin treatment could not produce a consistent pattern of 
ERK1,2 phosphorylation, despite using cells of different passage numbers, and 
cells which had been serum-starved for greater lengths of time (data not shown). 
Levels of phosphorylated STAT3 however, were analysed in response to leptin 
treatment in HUVECs and showed a time-dependent increase in STAT3 
phosphorylation, peaking at 60 minutes (16±2 fold increase over basal, p<0.01 
n=3 versus vehicle-treated control) (Figure 3.3), which is in contrast to the 
transient phosphorylation of ERK1,2 and STAT3 in response to IL-6/sIL-6α. 
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In AS-Ms, ERK1,2 phosphorylation levels following 15 minutes of IL-6/sIL-6α 
treatment were observed to be significantly increased over vehicle-treated control 
(31±11 fold, p<0.05 n=3). STAT3 phosphorylation levels following IL-6/sIL-6α 
stimulation peaked at 30 minutes (49±11 fold increase over basal, p<0.05 n=3 
versus vehicle-treated control) and declined to 70±2% (n=3) of peak levels at 60 
minutes (Figure 3.5). ERK1,2 phosphorylation in response to leptin in these cells 
was maximal at 60 minutes (6±0.3 fold increase over vehicle, p<0.001 n=3 versus 
vehicle-treated control) (Figure 3.6), whereas STAT3 phosphorylation levels in 
response to leptin peaked at 30 minutes (24±5 fold increase over vehicle, p<0.01 
n=3 versus vehicle-treated control) and declined to 81±22% of peak levels by 60 
minutes (Figure 3.7). Thus, these results demonstrate that IL-6/sIL-6α is capable 
of activating both the ERK1,2 and STAT3 pathways in HUVECs and AS-Ms, 
whereas leptin activates ERK1,2 in AS-Ms and STAT3 in both cell types.  
SOCS proteins function as classical negative feedback inhibitors of cytokine 
signalling, since most SOCS proteins are themselves induced by cytokines. 
Following the discovery of these proteins, their induction was almost exclusively 
attributed to the JAK/STAT pathway (Starr et al., 1998). This is due to the 
presence of putative STAT-binding elements in the promoter region of the SOCS3 
gene (He et al., 2003). SOCS3 is thus a well characterized STAT3 target gene and 
this was exploited in the present study for the initial examination of SOCS3 
expression in the cell system following IL-6/sIL-6α or leptin treatment (Bjorbaek et 
al., 1998; Dunn et al., 2005; Starr et al., 1997). Results from this would effectively 
test the antibodies and conditions to use for detection of SOCS3, and would 
contribute towards the validation of the cell system. Additionally, detection of 
SOCS3 in response to IL-6/sIL-6α or leptin treatment may also contribute towards 
the understanding of the observed transient signalling detailed earlier in this 
Results section. HUVECs or AS-Ms were treated with IL-6/sIL-6α or leptin over 0-
90 minutes. In HUVECs, SOCS3 protein began to accumulate at 60 minutes and 
peaked at 90 minutes in response to IL-6/sIL-6α (21±8 fold increase over vehicle, 
n=3) (Figure 3.8) and leptin (9±4 fold increase over vehicle, n=3) (Figure 3.9). The 
same pattern of SOCS3 expression was observed in AS-Ms, whereby SOCS3 
started to accumulate at 60 minutes and peaked at 90 minutes in response to IL-
6/sIL-6α (64±35 fold over vehicle, n=3) (Figure 3.10) and leptin (34±5 fold increase 
over vehicle, p<0.01 n=3 versus vehicle-treated control) (Figure 3.11). Statistical 
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analysis revealed that SOCS3 expression was not significantly increased over 
vehicle-treated control (p>0.05) (except for SOCS3 induction in response to leptin 
in AS-Ms). This is potentially due to the variability in the fold stimulation.   
Further studies on the regulation of SOCS proteins revealed that these proteins 
are not only induced by cytokines, but also by toll-like receptor (TLR) agonists 
(e.g. LPS, CpG-DNA), GH, prolactin, statins and importantly, cAMP (Dalpke et al., 
2001; Gasperini et al., 2002; Lang et al., 2003; Yoshimura et al., 2007). To test 
whether or not SOCS3 could be induced by cAMP elevation in the present study, 
and thus initially test the hypothesis of SOCS3 involvement in the anti-
inflammatory effects of cAMP, SOCS3 protein expression was examined in 
HUVECs and AS-Ms in response to the cAMP-elevating agents, forskolin and 
rolipram. The diterpene forskolin (from the Indian plant Coleus forskolhii) potently 
activates all isoforms of ACs, except for AC9 (Yan et al., 1998). Rolipram is a type 
4 phosphodiesterase inhibitor, which inhibits the degradation of cAMP in 
endothelial cells (Castro et al., 2005). SOCS3 accumulation in response to cAMP 
elevation in HUVECs has already been observed in the Palmer lab (Sands et al., 
2006). To re-affirm this finding in HUVECs and to examine SOCS3 induction in 
AS-Ms, since this has not previously been observed, a combination of forskolin 
(Fsk) and rolipram (Roli) was used to elevate cAMP levels. Treatment of HUVECs 
with Fsk and Roli over 0-5 hours produced a time-dependent accumulation of 
SOCS3 protein (Figure 3.12a [n=1]). The same pattern of accumulation was 
observed in AS-Ms, with greatest levels of SOCS3 protein at 5 hours (8±2 fold 
increase over vehicle, p<0.05 n=3 versus vehicle-treated control) (Figure 3.12b).  
cAMP has been shown to have several effectors, including PKA (Walsh et al., 
1968), Epac (de Rooij et al., 1998), cAMP-regulated ion channels (Fesenko et al., 
1985) and CNrasGEF (Pham et al., 2000). The best characterised of these are 
PKA and Epac. Although PKA has long been thought of as the sole intracellular 
effector of cAMP, the discovery of Epac in 1998 led to the emergence of a key 
player in PKA-independent effects of cAMP (Gonzalez-Robayna et al., 2000; 
Kashima et al., 2001; Laroche-Joubert et al., 2002; Rangarajan et al., 2003; 
Schmidt et al., 2001). Epac is of particular interest in the present study as it has 
been heavily implicated in the modulation of EC function (Fukuhara et al., 2005; 
Kooistra et al., 2005). To examine a role for Epac in the induction of SOCS3, an 
Epac-selective cAMP analogue, 8-(4-chloro-phenylthio)-2'-O-methyladenosine-
87 
 
3',5'-cyclic monophosphate (8CPT-2Me-cAMP [8-pCPT]) was used (Enserink et 
al., 2002). This analogue was used at concentrations ranging from 0-300 µM to 
identify a suitable concentration to use in subsequent experiments. 5 hours was 
chosen as a suitable timepoint to treat both cell types with 8-pCPT, since this was 
the timepoint that exhibited greatest accumulation of SOCS3 following forskolin 
and rolipram treatment. In HUVECs, SOCS3 levels peaked at 200µM (7±4 fold 
increase over vehicle, n=3 versus vehicle-treated control) (Figure 3.13). However, 
this was not found to be statistically significant when compared to vehicle-treated 
control (p>0.05). This is potentially due to the variability in the fold stimulation. In 
AS-Ms, the greatest accumulation of SOCS3 was seen at 300µM (3±1 fold 
increase over vehicle, p<0.01 n=3 versus vehicle-treated control) (Figure 3.14).  
Although 8-pCPT treatment was observed to induce SOCS3 expression, the 
results were not conclusive and they did not discount the involvement of other 
cAMP-dependent effectors. To further examine a role for Epac in cAMP-mediated 
effects, the selective PKA inhibitor H89 was used. H89 inhibits PKA via binding to 
the ATP binding sites of PKA and inhibiting the phosphorylation process (Lochner 
& Moolman, 2006). The use of this inhibitor could potentially discount the 
involvement of PKA (the other major cAMP sensor) in cAMP-mediated effects. 
Thus, to initially determine the effectiveness of this inhibitor in both cell types with 
the aim of using this inhibitor in further experiments to test the working hypothesis, 
cells were treated with forskolin over 0-30 minutes and the PKA-mediated 
phosphorylation of cAMP response element binding protein (CREB) was assessed 
in the presence or absence of H89. CREB is a well characterised PKA substrate 
and is directly phosphorylated by PKA at serine residue 133 (Mayr & Montminy, 
2001). The CREB co-activators CREB-binding protein (CBP) and p300 both bind 
to CREB to form a CREB-CBP/p300 complex, which can then go on to bind to 
cAMP response elements in target genes (Mayr & Montminy, 2001). In HUVECs, 
phosphorylation of CREB in response to forskolin stimulation peaked at 10 
minutes (18±9 fold increase over vehicle, p<0.001 n=3 versus vehicle-treated 
control) and was substantially inhibited by pre-treatment with H89 (87±6% 
inhibition, p<0.001 n=3 versus 10 minute forskolin-treated cells) (Figure 3.15). 
Similarly, levels of CREB phosphorylation in AS-Ms peaked at 10 minutes (22±0.7 
fold increase over vehicle, p<0.001 n=3 versus vehicle-treated control) and were 
abolished by pre-treatment with H89 (84±4% inhibition, p<0.001 n=3 versus 10 
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minute forskolin-treated cells) (Figure 3.16). No significant difference was found 
between vehicle-treated cells and cells treated with forskolin together with H89 
pre-treatment in both cell types. These observations suggest that H89 was 
effective at inhibiting PKA activity at the concentration used (5µM). In addition, 
these results also show that forskolin is an efficacious activator of PKA-mediated 
CREB phosphorylation, a principal downstream target of cAMP, and thus a potent 
elevator of cAMP at the concentration used (10µM). 
To summarise the major findings of this chapter, IL-6/sIL-6α was shown to activate 
both ERK1,2 and STAT3 pathways in HUVECs and AS-Ms, whereas leptin 
activated ERK1,2 in AS-Ms and STAT3 in both cell types. A trend of SOCS3 
accumulation was observed in both cell types in response to IL-6/sIL-6α and leptin. 
Furthermore, a time-dependent accumulation of SOCS3 in both cell types was 
also observed in response to Fsk and Roli. In addition, the Epac-selective cAMP 
analogue 8-pCPT was shown to induce SOCS3 expression in both cell types. 
However, the 8-pCPT results in HUVECs were not conclusive and this could 
potentially be due to the variability in the fold stimulation. Finally, the expression of 
the well characterised PKA substrate CREB was demonstrated to be inhibited by 
pre-treatment with the selective PKA inhibitor H89. 
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3.3 Discussion 
Two major intracellular pathways activated by gp130 and OB-Rb are the STAT 
and ERK1/2 pathways (Bromberg, 2001; Fruhbeck, 2006; Heinrich et al., 2003; 
Vaisse et al., 1996; Yang & Barouch, 2007). All IL-6-type cytokines are capable of 
activating STAT1 and STAT3 via their common receptor subunit gp130, which is 
ubiquitously expressed. However, STAT3 appears to be the preferred STAT 
protein activated by IL-6. Studies have shown that of the four distal tyrosine 
modules of gp130 involved in STAT activation, all four stimulate STAT3 activation, 
whereas STAT1 is only activated by the last two distal tyrosine modules(Gerhartz 
et al., 1996; Stahl et al., 1995). Furthermore, whereas STAT3 binds to pYXXQ 
motifs, STAT1 is recruited to a more restricted sequence (pYXPQ) in gp130 
(Gerhartz et al., 1996; Heinrich et al., 1998). Gene deletion studies have shown 
that STAT3 deletion in mouse livers abolishes a major IL-6-mediated cellular 
response. namely acute phase gene induction (Alonzi et al., 2001). Furthermore, 
IL-6-deficient mice demonstrated impaired acute phase gene induction, which 
correlated with defective STAT3 activation (Alonzi et al., 1998). Similarly, in vivo 
studies have demonstrated that leptin signalling via OB-Rb, which is expressed 
almost universally including expression on HUVECs (Bouloumie et al., 1998; 
Sierra-Honigmann et al., 1998), occurs principally via STAT3 (Bates & Myers, 
2004).  
Using ERK1,2 and STAT3 phosphorylation as readouts for the activation of both of 
these signalling pathways, the present results show that IL-6/sIL-6α is capable of 
similarly activating the ERK1,2 and STAT3 pathways in HUVECs and AS-Ms, 
whereas leptin activates ERK1,2 in AS-Ms and STAT3 in both cell types. Various 
lines of evidence have demonstrated ERK1,2 and STAT3 activation in response to 
IL-6/sIL-6α and leptin in endothelial cells (Bouloumie et al., 1998; Heinrich et al., 
1998; Romano et al., 1997). However, this is the only study that demonstrates the 
activation of ERK1,2 and STAT3 in response to IL-6/sIL-6α and leptin in the AS-M 
cell line. In HUVECs, both ERK1,2 and STAT3 phosphorylation is maximal by 15 
minutes in response to IL-6/sIL-6α. This is in agreement with other studies, such 
as Sobota and co-workers (2008), who demonstrated maximal STAT3 activation at 
15 minutes in human dermal fibroblasts following IL-6 treatment (Sobota et al., 
2008). Interestingly, another group (Wormald et al., 2006) describe a bi-phasic 
activation of STAT3 in response to IL-6 injection in mouse macrophages, an event 
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that could potentially be taking place in the present study, since STAT3 
phosphorylation peaks at between 15 and 30 minutes following treatment with IL-
6/sIL-6α or leptin in AS-Ms and IL-6/sIL-6α in HUVECs, and declines thereafter. 
Indeed, longer timepoints are required to confirm the existence of this bi-phasic 
pattern of activation in the present study. The present pattern of rapid activation 
and subsequent decline of STAT3 however has also been observed for ERK1,2 
activation following IL-6/sIL-6α treatment in both cell types. In contrast, ERK1,2 
activation in AS-Ms following leptin treatment was more sustained, increasing over 
time. Bouloumie and co-workers (1998) also showed a time-dependent increase in 
ERK1,2 activation in response to leptin, which they observed in HUVECs 
(Bouloumie et al., 1998). In the present study, a consistent pattern of ERK1,2 
activation in HUVECs could not be achieved. This could potentially be due to low 
levels of OB-Rb on the cell surface of HUVECs. Indeed, a number of studies 
examining leptin-mediated effects routinely use cells which have been transfected 
with either OB-Rb or a chimeric receptor comprising the erythropoietin (Epo) 
extracellular domain and the OB-Rb intracellular domain (ELR) (Dunn et al., 2005; 
Myers, 2004). This chimeric receptor is principally used to avoid potential artifacts 
which may be introduced as a result of endogenous short forms of the leptin 
receptor, since EpoR is expressed on very few cells or cell lines (Myers, 2004). 
Additionally, ELR has been shown by some studies to be expressed more robustly 
than OB-Rb (Dunn et al., 2005). The present study uses leptin at a concentration 
of 125ng/ml. Although this concentration is greater than the physiological 
concentration of leptin, which ranges between 5 and 15ng/ml in lean subjects 
(Sinha et al., 1996), and increases in response to overfeeding, insulin, 
glucocorticoids, endotoxins and cytokines (Yang & Barouch, 2007), the present 
study does not utilise transfected cells. This is in contrast to some studies which 
use leptin at a higher concentration than physiological concentrations in 
combination with transfected cells (Dunn et al., 2005).  
Results from the above experiments support the general consensus that cytokine 
signalling is typically a transient event, suggesting the involvement of negative 
regulatory mechanisms. In a classical negative feedback manner, SOCS induction 
is one such mechanism. A plethora of studies have demonstrated cytokine 
induction of SOCS3. Some of these cytokines include IL-2 (Cohney et al., 1999), 
leukemia inhibitory factor (Bousquet et al., 1999), IL-11 (Auernhammer & Melmed, 
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1999), IL-6 (Starr et al., 1997) and leptin (Bjorbaek et al., 1998). Additionally, there 
is evidence to support an early negative feedback of cytokine signalling by SOCS3 
induction. For example, SOCS3 protein expression and binding to JAK2 in murine 
corticotroph AtT20 cells has been shown to be maximal by 60 minutes following 
LIF treatment. This timepoint correlates with the dephosphoylation of JAK2 and 
ultimately the termination of signal transduction (Bousquet et al., 1999). 
Furthermore, work carried out by Wormald and co-workers (2006) showed that 
SOCS3 imposed bi-phasic kinetics upon IL-6 signalling (Wormald et al., 2006). 
Rapid STAT3 phosphorylation was observed in mouse macrophages by this group 
in response to IL-6 injection, with levels of phosphoylation declining between 30 
and 60 minutes and then accumulating again thereafter. To examine a role for 
SOCS3 in this biphasic pattern of expression, IL-6 signalling was analysed in 
SOCS3-deficient macrophages. Results revealed that in the absence of SOCS3, 
IL-6-mediated STAT3 activation was maximal and sustained rather than biphasic. 
This suggested that SOCS3 plays a role in the early phase of IL-6 signalling. 
(Wormald et al., 2006). These findings could potentially explain the pattern of 
STAT3 phosphorylation in HUVECs in response to IL-6/sIL-6α in the present 
study, since examination of SOCS3 induction in response to IL-6/sIL-6α in 
HUVECs showed SOCS3 accumulation at 60 and 90 minutes. This 60 minute 
accumulation correlates with the decline in STAT3 phosphorylation. Indeed, the 
detection of the SOCS3 transcript has been observed as early as 20 minutes after 
IL-6 injection in mouse liver, lung and spleen (Starr et al., 1997). SOCS3 induction 
in response to IL-6/sIL-6α and leptin in AS-Ms starts to accumulate at 60 minutes, 
with greatest levels observed at 90 minutes. Again, this induction of SOCS3 may 
contribute towards the suppression of IL-6- and leptin-mediated STAT3 
phophorylation. Alternatively, other negative regulatory mechanisms may also be 
playing a part in the downregulation of early phase signalling, such as the SH2-
domain containing protein tyrosine phosphatases SHP2. 
Although early inhibitory feedback signalling mechanisms are of interest, the main 
objective for the examination of SOC3 induction in response to IL-6/sIL-6α and 
leptin in both cell types in the present study was to ascertain whether SOCS3 
could be detected in the cell system under conditions whereby SOCS3 has been 
readily observed in a number of studies. Additionally, the ability of AS-Ms to 
induce SOCS3 should be confirmed, since studies carried in human cancer cells 
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have shown that the SOCS3 promotor can become inactivated as a result of 
methylation (Niwa et al., 2005; Sutherland et al., 2004; Tokita et al., 2007). The 
present results demonstrate a trend of SOCS3 induction in response to IL-6/sIL-6α 
and leptin treatment in HUVECs and AS-Ms, with highest levels of expression at 
90 minutes. These results corroborate with other studies, and therefore contribute 
towards the validation of the cell system. In addition, the results show that SOCS3 
protein expression can be detected under the conditions used.  
Not only are SOCS proteins induced by cytokines, but further studies have shown 
that SOCS1 and SOCS3 can also be induced by non-cytokine stimuli, thus 
providing a mechanism by which other signalling pathways can mediate the 
negative regulation of cytokine signalling. Dalpke and co-workers (2001) have 
demonstrated SOCS1 and SOCS3 induction by bacterial CpG-DNA in J774 
macrophages, RAW 264.7 macrophages, mouse bone marrow-derived dendritic 
cells, and peritoneal macrophages (Dalpke et al., 2001). CpG-DNA triggers TLR-
dependent signalling cascades, such as the NF-κB pathway (Hacker et al., 2002), 
which are independent of the JAK/STAT pathway (Yi & Krieg, 1998). Other stimuli 
which trigger similar pathways as CpG-DNA are LPS and TNFα, both of which 
have been shown to induce SOCS3 expression in murine macrophages (Bode et 
al., 1999; Stoiber et al., 1999). Furthermore, inhibition of the ERK1/2 pathway by 
treatment with the MEK inhibitor UO126 has been shown to reduce the induction 
of SOCS3 by CpG-DNA, suggesting the involvement of the ERK1/2 pathway in 
SOCS3 induction (Dalpke et al., 2001). This is supported by the findings that PMA 
induces SOCS3 expression via ERK1/2 activation and pre-treatment of HepG2 
and COS-7 cells with PMA inhibits STAT3 activation (Terstegen et al., 2000). The 
involvement of ERK1/2 in SOCS3 induction will be discussed in more detail in 
Chapter 4.  
Of interest to the present study is the induction of SOCS3 by cAMP-elevating 
agents, since this potentially represents a mechanism by which cAMP mediates its 
anti-inflammatory effects. Gasperini and colleagues (2002) have demonstrated the 
induction of SOCS3 mRNA and protein expression in response to prostaglandin 
E2 (PGE2), PGE1, forskolin, dibutyryl cAMP (dbcAMP) and cholera toxin in human 
leukocytes (Gasperini et al., 2002). While, Park and co-workers (2000) have 
shown that treatment of FRTL-5 thyroid cells with forskolin induces the expression 
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of SOCS1 and SOCS3 (Park et al., 2000). Previous work in this laboratory has 
demonstrated that SOCS3 is induced by forskolin and rolipram treatment in 
HUVECs, whereas SOCS1 is not induced in HUVECs under conditions that readily 
induce the expression of SOCS3 (Sands et al., 2006). To re-affirm these results, 
HUVECs were treated with forskolin and rolipram over a timecourse, and SOCS3 
expression was examined. Results showed a time-dependent accumulation of 
SOCS3 in response to these cAMP elevating stimuli, with greatest expression at 5 
hours. In AS-Ms, a similar pattern of expression was observed with greatest 
accumulation of SOCS3 at 5 hours. Thus, the present results not only confirm 
earlier results with HUVECs, but also demonstrate SOCS3 induction in AS-Ms for 
the first time 
Until relatively recently, the main intracellular mediator of cAMP effects was 
generally considered to be PKA. However, numerous studies have since 
discovered a new cAMP sensor, so-called Epac. Due to the roles that Epac has 
been ascribed to with regards to endothelial barrier function (Cullere et al., 2005; 
Fukuhara et al., 2005) it would be of interest in the present study to determine 
whether Epac too plays a role in the potential anti-inflammatory effects of cAMP in 
endothelial cells. Indeed, the finding that the SOCS3 promoter does not contain 
any classical cyclic AMP response elements (CREs) (He et al., 2003) may support 
a role for PKA-independent effectors of cAMP, that do not involve the PKA-
mediated activation of the transcription factor CREB. Furthermore, recent work 
carried out by Yarwood et al. (2008) showed that Epac can induce SOC3 
expression in HUVECs via activation of the C/EBP family of transcription factors 
(Yarwood et al., 2008). 
Currently, there are no pharmacological antagonists of Epac. However a selective 
agonist in the form of 8pCPT has been developed. 8pCPT is an Epac-Selective 
Cyclic AMP Analog (ESCA) which activates Epac but not PKA, due to the 
incorporation of a 2’-O-methyl substitution on the ribose ring (2’-O-Me-cAMP). 
Further work on 2’-O-Me-cAMP led to the finding that a parachlorophenylthio 
(pCPT) substitution at position 8 on the adenine moiety of 2’-O-Me-cAMP (8-
pCPT-2’-O-Me-cAMP [8-pCPT]) greatly increased its affinity for Epac, and also 
enhanced selectivity (107 fold greater affinity for Epac1 than for PKA) and 
increased cell permeability (Holz et al., 2008). 
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With the use of this selective anlogue, the current results demonstrate an 
accumulation of SOCS3 in response to 8-pCPT treatment at concentrations of 
200μM and 300μM in HUVECs and AS-Ms respectively. However, results in 
HUVECs were not consistent when using this analogue, which produced variability 
in the fold stimulation. Of interest, previous work in the lab has suggested the 
involvement of Epac in SOCS3 induction. For example, the accumulation of 
SOCS3 protein following forskolin treatment in HUVECs was not significantly 
inhibited by the PKA inhibitor H89, suggesting a PKA-independent induction of 
SOCS3 (Sands et al., 2006). Additionally, a constitutively active GTPase-deficient 
Val12Rap1a was capable of triggering SOCS3 induction, potentially suggesting 
the involvement of Epac (Sands et al., 2006). In further agreement were the 
findings that Rap1a siRNA and over-expression of RapGAP substantially inhibited 
the induction of SOCS3 by Fsk and Roli in HUVECs (Yarwood et al., 2008). 
Furthermore, Epac siRNA abolished the ability of Fsk and Roli to induce SOCS3 
(Yarwood et al., 2008). Many studies have demonstrated positive results when 
using 8pCPT in HUVECs, at concentrations within the range of that used in the 
current study (Cullere et al., 2005; Fukuhara et al., 2005). 8-pCPT has even been 
referred to as a “super activator” so-called because it activates Epac1 with greater 
efficacy than cAMP in vitro (Rehmann et al., 2003b).  
One explanation for the variation in the induction of SOCS3 in this study may be 
due to 8pCPT degradation by PDEs during the 5 hour incubation period (a 
timepoint chosen based on the maximal accumulation of SOCS3 in response to 
forskolin treatment in earlier experiments). Indeed, studies which have identified 
the positions on cAMP that allow interaction with PDEs, describe N1, N6 and N7 on 
the adenine moiety as particularly important for PDE interaction and the 2’-OH 
moiety as not required at all (Holz et al., 2008). Therefore, in theory, all ESCAs are 
capable of interacting with PDEs and undergoing degradation. To overcome this 
potential problem, a PDE-resistant 8pCPT has been developed (Sp-8-pCPT-2’-O-
Me-cAMPS), but was not used in the present study. 
In view of the above results with 8pCPT, other pharmacological tools were 
considered in the present study, namely H89. H89 belongs to the H-series of 
protein kinase inhibitors, developed by Hidaka and coworkers from 1977 onwards 
(Lochner & Moolman, 2006). It acts competitively with ATP to bind the ATP 
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binding sites of the catalytic subunits of PKA, and inhibit the phosphorylation 
process. Using this inhibitor throughout the course of the study could potentially 
not only assess the involvement of PKA in cAMP-mediated effects, but also 
indirectly examine the contribution of Epac. This is based on the assumption that 
PKA and Epac are the 2 main cAMP effectors in the present cell system under the 
conditions used. The involvement of other known cAMP effectors, such as cAMP-
regulated ion channels and the cyclic nucleotide rasGEF (CNrasGEF), plus the 
involvement of yet unknown effectors can therefore not be discounted. 
Furthermore, caution must be exercised when using this inhibitor as studies have 
shown that at a concentration of 10µM, H89 inhibits at least 8 other kinases by 80-
100% (Davies et al., 2000). The IC50 values revealed that three of these kinases, 
namely mitogen- and stress-activated protein kinase 1 (MSK1), p70 ribosomal 
protein S6 kinase (S6K1) and Rho-dependent protein kinase (ROCK-II) were 
inhibited with a potency similar to or greater than that for PKA (Davies et al., 
2000). In the present study, the possible inhibition of these three kinases does not 
appear to be of great concern, since CREB is a major substrate of PKA and 
results from these experiments should implicate PKA and not the other three 
kinases. However, MSK1 has also been shown to phosphorylate CREB. This 
kinase is principally a downstream target of ERK1,2 and p38 (Widmann et al., 
1999) and although the ERK1,2 pathway and the cAMP pathway have been 
shown to cross-talk (which will be described in more detail in Chapter 4) cAMP-
mediated CREB activation occurs predominantly via direct phosphorylation of 
serine residue 133 by the catalytic subunits of PKA (Daniel et al., 1998). Whilst the 
concentration of H89 used in the present study (5µM) may compromise its 
selectivity, it is nevertheless often required to achieve cell permeability, favorable 
stoichiometry between the inhibitor and the targets, and to compete with ATP, 
which is present in the cell at millimolar levels (Lochner & Moolman, 2006). Ideally, 
when examining the role of PKA, H89 should be used in conjunction with other 
PKA inhibitors, such as Rp-cAMPS and PKI analogues, or PKA-selective cAMP 
analogues such as 6-Bnz-cAMP. Thus, although H89 has been shown to be a 
potent inhibitor of PKA and has been used extensively for the assessment of the 
role of PKA in various biological processes, the specific inhibition of PKA is still not 
fully understood and this should be considered when using this inhibitor in studies. 
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When using this inhibitor in the present study to initially examine its effectiveness, 
results showed that pre-treatment of HUVECs or ASMs with H89 at a 
concentration of 5µM completely abolished forskolin-induced PKA-dependent 
CREB phosphorylation. H89 therefore appeared to be effectively inhibiting PKA at 
the concentration used. Indeed, many studies have used H89 at the same 
concentration to assess PKA involvement, including Fukuhara et al. (2005) to help 
identify the PKA-independent cAMP-Epac-Rap1 signalling pathway in endothelial 
barrier function (Fukuhara et al., 2005).  
In summary, results from this Chapter demonstrate that both HUVECs and AS-Ms 
may be considered useful cell models for the further examination of the working 
hypothesis. Both cell types were capable of activating the ERK1,2 and/or STAT3 
pathway(s) in response to IL-6/sIL-6α and leptin treatment. A trend of SOCS3 
induction was observed in both cell types in response to IL-6/sIL-6α and leptin 
treatment. Furthermore, accumulation of SOCS3 over time was observed in both 
cell types in response to cAMP elevation. Use of the Epac-selective cAMP 
analogue 8-pCPT in both cell types induced SOCS3 accumulation, but produced 
considerable variation in the fold stimulation. In comparison, the use of H89 in both 
cell types demonstrated consistent inhibition of the PKA substrate CREB. 
Collectively, these results are important in terms of establishing the cell systems 
and conditions to use for further experimentation. Of particular interest are the 
results from AS-Ms, since there are very limited studies on AS-Ms in the public 
domain, and these cells represent a more tractable and less costly cell model 
when compared to HUVECs.  
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Figure 3.1 The Effect of sIL-6Rα/IL-6 Treatment on ERK1, 2 Phosphorylation 
in HUVECs  
 
4 x 105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with PBS and serum-starved for 5 hrs. Following serum 
starvation, cells were treated with sIL-6Rα/IL-6 at a concentration of 
25ng/ml/5ng/ml respectively for 5, 15, 30 and 60 minutes. The controls in this 
experiment included vehicle (V) treated cells, which were treated with PBS alone 
at the same volume as sIL-6Rα/IL-6 treatment, and 1µM PMA treated cells, a 
potent activator of ERK1,2 in endothelial cells. Following treatment, soluble cell 
extracts equalised for protein concentration were fractionated by SDS-PAGE for 
immunoblotting with the indicated antibodies. Quantitative analysis of 
phosphorylated ERK1,2 levels in HUVECs from three experiments is presented as 
mean values +/- standard error (*p<0.05 versus phosphorylated ERK1,2 levels in 
vehicle-treated cells). Basal is set at 100. Total ERK1,2 expression is also shown 
as a representative immunoblot to control for protein loading.   
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Figure 3.2 The Effect of sIL-6Rα/IL-6 Treatment on STAT3 Phosphorylation in 
HUVECs  
 
4 x 105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with PBS and serum-starved for 5 hrs. Following serum 
starvation, cells were treated with sIL-6Rα/IL-6 at a concentration of 
25ng/ml/5ng/ml respectively for 5, 15, 30 and 60 minutes. Vehicle (V) treated cells 
were treated with PBS alone at the same volume as sIL-6Rα/IL-6 treatment. 
Following treatment, soluble cell extracts equalised for protein concentration were 
fractionated by SDS-PAGE for immunoblotting with the indicated antibodies. 
Quantitative analysis of phosphorylated STAT3 levels in HUVECs from three 
experiments is presented as mean values +/- standard error (*p<0.05 versus 
phosphorylated STAT3 levels in vehicle-treated cells). Basal is set at 100. Total 
STAT3 expression is also shown as a representative immunoblot to control for 
protein loading.   
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Figure 3.3 The Effect of Leptin Treatment on STAT3 Phosphorylation in 
HUVECs  
 
4 x 105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with PBS and serum-starved for 5 hrs. Following serum 
starvation, cells were treated with leptin at a concentration of 125ng/ml for 5, 15, 
30 and 60 minutes. Vehicle (V) treated cells were treated with PBS alone at the 
same volume as leptin treatment. Following treatment, soluble cell extracts 
equalised for protein concentration were fractionated by SDS-PAGE for 
immunoblotting with the indicated antibodies. Quantitative analysis of 
phosphorylated STAT3 levels in HUVECs from three experiments is presented as 
mean values +/- standard error (**p<0.01 versus phosphorylated STAT3 levels in 
vehicle-treated cells). Basal is set at 100. Total STAT3 expression is also shown 
as a representative immunoblot to control for protein loading.   
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Figure 3.4 The Effect of sIL-6Rα/IL-6 Treatment on ERK1, 2 Phosphorylation 
in AS-Ms  
 
4 x 105 AS-Ms / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with PBS and serum-starved for 5 hrs. Following serum 
starvation, cells were treated with sIL-6Rα/IL-6 at a concentration of 
25ng/ml/5ng/ml respectively for 5, 15, 30 and 60 minutes. The controls in this 
experiment included vehicle (V) treated cells, which were treated with PBS alone 
at the same volume as sIL-6Rα/IL-6 treatment, and 1µM PMA treated cells, a 
potent activator of ERK1,2 in endothelial cells. Following treatment, soluble cell 
extracts equalised for protein concentration were fractionated by SDS-PAGE for 
immunoblotting with the indicated antibodies. Quantitative analysis of 
phosphorylated ERK1,2 levels in AS-Ms from three experiments is presented as 
mean values +/- standard error (*p<0.05 versus phosphorylated ERK1,2 levels in 
vehicle-treated cells) Basal is set at 100. The expression of the cytoskeleton 
protein, tubulin is also shown as a representative immunoblot to control for protein 
loading.   
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Figure 3.5 The Effect of sIL-6Rα/IL-6 Treatment on STAT3 Phosphorylation in 
AS-Ms  
 
4 x 105 AS-Ms / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with PBS and serum-starved for 5 hrs. Following serum 
starvation, cells were treated with sIL-6Rα/IL-6 at a concentration of 
25ng/ml/5ng/ml respectively for 5, 15, 30 and 60 minutes. Vehicle (V) treated cells 
were treated with PBS alone at the same volume as sIL-6Rα/IL-6 treatment. 
Following treatment, soluble cell extracts equalised for protein concentration were 
fractionated by SDS-PAGE for immunoblotting with the indicated antibodies. 
Quantitative analysis of phosphorylated STAT3 levels in AS-Ms from three 
experiments is presented as mean values +/- standard error (*p<0.05 versus 
phosphorylated STAT3 levels in vehicle-treated cells). Basal is set at 100. Total 
STAT3 expression is also shown as a representative immunoblot to control for 
protein loading. 
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Figure 3.6 The Effect of Leptin Treatment on ERK1, 2 Phosphorylation in AS-
Ms  
 
4 x 105 AS-Ms / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with PBS and serum-starved for 5 hrs. Following serum 
starvation, cells were treated with leptin at a concentration of 125ng/ml for 5, 15, 
30 and 60 minutes. The controls in this experiment included vehicle (V) treated 
cells, which were treated with PBS alone at the same volume as leptin treatment, 
and 1µM PMA treated cells, a potent activator of ERK1,2 in endothelial cells. 
Following treatment, soluble cell extracts equalised for protein concentration were 
fractionated by SDS-PAGE for immunoblotting with the indicated antibodies. 
Quantitative analysis of phosphorylated ERK1,2 levels in AS-Ms from three 
experiments is presented as mean values +/- standard error (***p<0.001 versus 
phosphorylated ERK1,2 levels in vehicle-treated cells). Basal is set at 100. Total 
ERK1,2 expression is also shown as a representative immunoblot to control for 
protein loading.   
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Figure 3.7 The Effect of Leptin Treatment on STAT3 Phosphorylation in AS-
Ms  
 
4 x 105 AS-Ms / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with PBS and serum-starved for 5 hrs. Following serum 
starvation, cells were treated with leptin at a concentration of 125ng/ml for 5, 15, 
30 and 60 minutes. Vehicle (V) treated cells were treated with PBS alone at the 
same volume as leptin treatment. Following treatment, soluble cell extracts 
equalised for protein concentration were fractionated by SDS-PAGE for 
immunoblotting with the indicated antibodies. Quantitative analysis of 
phosphorylated STAT3 levels in AS-Ms from three experiments is presented as 
mean values +/- standard error (**p<0.01 versus phosphorylated STAT3 levels in 
vehicle-treated cells. Basal is set at 100. Total STAT3 expression is also shown as 
a representative immunoblot to control for protein loading. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
110 
 
 
 
 
: Exposure time (mins) to Leptin
Phospho-STAT3
Total STAT3
V       5     15     30      60   
0
5
15
30
60
0
500
1000
1500
2000
2500
3000
0 10 20 30 40 50 60
S
TA
T3
 P
ho
sp
ho
ry
la
tio
n 
(b
as
al
 s
et
 a
t 
10
0)
Time (mins)
**
 
 
 
 
 
 
 
 
 
111 
 
Figure 3.8 The Effect of sIL-6Rα/IL-6 Treatment on SOCS3 Induction in 
HUVECs 
 
4 x 105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with PBS, before replacing the medium with serum-free 
medium. Cells were then treated with sIL-6Rα/IL-6 at a concentration of 
25ng/ml/5ng/ml respectively for 5, 15, 30, 60 and 90 minutes, in the presence of 
the proteosome inhibitor, MG132 at a concentration of 6μM. Vehicle (V) treated 
cells were treated with PBS at the same volume as sIL-6Rα/IL-6 treatment, and 
also MG132 at a concentration of 6μM. Following treatment, soluble cell extracts 
equalised for protein concentration were fractionated by SDS-PAGE for 
immunoblotting with the indicated antibodies. Quantitative analysis of SOCS3 
levels in HUVECs from three experiments is presented as mean values +/- 
standard error (basal is set at 100). The expression of the cytoskeleton protein, 
tubulin is also shown as a representative immunoblot to control for protein loading. 
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Figure 3.9 The Effect of Leptin Treatment on SOCS3 Induction in HUVECs 
 
4 x 105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with PBS, before replacing the medium with serum-free 
medium. Cells were then treated with leptin at a concentration of 125ng/ml for 5, 
15, 30, 60 and 90 minutes, in the presence of the proteosome inhibitor, MG132 at 
a concentration of 6μM. Vehicle (V) treated cells were treated with PBS at the 
same volume as leptin treatment, and also MG132 at a concentration of 6μM. 
Following treatment, soluble cell extracts equalised for protein concentration were 
fractionated by SDS-PAGE for immunoblotting with the indicated antibodies. 
Quantitative analysis of SOCS3 levels in HUVECs from three experiments is 
presented as mean values +/- standard error (basal is set at 100). The expression 
of the cytoskeleton protein, tubulin is also shown as a representative immunoblot 
to control for protein loading. 
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Figure 3.10 The Effect of sIL-6Rα/IL-6 Treatment on SOCS3 Induction in AS-
Ms 
 
4 x 105 AS-Ms / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with PBS, before replacing the medium with serum-free 
medium. Cells were then treated with sIL-6Rα/IL-6 at a concentration of 
25ng/ml/5ng/ml respectively for 5, 15, 30, 60 and 90 minutes, in the presence of 
the proteosome inhibitor, MG132 at a concentration of 6μM. Vehicle (V) treated 
cells were treated with PBS at the same volume as sIL-6Rα/IL-6 treatment, and 
also MG132 at a concentration of 6μM. Following treatment, soluble cell extracts 
equalised for protein concentration were fractionated by SDS-PAGE for 
immunoblotting with the indicated antibodies. Quantitative analysis of SOCS3 
levels in AS-Ms from three experiments is presented as mean values +/- standard 
error (basal is set at 100). The expression of the cytoskeleton protein, tubulin is 
also shown as a representative immunoblot to control for protein loading. 
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Figure 3.11 The Effect of Leptin Treatment on SOCS3 Induction in AS-Ms 
 
4 x 105 AS-Ms / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with PBS, before replacing the medium with serum-free 
medium. Cells were then treated with leptin at a concentration of 125ng/ml for 5, 
15, 30, 60 and 90 minutes, in the presence of the proteosome inhibitor, MG132 at 
a concentration of 6μM. Vehicle (V) treated cells were treated with PBS at the 
same volume as leptin treatment, and also MG132 at a concentration of 6μM. 
Following treatment, soluble cell extracts equalised for protein concentration were 
fractionated by SDS-PAGE for immunoblotting with the indicated antibodies. 
Quantitative analysis of SOCS3 levels in AS-Ms from three experiments is 
presented as mean values +/- standard error (**p<0.01 versus SOCS3 expression 
levels in vehicle-treated cells). Basal is set at 100. The expression of the 
cytoskeleton protein, tubulin is also shown as a representative immunoblot to 
control for protein loading. 
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Figure 3.12 The Effect of cAMP Elevation on SOCS3 Induction in HUVECs 
and AS-Ms 
 
a. 4 x 105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, 
cells were washed twice with PBS before replacing the medium with serum-
free medium. Cells were then treated with the adenylyl cyclase activator, 
forskolin (fsk) at a concentration of 10μM and the phosphodiesterase type 4 
inhibitor, rolipram (roli) at a concentration of 10μM over a time course 
ranging from 5 minutes to 5 hours in the presence of the proteosome 
inhibitor, MG132 at a concentration of 6μM. Vehicle (V) treated cells were 
treated with ethanol and DMSO at the same volume as forskolin and 
rolipram treatment respectively, and also MG132 at a concentration of 6μM. 
Following treatment, soluble cell extracts equalised for protein 
concentration were fractionated by SDS-PAGE for immunoblotting with the 
indicated antibodies. The immunoblot shows the expression of SOCS3 in 
HUVECs from one experiment, since previous work in the lab has 
demonstrated this effect consistently. The expression of the cytoskeleton 
protein, tubulin is also shown as an immunoblot from 1 experiment, to 
control for protein loading. 
b. AS-Ms were treated exactly as described above. Following treatment, 
soluble cell extracts equalised for protein concentration were fractionated 
by SDS-PAGE for immunoblotting with the indicated antibodies. 
Quantitative analysis of SOCS3 levels in AS-Ms from three experiments is 
presented as mean values +/- standard error (*p<0.05 versus SOCS3 
expression levels in vehicle-treated cells). Basal is set at 100. The 
expression of the cytoskeleton protein, tubulin is also shown as a 
representative immunoblot, to control for protein loading. 
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Figure 3.13 The Effect of 8pCPT on SOCS3 Induction in HUVECs 
 
4 x 105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with PBS before replacing the medium with serum-free 
medium. Cells were treated with the Epac selective cAMP analogue, 8pCPT at 
concentrations of 1, 50, 100 and 200μM over 5 hours in the presence of the 
proteosome inhibitor, MG132 at a concentration of 6μM. Vehicle (V) treated cells 
were treated with DMSO at the same volume as 8pCPT treatment, and also 
MG132 at a concentration of 6μM. Following treatment, soluble cell extracts 
equalised for protein concentration were fractionated by SDS-PAGE for 
immunoblotting with the indicated antibodies. Quantitative analysis of SOCS3 
levels in HUVECs from three experiments is presented as mean values +/- 
standard error (basal is set at 100). The expression of the cytoskeleton protein, 
tubulin is also shown as a representative immunoblot, to control for protein 
loading. 
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Figure 3.14 The Effect of 8pCPT on SOCS3 Induction in AS-Ms 
 
4 x 105 AS-Ms / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with PBS before replacing the medium with serum-free 
medium. Cells were treated with the Epac selective cAMP analogue, 8pCPT at 
concentrations of 1, 50, 100 and 200μM over 5 hours in the presence of the 
proteosome inhibitor, MG132 at a concentration of 6μM. Vehicle (V) treated cells 
were treated with DMSO at the same volume as 8pCPT treatment, and also 
MG132 at a concentration of 6μM. Following treatment, soluble cell extracts 
equalised for protein concentration were fractionated by SDS-PAGE for 
immunoblotting with the indicated antibodies. Quantitative analysis of SOCS3 
levels in AS-Ms from three experiments is presented as mean values +/- standard 
error (*p<0.05 versus SOCS3 expression levels in vehicle-treated cells). Basal is 
set at 100. The expression of the cytoskeleton protein, tubulin is also shown as a 
representative immunoblot, to control for protein loading. 
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Figure 3.15 The Effect of H89 on Forskolin Induced CREB Phosphorylation in 
HUVECs 
 
4 x 105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with PBS before replacing the medium with serum-free 
medium. 1 well from each 6 well plate was pre-treated with the cAMP dependent 
protein kinase A inhibitor, H89 for 30 minutes at a concentration of 5μM before 
being treated with the adenylyl cyclase activator forskolin (fsk) at a concentration 
of 10μM for 10 minutes. The remaining wells were treated with fsk for 5, 10, 15 
and 30 minutes. The Vehicle (V) treated cells were treated with ethanol at the 
same volume as fsk treatment. Following treatment, soluble cell extracts equalised 
for protein concentration were fractionated by SDS-PAGE for immunoblotting with 
the indicated antibodies. Quantitative analysis of phosphorylated Ser133 CREB 
levels in HUVECs from three experiments is presented as mean values +/- 
standard error (***p<0.001 versus phosphorylated CREB levels in vehicle-treated 
cells, ***p<0.001 versus 10 minute fsk treated cells). Maximum response is set at 
100. The expression of the cytoskeleton protein, tubulin is also shown as a 
representative immunoblot, to control for protein loading. (ATF1 = Activating 
Transcription Factor 1, a member of the ATF/CREB family) 
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Figure 3.16 The Effect of H89 on Forskolin Induced CREB Phosphorylation in 
AS-Ms 
 
4 x 105 AS-Ms / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with PBS before replacing the medium with serum-free 
medium. 1 well from each 6 well plate was pre-treated with the cAMP dependent 
protein kinase A inhibitor, H89 for 30 minutes at a concentration of 5μM before 
being treated with the adenylyl cyclase activator forskolin (fsk) at a concentration 
of 10μM for 10 minutes. The remaining wells were treated with fsk for 5, 10, 15 
and 30 minutes. The Vehicle (V) treated cells were treated with ethanol at the 
same volume as fsk treatment. Following treatment, soluble cell extracts equalised 
for protein concentration were fractionated by SDS-PAGE for immunoblotting with 
the indicated antibodies. Quantitative analysis of phosphorylated Ser133 CREB 
levels in AS-Ms from three experiments is presented as mean values +/- standard 
error (***p<0.001 versus phosphorylated CREB levels in vehicle-treated cells, 
***p<0.001 versus 10 minute fsk treated cells). Maximum response is set at 100. 
The expression of the cytoskeleton protein, tubulin is also shown as a 
representative immunoblot, to control for protein loading. (ATF1 = Activating 
Transcription Factor 1, a member of the ATF/CREB family) 
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Chapter 4 
 
Testing the Working Hypothesis - cAMP-Mediated Inhibition 
of sIL-6Rα/IL-6 and Leptin Signalling in Endothelial Cells 
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4.1 Introduction 
The downregulation of cytokine signalling has been attributed to several inhibitory 
mechanisms, all of which are crucial for the prevention of inappropriately sustained 
signalling (Wormald & Hilton, 2004). These include, but are not limited to, protein 
inhibitors and activators of STATs (PIAS), proteosomal degradation following 
Lys48 polyubiquitylation, protein tyrosine phosphatases (PTPs) and suppressor of 
cytokine signalling (SOCS) proteins.  
The family of PIAS proteins are constitutively expressed and every member of the 
family has been shown to regulate STAT signalling (Shuai & Liu, 2005). In 
particular, PIAS3 has  been shown to inhibit the DNA-binding activity of STAT3 
(Chung et al., 1997). Interestingly, PIAS proteins have also been shown to act as 
E3 ligases for “small ubiquitin-related modifier” (SUMO) conjugation. For example, 
SUMOylation of STAT1 by PIASx-alpha has been observed. However the 
consequence of this modification has yet to be determined (Rogers et al., 2003). It 
was recently proposed that the phosphorylation of Ser727 on STAT1 by MAPK 
(p38 and ERK1/2) enhances STAT1 SUMOylation by PIAS1 (Vanhatupa et al., 
2008), thereby implicating the MAPK pathway in the SUMOylation process. SUMO 
is very similar to ubiquitin, and is classed as a ubiquitin-like protein (ULP) on this 
basis. A STAT-interacting LIM protein (SLIM) has been shown to act as a ubiquitin 
E3 ligase targeting Tyr phosphorylated STAT1 and STAT4 for proteasomal-
mediated degradation in T cells and STAT1 in macrophages (Gao et al., 2007; 
Tanaka et al., 2005). 
PTPs comprise a large family of protein phosphatases. Of interest, PTP1B has 
been shown to inhibit leptin signalling via JAK2 dephosphorylation (Cheng et al., 
2002) and TC45 has been demonstrated to suppress IL-6 induced STAT3 
activation in 293T cells (Yamamoto et al., 2002). Of particular significance to the 
present study is SHP2, which not only functions as an adapter protein facilitating 
the activation of the ERK pathway, but also acts as a protein phosphatase, 
dephosphorylating Tyr-phosphorylated cytokine receptors, JAKs and STATs 
(Chen et al., 2003; Heinrich et al., 2003; Yu et al., 2000). The dual function of 
SHP2 as a protein phosphatase and as a SH2 domain-containing protein allows 
this protein to potentially serve as a positive or negative regulator of IL-6 and leptin 
signalling. As discussed earlier in section 1.4.4 of the Introduction, it is evident that 
further research is required to better understand the involvement of SHP2 in these 
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signalling pathways. Another level of complexity to SHP2 involvement comes from 
the findings that SHP2 binds to the same site on gp130 and OB-Rb, namely 
Tyr759 and Tyr985 respectively, as SOCS3. The relative contribution of both 
SHP2 and SOCS3 on gp130 and OB-Rb signalling constitutes another area of 
research requiring more investigation. 
The SOCS family of proteins are the main focus of the present study, and 
numerous studies have documented a role for SOCS3 in gp130 and Ob-Rb 
signalling, most notably studies using conditional SOCS3-deficient mice. These 
studies have demonstrated prolonged, unrestricted STAT3 activation in response 
to IL-6 and leptin in SOCS3-deficient macrophages, hepatocytes and neurons 
(Croker et al., 2003; Mori et al., 2004; Yasukawa et al., 2003). There are 3 known 
mechanisms by which SOCS3 can downregulate cytokine signalling. The first 
mechanism involves SOCS3 binding to Tyr759 on gp130 and Tyr985 on OB-Rb 
and physically occupying the same site as other SH2-domain-containing signalling 
components, such as SHP2. In this way, SOCS3 competes with and inhibits other 
signalling pathways (De Souza et al., 2002; Heinrich et al., 2003; Schmitz et al., 
2000). The second mechanism involves the kinase inhibitory region (KIR) of 
SOCS3, which binds to the kinase domain of JAKs. SOCS3 acts as a 
pseudosubstrate, inhibiting the catalytic activity of JAKs and consequently 
inhibiting subsequent receptor activation (Sasaki et al., 1999). The third 
mechanism of SOCS3 inhibition involves the C terminal SOCS3 box, which can 
recruit an elongin B and C E3 ubiquitin-ligase complex. This complex can trigger 
the polyubiquitylation and proteasomal degradation of SH2 domain-bound 
signalling partners, such as JAK2 (Kamura et al., 2004; Rui et al., 2002; Zhang et 
al., 1999a). 
In view of the findings that SOCS3 is induced in response to cAMP-elevating 
agents, in the present study and other studies (Gasperini et al., 2002; Sands et al., 
2006), it would be of interest to investigate the effect of cAMP elevation and 
SOCS3 induction on the signalling pathways of both leptin and IL-6. A cAMP-
mediated, SOCS3- dependent inhibition of IL-6 and leptin signalling represents a 
novel mechanism by which cAMP can mediate its anti-inflammatory effects. 
Although the mechanism of inhibition may be novel, cross-regulation of the 
ERK1,2 and STAT signalling pathways by cAMP is not a new concept. Numerous 
studies have documented a cAMP-mediated inhibition of ERK1,2 and STAT3 
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signalling, some of which are detailed below. A particular focus of the present 
study is the cross-regulation of the ERK pathway by cAMP.  
Crosstalk between the cAMP and ERK pathways has been observed since the 
early 1990s, whereby the cAMP analogues 8-chloro-cAMP (8-Cl-cAMP) or di-
butyryl cAMP have been shown to inhibit growth factor stimulated ERK activation 
in fibroblasts. (Burgering et al., 1993; Cook & McCormick, 1993; Wu et al., 1993). 
In more detail, all three studies have shown that cAMP agonists are capable of 
inhibiting EGF-mediated MAPK in Rat-1 cells (Burgering et al., 1993; Cook & 
McCormick, 1993; Wu et al., 1993). Furthermore, Burgering and colleagues (1993) 
demonstrated a cAMP-mediated inhibition of PDGF- and insulin-stimulated ERK 
activation in NIH3T3 and Rat-1 fibroblasts (Burgering et al., 1993). Other cell types 
have also been examined in the context of cAMP-mediated inhibition, and results 
from these studies have shown inhibition of EGF- and insulin-stimulated ERK 
signalling in adipocytes and inhibition of thrombin-stimulated ERK signalling in 
smooth muscle cells (Osinski & Schror, 2000; Sevetson et al., 1993). Thus, cAMP-
mediated inhibition appears to occur in multiple cell types and affects the signalling 
of multiple growth factors. However, less is known about the crosstalk between 
cAMP and cytokine-induced ERK activation. The inhibitory effect of cAMP has 
been demonstrated in response to TNFα, whereby TNFα-mediated expression of 
E-selectin is suppressed following cAMP elevation in HUVECs and human lung 
microvascular endothelial cells (HLMECs) (Blease et al., 1998; Morandini et al., 
1996). Of particular relevance to the present study is the work carried out by 
Sobota and co-workers (2008). These investigators demonstrated a cAMP-
mediated inhibition of sIL-6Rα/IL-6-stimulated ERK1,2 activation, but not STAT3 
activation in human dermal fibroblasts and murine embryonic fibroblasts (MEFs). 
Additionally, the cAMP-mediated inhibition of sIL-6Rα/IL-6-stimulated ERK1,2 
activation in MEFs was shown to be independent of Epac, and dependent on PKA. 
(Sobota et al., 2008). Although not a focus of the present study, the STAT pathway 
has also been shown to be modulated by the cAMP pathway, wherein cAMP 
elevation has been shown to inhibit sIL-6Rα/IL-6-stimulated STAT3 signalling in 
human monocytes (Sengupta et al., 1996) Previous work in the Palmer lab has 
also demonstrated inhibition of IL-6-stimulated STAT3 phosphorylation following 
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chronic cAMP elevation in HUVECs and MEFs (Sands & Palmer, 2005; Sands et 
al., 2006). 
The biological relevance of this cAMP-mediated inhibition on downstream effects 
of ERK1,2 signalling has also been investigated. For example, numerous studies 
have demonstrated inhibition of proliferation in response to cAMP elevation, which 
is largely attributed to cAMP-mediated effects on growth factor-induced ERK1,2 
activation (Bornfeldt & Krebs, 1999; Budillon et al., 1999; Hecquet et al., 2002; 
Schmitt & Stork, 2001; Tortora et al., 1989). For example, cAMP elevation in 
smooth muscle cells has been shown to inhibit proliferation and migration by 
blocking growth factor receptor activation (Bornfeldt & Krebs, 1999). Proliferation 
and migration of smooth muscle cells have been shown to contribute towards the 
thickening of vessel walls, a major feature of the development of atherosclerosis. 
In support of these observations, the expression of many cell cycle regulatory 
proteins such as cyclin D and cyclin A, which are downstream targets of the ERK 
pathway, have been demonstrated to be inhibited by cAMP elevation (Dumaz & 
Marais, 2005; L'Allemain et al., 1997). cAMP-mediated inhibitory effects are not 
limited to ERK1,2-dependent proliferation. cAMP elevation has also been shown to 
inhibit other ERK1,2-mediated effects, such as monocyte chemoattractant protein-
1 (MCP-1) induction. MCP-1 induction by IL-6 in human dermal fibroblasts has 
been shown to be inhibited by prostaglandin E1 (PGE1), an initiator of cAMP 
signalling via activation of the EP2 prostaglandin G-protein-coupled receptor 
(GPCR). This induction of MCP-1 was shown to be ERK sensitive by 
demonstrating inhibition of MCP-1 following treatment with the MEK inhibitor 
U0126 (Sobota et al., 2008). In corroboration, work carried out in the Palmer lab 
has demonstrated inhibition of MCP-1 accumulation by sIL-6Rα/IL-6 in response 
to cAMP elevation by Fsk and Roli or 8pCPT treatment in HUVECs (Sands et al., 
2006). MCP-1 plays a crucial part in the development of atherosclerosis via 
recruitment of monocytes to the endothelium at sites of vascular injury (Charo & 
Taubman, 2004). Of interest to the present study is the ERK transcription factor 
Elk-1. Elk-1 belongs to the E twenty-six (Ets) family of transcription factors, which 
have been shown to play roles in development, differentiation, transformation and 
proliferation. Elk-1, together with Net and Sap-1, forms a subfamily of the Ets 
family known as the ternary complex factors (TCFs) (Buchwalter et al., 2004). All 
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three TCFs characteristically form ternary complexes with serum response factor 
(SRF) dimers on serum response elements (SREs) present in c-fos and other 
early immediate gene (EIG) promoters. The TCFs represent final effectors of the 
MAP kinase cascade and Elk-1 is a target of all 3 MAP kinases; ERK1,2, JNK and 
p38 (Buchwalter et al., 2004). As such, Elk-1 represents a potential target of sIL-
6Rα/IL-6- or leptin-stimulated ERK1,2 signalling, which could be investigated to 
assess the downstream effects of cAMP-mediated inhibition. The inhibition of Elk-
1 by cAMP could have beneficial effects on vascular disease, such as 
atherosclerosis. For example, the anti-inflammatory cytokine IL-10 has been 
shown to suppress tissue factor (TF) expression in LPS-stimulated mouse 
macrophages via inhibition of early growth response gene 1 (Egr-1) and a MEK-
ERK1,2/Elk-1 pathway (Kamimura et al., 2005). Elk-1, together with serum 
response factor has been shown to bind and activate serum response elements in 
the promoter of Egr-1, and Egr-1 in association with AP-1 and NFκB has been 
shown to activate the TF promoter. These findings together with the pro-
atherogenic role of TF in thrombus formation in acute coronary syndromes, 
implicate Elk-1 in the disease progression of atherosclerosis (Kamimura et al., 
2005). Of interest, Egr-1 has also been shown to be a key regulator of genes such 
as membrane type 1 matrix metalloproteinase and intercellular adhesion molecule 
1 (ICAM-1), both of which have been demonstrated to be involved in the 
development of atherosclerosis (Haas et al., 1999; Maltzman et al., 1996).  
These downstream effects are interesting in terms of contributing towards the 
understanding of the physiological relevance of the inhibition on sIL-6Rα/IL-6 and 
leptin signalling. However, the emphasis of the present study was on the further 
elucidation of the molecular mechanism of cAMP-mediated inhibition. A number of 
models exist to try to explain the inhibitory mechanism of cAMP on ERK signalling. 
One of which involves the direct phosphorylation of Raf by PKA. Raf 
serine/threonine kinases are the main effectors of Ras in the MAPK pathway. Raf-
1 has been shown to be phosphorylated by PKA at 3 serine residues; S43, S233 
and S259 (Dhillon et al., 2002b; Dumaz et al., 2002; Wu et al., 1993). All three 
sites have been shown to block Raf-1 interaction with Ras; S43 blocks interaction 
via steric hindrance (Wu et al., 1993), while S233 and S259 block interaction via 
recruitment of the adapter/scaffolding proteins 14-3-3, which prevent Raf-1 
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recruitment to the membrane (Dumaz & Marais, 2003; Light et al., 2002). Although 
this mode of inhibition has been well described for the cAMP-mediated inhibition of 
growth factor signalling, the inhibitory effects on cytokine signalling are less 
understood. In relation to the cAMP-mediated STAT3 inhibitory mechanism, 
studies have shown that expression of catalytically inactive dominant negative 
SHP2 mutants results in increased gp130, Jak and STAT3 phosphorylation as well 
as gene induction (Lehmann et al., 2003; Symes et al., 1997). Since SHP-2 has 
been shown to be positively regulated by cAMP via phosphorylation by PKA 
(Rocchi et al., 2000), a cAMP-mediated SHP-2-dependent inhibition of STAT3 
activation describes a mode of STAT3 inhibition. 
The objective of this results chapter was to initially determine whether or not cAMP 
elevation in HUVECs and AS-Ms exert inhibitory effects on the signalling pathways 
of sIL-6Rα/IL-6 and leptin. This was examined using ERK1,2 and STAT3 
phosphorylation levels as end-points of sIL-6Rα/IL-6 and leptin signalling. 
Additionally, the downstream transcriptional activation of an ERK1,2 effector, 
namely Elk-1 was examined in an attempt to assess the biological consequences 
of cAMP-mediated inhibition of ERK1,2 activation. The focus of the present 
chapter however was to better understand the mechanism of inhibition, with a 
particular emphasis on SOCS3 as a potential mediator of the inhibitory effects (as 
a follow-up to previous work carried out in the Palmer lab). cAMP-mediated 
inhibition of ERK1,2 activation as opposed to STAT3 activation was more closely 
examined during this research. 
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4.2 Results 
Inhibition of sIL-6Rα/IL-6 and Leptin Signalling by cAMP Elevation  
In endothelial cells, specifically HUVECs, cAMP has been shown to play a pivotal 
role in reducing pro-inflammatory events and limiting vascular permeability. 
(Blease et al., 1998; Cullere et al., 2005; Fukuhara et al., 2005; Morandini et al., 
1996). Further to the use of HUVECs in the present study, AS-Ms were utilised to 
potentially identify an alternative and possibly more tractable cell model when 
compared to HUVECs. In the present study, pre-treatment of HUVECs with the 
cAMP elevating agents forskolin (Fsk) and rolipram (Roli) had the effect of 
significantly inhibiting both ERK1,2 phosphorylation in response to sIL-6Rα/IL-6 
(60±5% inhibition by Fsk + Roli versus sIL-6Rα/IL-6-treated alone cells, p<0.001, 
n=3) (Figure 4.2) and STAT3 phosphorylation in response to sIL-6Rα/IL-6 (70±7% 
inhibition by Fsk + Roli versus sIL-6Rα/IL-6-treated alone cells, p<0.001, n=3) 
(Figure 4.3). However, neither treatment alone had a significant effect on ERK1,2 
or STAT3 phosphorylation in response to sIL-6Rα/IL-6. In contrast, leptin-
mediated STAT3 activation could be inhibited by forskolin and rolipram in 
combination (62±10% inhibition by Fsk + Roli versus leptin-treated alone cells, 
p<0.01, n=3) as well as forskolin alone (52±16% inhibition by Fsk versus leptin-
treated alone cells, p<0.05, n=3) (Figure 4.4). In AS-Ms, basal levels of ERK 
phosphorylation were high and neither sIL-6Rα/IL-6- or leptin-induced ERK 
phosphorylation were significantly above these levels (p>0.05). Thus, the inhibitory 
effect of cAMP on sIL-6Rα/IL-6 and leptin signalling could not be assessed. 
However, it should be noted that forskolin and rolipram in combination, as well as 
either treatment alone could significantly inhibit “sIL-6Rα/IL-6-treated” levels of 
ERK phosphorylation (76±7%, 79±8%, 80±7% inhibition by Fsk, Roli and Fsk + 
Roli respectively versus sIL-6Rα/IL-6-treated alone cells, p<0.001 in all 3 
comparisons, n=3) (Figure 4.5) and “leptin-treated” levels of ERK phosphorylation 
(80±7%, 86±2%, 87±2% inhibition by Fsk, Roli and Fsk + Roli respectively versus 
leptin-treated alone cells, p<0.001 in all 3 comparisons, n=3) (Figure 4.7). When 
examining STAT3 levels in AS-Ms, sIL-6Rα/IL-6-stimulated phosphorylation of 
STAT3 (29±3 fold increase over vehicle, p<0.001 n=3 versus vehicle-treated 
control) was modestly inhibited by forskolin and rolipram in combination (34±8% 
inhibition by Fsk + Roli versus sIL-6Rα/IL-6-treated alone cells, p<0.05, n=3) and 
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forskolin alone (25±8% inhibition by Fsk versus sIL-6Rα/IL-6-treated alone cells, 
p<0.05, n=3) (Figure 4.6). No inhibition of leptin induced STAT3 activation was 
observed in response to Fsk and Roli treatment (Figure 4.8).  
In summary, these results show that pre-treatment of HUVECs with the cAMP 
elevating agents Fsk and Roli in combination for 5 hours substantially reduces the 
MEK-stimulated Thr and Tyr phosphorylation of ERK1,2 and the JAK stimulated 
Tyr phosphorylation of STAT3 in response to sIL-6Rα/IL-6. Additionally, Fsk and 
Roli pre-treatment in combination and Fsk treatment alone substantially inhibits 
leptin-induced Tyr phosphorylation of STAT3. In AS-Ms, the Tyr phosphorylation of 
STAT3 in response to sIL-6Rα/IL-6 was only modestly inhibited by Fsk and Roli in 
combination and Fsk alone. Leptin-induced Tyr phosphorylation of STAT3 was not 
inhibited by Fsk and Roli in combination or by either treatment alone. Levels of 
cAMP were not measured following 5 hours treatment with Fsk and Roli, since 
accumulation of SOCS3 was detected much earlier than 5 hours (Figure 3.12) and 
this was demonstrated to be preceeded by cAMP elevation, as determined by 
CREB phosphorylation (Figures 3.15 & 3.16). Lastly, Thr and Tyr phosphorylation 
levels of ERK1,2 in response to sIL-6Rα/IL-6 and leptin in AS-Ms were no greater 
than basal levels of ERK1,2 phosphorylation. Thus, the effect of Fsk and Roli on 
sIL-6Rα/IL-6- or leptin-stimulated ERK1,2 phosphorylation could not be assessed 
in AS-Ms. 
Downstream Effects of cAMP-Mediated ERK1,2 Inhibition 
The above results demonstrate a cAMP-mediated inhibition of sIL-6Rα/IL-6 and 
leptin signalling, but only demonstrate this inhibition at the level of ERK1,2 and 
STAT3 phosphorylation. To assess the inhibitory effect of cAMP further 
downstream and to potentially better understand possible biological consequences 
of this inhibitory effect in both cell types, a downstream effector of ERK1,2 was 
analysed. The well characterised ERK-responsive transcription factor Elk-1 has 
been demonstrated to become phosphorylated at multiple sites within the C-
terminal transcriptional activation domain following binding of MAP kinases to the 
MAP kinase docking motif. This leads to increased Elk-1 transcriptional activation 
potential (Gille et al., 1995; Yang et al., 2002). To initially determine whether Elk-1 
transcriptional activity increases following sIL-6Rα/IL-6 and leptin treatment in both 
cell types, a trans-acting reporter gene assay system was used. Cells were co-
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transfected with a trans-activator plasmid (Gal4-Elk-1), a luciferase reporter 
plasmid (Gal4-luc) and a normalisation Renilla plasmid (pRL-CMV). Gal4-Elk-1 
encodes a protein comprising the yeast Gal4 DNA-binding domain fused to the 
activation domain of Elk-1 and Gal4-luc contains the Gal4-binding element 
upstream of a luciferase reporter gene. Gal4-Elk-1 chimeric protein will 
accumulate in the cell as a result of the CMV promoter. Once activated by 
ERK1,2, a conformational change will allow the Gal4 DNA-binding domain to bind 
to the Gal4-binding element, which will drive transcription of luciferase. Both these 
constructs (Gal4-Elk-1 and Gal4-luc) have been used successfully to demonstrate 
Elk-1 activation following nociceptin treatment in CHO cells stably expressing the 
human opioid receptor-like 1 (ORL1) receptor (Bevan et al., 1998). In the present 
study, cells were treated with sIL-6Rα/IL-6, leptin and PMA for 6 hrs and 
luminescence was read using a luminometer. The readings were expressed as 
average ratios of Firefly over Renilla luciferase activity from 3 independent 
experiments performed in triplicate. Results revealed a trend of increased Elk-1 
transcriptional activity in response to PMA treatment in both HUVECs and AS-Ms. 
However, this increase was not found to be statistically significant over basal 
levels of Elk-1 transcriptional activity in both cell types. Furthermore, Elk-1 
transcriptional activity following either sIL-6Rα/IL-6 and leptin treatment was either 
not increased or very modestly increased over basal levels of Elk1 transcriptional 
activity and was again found to be not statistically significant (Figure 4.9a & b). 
Thus, the further utilisation of these reporter gene assays to test the inhibitory 
effects of cAMP elevation on Elk-1 transcriptional activity was not feasible. It 
should, however be noted that some individual biological replicates of these 
assays did display statistically significant increases in Elk-1 transcriptional activity 
in response to PMA when compared to basal levels of Elk-1 transcriptional activity, 
and these increases were shown to be ERK dependent, since pre-treatment of the 
cells with the MEK inhibitor U0126 abolished Elk-1 activity. An example of one 
such replicate in HUVECs is shown in Figure 4.9c. Additionally, experiments were 
carried out for 12 hr treatments of sIL-6Rα/IL-6, leptin and PMA, but no increase in 
Elk-1 transcriptional activity over basal levels was observed (data not shown).  
As a follow-up to the reporter gene assay results above, experiments were 
conducted to assess the translocation of ERK1,2 into the nucleus following sIL-
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6Rα/IL-6 and leptin treatment. These experiments were carried out to assess 
whether or not the inability of sIL-6Rα/IL-6 and leptin treatment to induce Elk-1 
transcriptional activity, was possibly due to poor translocation of ERK1,2 into the 
nucleus after stimulation with sIL-6Rα/IL-6 and leptin. HUVECs and AS-Ms were 
treated with sIL-6Rα/IL-6 and leptin for 30 minutes before isolating both nuclear 
and cytoplasmic cell fractions for detection of phosphorylated ERK1/2 and STAT3 
by immunoblotting. SP1, a transcription factor, which binds to GC box promoter 
elements and tubulin, a cytoskeleton protein, were analysed in both fractions to 
confirm the isolation of nuclear and cytosolic preparations respectively. PMA-
treated cells were used as a positive control in these experiments. In HUVECs, an 
increase in ERK1,2 phosphorylation in response to PMA treatment was observed 
in both the nuclear cell fraction (6±2 fold increase over vehicle, p<0.05 n=3 versus 
vehicle-treated control) and the cytoplasmic cell fraction (10±1 fold increase over 
vehicle, p<0.001 n=3 versus vehicle-treated control). Levels of ERK1,2 
phosphorylation in response to sIL-6Rα/IL-6 in HUVECs were increased in the 
nuclear fraction only (3±0.4 fold increase over vehicle, p<0.05 n=3 versus vehicle-
treated control), whereas leptin treatment did not induce ERK1,2 phosphorylation 
in either cytoplasmic or nuclear fractions (Figure 4.10). When examining STAT3 
activation in HUVECs, levels of phosphorylated STAT3 were increased in 
response to sIL-6Rα/IL-6 in the cytoplasmic fraction (22±4 fold increase over 
vehicle, p<0.01 n=3 versus vehicle-treated control). STAT3 phosphorylation levels 
were also increased in response to leptin in the nuclear fraction (5±0.5 fold 
increase over vehicle, p<0.01 n=3 versus vehicle-treated control). In AS-Ms, 
ERK1,2 phosphorylation in response to PMA treatment was increased in both the 
cytoplasmic fraction (17±5 fold increase over vehicle, p<0.05 n=3 versus vehicle-
treated control) and the nuclear fraction (16±5 fold increase over vehicle, p<0.05 
n=3 versus vehicle-treated control). However, neither sIL-6Rα/IL-6- or leptin-
induced ERK1,2 phosphorylation was significantly above basal levels of ERK1,2 
phosphorylation in either fractions (p>0.05). When examining STAT3 activation in 
AS-Ms, an increase in STAT3 phosphorylation was observed in response to sIL-
6Rα/IL-6 (8±1 fold increase over vehicle, p<0.01 n=3 versus vehicle-treated 
control) and leptin treatment (3±1 fold increase over vehicle, p<0.05 n=3 versus 
vehicle-treated control) in the nuclear fraction. Levels of STAT3 phosphorylation in 
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response to both sIL-6Rα/IL-6 and leptin in the cytoplasmic fractions were not 
significantly greater than basal levels of STAT3 phosphorylation (p>0.05) (Figure 
4.11).  
To summarise the results, which are relevant to the reporter gene assay, a marked 
increase in ERK1,2 phosphorylation levels in both cell fractions was observed 
following PMA treatment in both cell types. However, when examining sIL-6Rα/IL-
6- and leptin-stimulated ERK1,2 phosphorylation in both cell types, only sIL-
6Rα/IL-6-stimulated ERK1,2 phosphorylation in the nuclear fraction of HUVECs 
was significantly above basal levels of ERK1,2 phosphorylation. 
Mechanism of Inhibition – Examining a Role for PKA and/or Epac 
Although the above results were of interest in terms of the downstream effect of 
cAMP elevation on sIL-6Rα/IL-6 and leptin signalling, the present study aimed to 
focus on the molecular mechanism of cAMP inhibition. Therefore, to further 
investigate the working hypothesis, experiments were carried out to assess the 
contribution of the two major cAMP sensors; PKA and Epac in the observed 
inhibition of ERK1,2 and STAT3 phosphorylation following cAMP elevation. Both 
H89 and 8pCPT were optimised in previous experiments, which are detailed in 
Chapter 3. In the first instance, when examining a role for PKA in cAMP-mediated 
effects, pre-treatment of HUVECs with 5µM H89 followed by Fsk and Roli 
treatment for 5 hrs had the effect of significantly inhibiting both ERK1,2 
phosphorylation (70±17% inhibition by Fsk + Roli + H89 versus sIL-6Rα/IL-6-
treated alone cells, p<0.05, n=3) and STAT3 phosphorylation (73±5% inhibition by 
Fsk + Roli + H89 versus sIL-6Rα/IL-6-treated alone cells, p<0.001, n=3) in 
response to sIL-6Rα/IL-6. The inhibition of sIL-6Rα/IL-6-stimulated ERK1,2 
phosphorylation observed in the presence of H89 was not significantly different 
from that seen in HUVECs pre-treated with Fsk and Roli in the absence of H89 
(p>0.05). Indeed, the inhibition of sIL-6Rα/IL-6-stimulated STAT3 phosphorylation 
following Fsk and Roli treatment in the presence of H89 was even shown to be 
greater than the inhibition of sIL-6Rα/IL-6-stimulated STAT3 phosphorylation 
following Fsk and Roli treatment alone (73±5% inhibition by Fsk + Roli + H89 
versus 50±3% inhibition by Fsk + Roli, p<0.05 n=3) (Figures 4.12 & 4.13). Thus, 
pre-treatment of HUVECs with H89 at a concentration shown to be effective in 
previous experiments (Figure 3.15) could not reverse the inhibitory effect of Fsk + 
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Roli on sIL-6Rα/IL-6-stimulated ERK1,2 and STAT3 phosphorylation. These 
results discount a role for PKA in cAMP-mediated inhibition, and may even 
suggest a partial repressive effect of PKA on cAMP-mediated inhibition of STAT3 
activation in response to sIL-6Rα/IL-6. In comparison, the effect of H89 in AS-Ms 
could not be assessed, since basal levels of ERK1,2 phosphorylation were high 
and neither sIL-6Rα/IL-6- or leptin-induced ERK phosphorylation were significantly 
above these levels (p>0.05 n=3) (Figures 4.14 & 4.15), as observed in previous 
experiments (Figures 4.5 & 4.7).  
When examining a role for Epac in cAMP-mediated inhibition of ERK1,2 and 
STAT3 phosphorylation in response to sIL-6Rα/IL-6 , HUVECs and AS-Ms were 
pre-treated with the Epac-selective cAMP analogue 8pCPT at 100µM for 5 hrs and 
ERK1,2 and STAT3 phosphorylation was assessed by immunoblotting. The 
experiment aimed to test whether or not 8pCPT could mimic the inhibitory effect of 
Fsk and Roli on sIL-6Rα/IL-6-stimulated ERK1,2 and STAT3 phosphorylation, and 
thus determine a potential role for Epac in this inhibition. The present results 
revealed that there was no significant difference between the levels of ERK1,2 
phosphorylation in response to sIL-6Rα/IL-6 following 8pCPT treatment (with or 
without H89), and sIL-6Rα/IL-6-treated alone cells (p>0.05 n=3) (Figure 4.12). 
8pCPT treatment therefore had no effect on IL-6Rα/IL-6-stimulated ERK1,2 
phosphorylation and could not recapitulate the effects of Fsk and Roli treatment on 
sIL-6Rα/IL-6-stimulated ERK1,2 phosphorylation in HUVECs. It should be noted 
that the effects of 8pCPT treatment on ERK1,2 phosphorylation in HUVECs were 
variable, and as a consequence produced large standard error values. Variability 
using 8pCPT was also demonstrated in earlier experiments in Chapter 3 (Figure 
3.13). Thus, a possible effect of 8pCPT on ERK1,2 phosphorylation may be 
masked by the variability in the fold stimulation. In comparison, when analysing 
STAT3 phosphorylation, 8pCPT treatment was shown to cause a 47±13% 
inhibition of STAT3 phosphorylation in the absence of H89 (p<0.05 n=3 versus IL-
6Rα/IL-6-treated alone cells) and a 63±14% inhibition of STAT3 phosphorylation in 
the presence of H89 (p<0.05 n=3 versus IL-6Rα/IL-6-treated alone cells) which 
were comparable and not significantly different from the levels of STAT3 
phosphorylation in response to sIL-6Rα/IL-6 following Fsk and Roli pre-treatment 
with or without H89 (p>0.05 n=3) (Figure 4.13). In addition, there was no 
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significant difference between the STAT3 phosphorylation levels following 8pCPT 
treatment with or without H89 pre-treatment (p>0.05 n=3). 
Mechanism of Inhibition – Examining a Role for SOCS3 
The above experiments suggest a PKA-independent inhibition of IL-6Rα/IL-6-
stimulated ERK1,2 and STAT3 activation following Fsk and Roli treatment in 
HUVECs. Furthermore, they also suggest a potential role for Epac in the inhibition 
of IL-6Rα/IL-6-stimulated STAT3 activation. The present study focuses on SOCS3 
as a possible mediator of these inhibitory effects and since previous experiments 
in the Palmer lab have suggested the involvement of Epac in SOCS3 induction 
(Sands et al., 2006), it would be of interest to further investigate a role for SOCS3 
in cAMP-mediated inhibition. Results from Chapter 3 demonstrated SOCS3 
induction following treatment of HUVECs and AS-Ms with Fsk and Roli (Figure 
3.12). Results from the Palmer lab showed that this induction was PKA-
independent, by pre-treating the cells with H89 and observing no inhibition of 
SOCS3 induction following Fsk treatment. Additionally, expression of a 
constitutively active GTPase-deficient Val12Rap1a was shown to be capable of 
triggering SOCS3 accumulation (Sands et al., 2006). Collectively, these results, 
together with results from Chapter 3 showing a trend of SOCS3 accumulation 
following 8pCPT treatment in HUVECs and AS-Ms (Figure 3.13 & 3.14) suggest 
an Epac-mediated SOCS3 induction, which is independent of PKA and potentially 
leads to the inhibition of IL-6Rα/IL-6-stimulated ERK1,2 and STAT3 activation. 
To specifically test the involvement of SOCS3 in the inhibitory effects of cAMP on 
IL-6Rα/IL-6 and leptin signalling, siRNA was employed. In the first instance, 
HUVECs and AS-Ms were treated with increasing concentrations of SOCS3 
siRNA and Fsk and Roli-mediated induction of SOCS3 was detected by 
immunoblotting. These experiments were conducted to identify a suitable 
concentration of SOCS3 siRNA for use in future experiments. The immunoblots 
show that concentrations as low as 1nM were sufficient to substantially attenuate 
Fsk and Roli-mediated induction of SOCS3 (Figure 4.16a. & b.). The control 
siRNA used in this experiment comprised of a scrambled, non-targeting sequence. 
Therefore, it was used as a negative control in the present experiment and all 
subsequent SOCS3 siRNA experiments. Results from these experiments identified 
10nM as a suitable concentration to use in further SOCS3 siRNA experiments, 
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based on extent of knock-down of SOCS3 in both cell types, and cost 
effectiveness. Under conditions in which Fsk and Roli-mediated induction of 
SOCS3 was significantly attenuated (14±3 fold increase over vehicle in control 
siRNA-treated HUVECs versus 5±1 fold increase over vehicle in SOCS3 siRNA-
treated HUVECs, p<0.05 n=3) (Figure 4.17), Fsk and Roli- mediated inhibition of 
IL-6Rα/IL-6-stimulated ERK1,2 phosphorylation was completely abolished (70±7% 
inhibition in control siRNA-treated HUVECs versus 5±18% inhibition [not 
significantly different from IL-6Rα/IL-6-treated alone cells] in SOCS3 siRNA-
treated HUVECs, p<0.05 n=3) (Figure 4.18). The inhibition of IL-6Rα/IL-6-
stimulated STAT3 phosphorylation following Fsk and Roli treatment in the 
presence of SOCS3 siRNA was also attenuated in HUVECs, although not to the 
same extent as the attenuation of phosphorylated ERK1,2 inhibition shown above 
(71±2% inhibition in control siRNA-treated HUVECs versus 23±3% inhibition in 
SOCS3 siRNA-treated HUVECs, p<0.001 n=3) (Figure 4.19). When examining the 
inhibition of leptin-stimulated STAT3 phosphorylation following Fsk and Roli 
treatment in HUVECs, a modest attenuation of inhibition was observed in the 
presence of SOCS3 siRNA (76±4% inhibition in control siRNA-treated HUVECs 
versus 56±5% inhibition in SOCS3 siRNA-treated HUVECs, p<0.001 n=4) (Figure 
4.20). In AS-Ms, under conditions in which Fsk and Roli-mediated induction of 
SOCS3 was attenuated (Figure 4.21) Fsk and Roli- mediated inhibition of IL-
6Rα/IL-6-stimulated ERK1,2 and STAT3 phosphorylation was not significantly 
attenuated by SOCS3 siRNA treatment ([ERK1,2] 70±7% inhibition in control 
siRNA-treated AS-Ms versus 54±13% inhibition in SOCS3 siRNA-treated AS-Ms, 
p>0.05 n=3 [STAT3] 37±12% inhibition in control siRNA-treated AS-Ms versus 
36±10% inhibition in SOCS3 siRNA-treated AS-Ms, p>0.05 n=3) (Figures 4.22 & 
4.23 respectively). 
Further to these siRNA experiments, a second approach was employed to 
specifically test the involvement of SOCS3 in the inhibitory effects of cAMP 
elevation. This approach utilised W/T (SOCS3+/+) and SOCS3-/- murine embryonic 
fibroblasts (MEFs) to compare the inhibitory effect of Fsk and Roli treatment in 
both cell types. To initially confirm the absence of SOCS3 in SOCS3-/- MEFs, cells 
were treated with Fsk and Roli for 5 hours prior to detection of SOCS3 expression 
by immunoblotting. Results revealed a 4±0.2 fold increase in SOCS3 expression 
144 
 
over vehicle in W/T MEFs following Fsk and Roli treatment (p<0.001 n=3 versus 
vehicle-treated control), but no expression of SOCS3 was detected in SOCS3-/- 
MEFs with or without Fsk and Roli treatment (Figure 4.24). When examining the 
inhibitory effects of cAMP in both cell types, Fsk and Roli-mediated inhibition of IL-
6Rα/IL-6-stimulated ERK1,2 phosphorylation was significantly attenuated in 
SOCS3-/- MEFs (64±0.4% inhibition in W/T MEFs versus 19±2% inhibition in 
SOCS3-/- MEFs, p<0.001 n=3) (Figure 4.25). Further to this, the inhibition of IL-
6Rα/IL-6-stimulated STAT3 phosphorylation was completely abolished in SOCS3-/- 
MEFs (46±10% inhibition in W/T MEFs versus 3±8% inhibition [not significantly 
different from IL-6Rα/IL-6-treated alone cells] in SOCS3-/- MEFs, p<0.05 n=3) 
(Figure 4.26).  
Taken together, the results from the siRNA experiments and the MEFs 
experiments demonstrate that SOCS3 does have a role to play in the cAMP-
mediated inhibition of IL-6Rα/IL-6-stimulated ERK1,2 phosphorylation in HUVECs 
and MEFs. Additionally, the involvement of SOCS3 in cAMP-mediated STAT3 
inhibition was demonstrated in response to leptin in HUVECs and in response to 
IL-6Rα/IL-6 in MEFs. These results also show that the SOCS3-mediated inhibitory 
effects of cAMP on IL-6Rα/IL-6 signalling are not only limited to endothelial cells 
and may be a feature common to various cell types. On the other hand, SOCS3 
siRNA appeared to have no effect on the cAMP-mediated inhibition of both 
ERK1,2 and STAT3 phosphorylation in response to IL-6Rα/IL-6 in AS-Ms, implying 
that SOCS3 is not involved in this inhibitory mechanism in AS-Ms. 
Mechanism of Inhibition – Effects of PMA 
To strengthen the involvement of SOCS3 in the cAMP-mediated inhibitory 
mechanism, experiments were conducted to investigate the level at which the 
inhibition was occurring within the ERK1,2 signalling pathway. PMA, a direct 
protein kinase C activator (PKC) is known to intercept the ERK1,2 pathway at the 
level of Raf via PKC phosphorylation of Raf-1 (Kolch et al., 1993). However, 
studies have also demonstrated a Ras-dependent activation of ERK1,2 by PMA-
induced PKC activation (Verin et al., 2000). Additionally, other 
diacylglycerol/phorbol ester effectors exist, including RasGRPs, which can activate 
Ras independent of PKC (Brose & Rosenmund, 2002). SOCS3 intercepts the 
ERK1,2 pathway at the level of the receptor, upstream of Raf-1 and Ras. A very 
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well documented mode of cAMP inhibition on growth factor-stimulated  ERK1,2 
activation is the direct phosphorylation of Raf-1 by PKA at 3 serine residues; S43, 
S233 and S259, all of which have been shown to block Raf-1 interaction with GTP-
Ras (Dhillon et al., 2002b; Dumaz et al., 2002; Wu et al., 1993). Thus, to reinforce 
the notion that cAMP-mediated inhibition observed in the present study is due to 
SOCS3 and is independent of PKA, HUVECs were pre-treated with Fsk and Roli 
for 5 hours prior to 1 µM PMA treatment for 5 minutes. It was hypothesised that 
Fsk and Roli pre-treatment would have no effect on PMA-stimulated ERK1,2 
activation if indeed the cAMP-mediated mechanism of inhibition was SOCS3-
dependent and PKA-independent. However, if the well described PKA-mediated 
inhibition at the level of Raf-1 was involved, an inhibition of ERK1,2 
phosphorylation may be observed. Further to testing these assumptions, this 
experiment would also test whether or not the inhibition observed in the present 
study was specific for the signalling pathways examined. Results revealed that 
there was no inhibition of PMA-stimulated ERK1,2 phosphorylation following Fsk 
and Roli pre-treatment in the presence or absence of H89 in HUVECs (Figure 
4.27). To rule out the possibility that the concentration of PMA was masking any 
inhibitory effects of Fsk and Roli, varying concentrations of PMA were tested and 
even at concentrations as low as 0.2nM no inhibitory effects were observed (data 
not shown). Thus, the results supported the involvement of SOCS3 in the 
inhibitory mechanism and possibly further discounted a role for PKA in this 
mechanism. Additionally, the results also suggested a mode of inhibition which is 
specific for IL-6Rα/IL-6 and leptin signalling. 
As a follow-up to this, experiments were conducted to examine the effect of Fsk 
and Roli treatment over a shorter duration prior to PMA treatment, since studies 
have demonstrated cAMP-mediated inhibition of phorbol ester-stimulated ERK1,2 
phosphorylation following treatment with cAMP-elevating agents for 10 minutes in 
A14 cells (Burgering et al., 1993) and 15 minutes in MC3T3-E1 osteoblasts 
(Siddhanti et al., 1995). However, results revealed that there was no inhibition of 
PMA-stimulated ERK1,2 phosphorylation following Fsk and Roli pre-treatment for 
15 minutes in the presence or absence of H89 in HUVECs (Figure 4.28). Of 
interest, phosphorylated ERK1,2 levels were increased above basal in response to 
Fsk and Roli treatment alone for 15 minutes (6±1 fold increase over vehicle, 
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p<0.05 n=3 versus vehicle-treated control). Moreover, levels of ERK1,2 
phosphorylation were inhibited by pre-treating the cells with H89 (6±1 fold increase 
over vehicle versus 2±0.1 fold increase over vehicle, p<0.05 n=3). This is in 
contrast to the lack of ERK1,2 phosphorylation in response to Fsk and Roli 
treatment over 5 hours with or without H89 (Figure 4.27). These results are of 
interest since studies in the Palmer lab have demonstrated an ERK-dependent 
and JAK-independent induction of SOCS3 following Fsk and Roli treatment in 
HUVECs (Sands et al., 2006). The present results may therefore strengthen the 
involvement of ERK1,2 in SOCS3 induction. 
Mechanism of Inhibition – Examining a Role for ERK1,2 
However, to put this result in the context of cAMP-mediated inhibition, the next 
experiments investigated the effect of the MEK1,2 inhibitor U0126 on cAMP-
mediated inhibition of STAT3 phosphorylation in HUVECs. Cells were pre-treated 
with and without U0126 prior to Fsk and Roli treatment for 5 hours. Levels of 
ERK1,2 and STAT3 phosphorylation were examined in response to IL-6Rα/IL-6 by 
immunoblotting. In the first instance, results from these experiments revealed that 
levels of ERK1,2 phosphorylation were not significantly above basal following IL-
6Rα/IL-6 or PMA treatment in the presence of U0126 (p>0.05), which is in contrast 
to ERK1,2 phosphorylation levels following IL-6Rα/IL-6 and PMA treatment in the 
absence of U0126 (5±0.1 fold increase over vehicle, p<0.001 n=3, 12±4 fold 
increase over vehicle, p<0.05 n=3, respectively). Furthermore, a cAMP-mediated 
inhibition of IL-6Rα/IL-6-stimulated ERK1,2 phosphorylation was observed in 
HUVECs in the absence of U0126 (54±11% inhibition by Fsk + Roli versus sIL-
6Rα/IL-6-treated alone cells, p<0.05, n=3) (Figure 4.29). Thus, under conditions in 
which ERK1,2 phosphorylation was abolished, the ability of Fsk and Roli to inhibit 
sIL-6Rα/IL-6-stimulated STAT3 phosphorylation was severely impaired (56±2% 
inhibition in control HUVECs versus sIL-6Rα/IL-6-treated alone cells, p<0.001 n=3, 
12±20% inhibition in U0126-treated HUVECs versus sIL-6Rα/IL-6-treated alone 
cells, p>0.05 n=3) (Figure 4.30). These experiments suggest that ERK1,2 
activation is required for cAMP-mediated inhibition of sIL-6Rα/IL-6-stimulated 
STAT3 activation in HUVECs. To further test this assumption in AS-Ms, cells were 
initially treated with Fsk and Roli for 15 minutes to determine whether or not cAMP 
elevation could activate ERK1,2. Results showed that ERK1,2 phosphorylation 
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was not increased over basal following Fsk and Roli treatment in AS-Ms, which is 
in contrast to the marked increase of ERK1,2 phosphorylation levels following 
PMA treatment (41±9 fold increase over vehicle, p<0.01 n=3) (Figure 4.31). The 
absence of ERK1,2 phosphorylation in these cells potentially suggests an absence 
of ERK1,2-mediated SOCS3 induction, and may help explain earlier results 
wherein SOCS3 siRNA had no effect on the inhibition of sIL-6Rα/IL-6-stimulated 
ERK1,2 and STAT3 phosphorylation in AS-Ms (Figure 4.22 & 4.23). However, 
earlier results also demonstrated the induction of SOCS3 following Fsk and Roli 
treatment in AS-Ms (Figure 3.12). Thus, although Fsk and Roli treatment triggers 
SOCS3 induction in these cells, the induction may be completely distinct from the 
cAMP-mediated inhibitory effects on sIL-6Rα/IL-6-stimulated ERK1,2 and STAT3 
phosphorylation in AS-Ms. However, it must be noted that only one time point was 
used to detect ERK activation following Fsk and Roli treatment in AS-Ms, and 
conclusions should not be made based on this result alone.   
Mechanism of Inhibition – Examining a Role for Epac1 
Since experiments conducted in HUVECs were generating results which were of 
greater relevance to the working hypothesis of the current study, the next 
experiments focused on HUVECs alone. Thus far, overall experiments in HUVECs 
have suggested a cAMP-mediated, SOCS3- and ERK1,2-dependent or SOCS3-
dependent inhibition of sIL-6Rα/IL-6-stimulated STAT3 and ERK1,2 
phosphorylation respectively, which is independent of PKA, and may potentially 
involve Epac. Since results from 8-pCPT experiments were not completely clear, 
another approach was used to determine the role of Epac in cAMP-mediated 
inhibition. This approach utilised Epac1 siRNA to examine the effect of Epac1 
knock-down on sIL-6Rα/IL-6-stimulated STAT3 and ERK1,2 phosphorylation 
following Fsk and Roli treatment. In the first instance, a concentration of 20nM 
Epac1 siRNA (previously optimised in the Palmer lab) was shown to cause a 
72±11% knock-down of Epac1 protein expression under basal conditions (p<0.001 
n=5 versus control siRNA-treated control) (Figure 4.32). When examining the 
effect of this knock-down on cAMP-mediated inhibition, results revealed that Fsk- 
and Roli-mediated inhibition of sIL-6Rα/IL-6-stimulated ERK1,2 phosphorylation 
was completely abolished in Epac1 siRNA-treated cells (60±5% inhibition in 
control siRNA-treated cells versus 7±15% inhibition [not significantly different from 
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IL-6Rα/IL-6-treated alone cells] in Epac1 siRNA-treated cells, p<0.05 n=5) (Figure 
4.33). Furthermore, treatment of cells with Epac1 siRNA also had the effect of 
substantially attenuating the Fsk and Roli-mediated inhibition of sIL-6Rα/IL-6-
stimulated STAT3 phosphorylation (41±3% inhibition in control siRNA-treated cells 
versus 13±4% inhibition in Epac1 siRNA-treated cells, p<0.01 n=4) (Figure 4.34). 
It may be worth noting in these Epac1 siRNA experiments that basal levels of 
ERK1,2 phosphorylation in Epac1 siRNA-treated cells were high. This may be the 
result of the broader effects of Epac1 knock-down in these cells. Epac has been 
shown to play important roles in integrin-mediated cell adhesion and cell-cell 
junction formation in endothelial cells (Fukuhara et al., 2005; Kooistra et al., 2005). 
Thus, disruption of these effects by Epac1 knock-down may be potentially 
obscuring the results. Indeed, micrograph images of the cells following siRNA 
transfection show that cells transfected with Epac1 siRNA look unhealthy 
compared with control siRNA and SOCS3 siRNA (Figure 4.35). Although this is an 
important point to consider when making any conclusions from the phosphorylated 
ERK1,2 immunblots, the basal levels of STAT3 phosphorylation following 
treatment of cells with Epac1 siRNA were not significantly different from the control 
siRNA-treated cells (p>0.05). Thus, the broader effects of Epac1 knock-down on 
the STAT3 signalling pathway appears to be unaffected. 
Mechanism of Inhibition – Summary 
To summarise the major findings in relation to the mechanism of inhibition, results 
from the present study suggest a cAMP-mediated inhibition of sIL-6Rα/IL-6-
stimulated ERK1,2 and STAT3 activation, and leptin-stimulated STAT3 activation 
in HUVECs. Results from AS-Ms were less clear, as basal levels of ERK1,2 
phosphorylation were high and assessment of cAMP-mediated inhibition of sIL-
6Rα/IL-6- and leptin-stimulated ERK1,2 activation was not feasible. Moreover, only 
a modest or indeed no inhibition of sIL-6Rα/IL-6- and leptin-stimulated STAT3 
activation respectively was observed following Fsk and Roli treatment in these 
cells. The cAMP-mediated inhibition of sIL-6Rα/IL-6-stimulated ERK1,2 and 
STAT3 activation observed in HUVECs appeared to be independent of PKA. 
Furthermore, the Fsk and Roli-mediated inhibitory effect on STAT3 activation was 
shown to be mimicked by the activation of Epac in HUVECs, suggesting the 
involvement of Epac. This result was verified by the findings that Epac1 knock-
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down in HUVECs significantly impaired sIL-6Rα/IL-6-stimulated ERK1,2 and 
STAT3 activation. Further to Epac1 involvement, SOCS3 was also shown to play a 
crucial role in the inhibition of sIL-6Rα/IL-6-stimulated ERK1,2 and STAT3 
activation in HUVECs. However, SOCS3 siRNA results suggested no involvement 
of SOCS3 in the inhibition of leptin-stimulated STAT3 activation, or sIL-6Rα/IL-6-
stimulated ERK1,2 and STAT3 activation in AS-Ms. Nevertheless, SOCS3 
involvement in the inhibitory mechanism in HUVECs was strengthened by the 
findings that SOCS3 absence in MEFs either severely attenuated or abolished 
cAMP-mediated inhibition of sIL-6Rα/IL-6-stimulated ERK1,2 and STAT3 
activation, respectively. This inhibitory effect was demonstrated to be specific for 
the sIL-6Rα/IL-6 and leptin signalling pathway, as opposed to the PMA signalling 
pathway. In addition, the inhibitory effect on sIL-6Rα/IL-6-stimulated STAT3 
activation (and presumably ERK1,2 activation) was shown to be dependent on 
ERK1,2 activation.  
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4.3 Discussion 
4.3.1 Inhibition of sIL-6Rα/IL-6 and Leptin Signalling by cAMP Elevation  
From the results of the present chapter, a potentially new pathway has been 
identified which inhibits cytokine receptor activation of ERK1,2 and STAT3 in 
endothelial cells. An inhibition of both IL-6 and leptin signalling in response to 
cAMP elevation in HUVECs has been observed. Of particular relevance to the 
present study is the inhibition of sIL-6Rα/IL-6–induced ERK1,2 activation following 
cAMP elevation. These findings are in agreement with other studies; for example, 
Sobota and co-workers have demonstrated an inhibition of IL-6-induced ERK1,2 
activation following forskolin (Fsk) treatment in human dermal fibroblasts (Sobota 
et al., 2008).  
In general, inhibition of ERK1,2 by cAMP has been documented in numerous cell 
types, including NIH3T3 fibroblasts, Rat-1 fibroblasts, adipocytes and smooth 
muscle cells (Burgering et al., 1993; Cook & McCormick, 1993; Osinski & Schror, 
2000; Sevetson et al., 1993; Wu et al., 1993). In comparison, cAMP elevation has 
also been shown to activate the ERK1,2 pathway in certain cell types, such as rat 
PC12 cells, N1E-115 neuroblastoma cells and melanocytes (Keiper et al., 2004; 
Wang et al., 2006). cAMP has been shown to exert these positive or negative 
effects on ERK1,2 signalling via a number of mechanisms. For example, when 
examining the activation of ERK1,2 by cAMP in PC12 rat pheochromocytoma 
cells, Wang et al. (2006) described a PKA-dependent activation of Rap1 via the 
Rap-GEF Crk SH3 domain Guanine nucleotide exchange (C3G). Active GTP-
bound Rap1, in turn, directly binds and activates B-Raf, leading to ERK1,2 
activation (Wang et al., 2006). A PKA-dependent activation of ERK1,2 via Rap1 
and B-Raf activation has also been demonstrated in HEK293 cells (Schmitt & 
Stork, 2000). Alternatively, Keiper and co-workers have described a more indirect 
pathway leading to ERK1,2 activation by cAMP, which is independent of PKA. 
These investigators provided evidence for a Rap2b/phospholipase C (PLC)-
ε/RasGRP pathway, leading to the accumulation of GTP-bound Ras and 
subsequent ERK1,2 activation in HEK293 cells and N1E neuroblastoma cells. 
Specifically, Epac-mediated activation of Rap2B was shown to activate PLC-ε, 
leading to an increase in intracellular calcium, and the subsequent activation of the 
RasGRP family of Ras-specific GEFs. This was followed by the activation of H-
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Ras and finally ERK1,2 (Keiper et al., 2004). Yet another pathway describes how 
cAMP can activate ERK1,2 via activation of the GEF CNRasGEF, which leads to 
Ras activation and subsequent ERK1,2 activation in melanoma cells (Amsen et 
al., 2006). 
Conversely, cAMP can inhibit ERK1,2 activation via several mechanisms. One of 
which (detailed in Chapter 4 Introduction) involves the direct phosphorylation of 
Raf-1 by PKA at multiple sites in its N-terminal domain, which block Raf-1 
interaction with Ras (Dhillon et al., 2002b; Dumaz & Marais, 2005). This 
mechanism has been well described for the cAMP-mediated inhibition of growth 
factor signalling and more recently has been proposed to be responsible for the 
cAMP-mediated PKA-dependent inhibition of sIL-6Rα/IL-6–induced ERK1,2 
activation (Sobota et al., 2008). Another model of ERK1,2 inhibition by cAMP 
involves the phosphorylation and activation of Src-kinase by PKA, which leads to 
the activation of Rap1. GTP-bound Rap1 is then believed to sequester Raf-1, 
preventing its activation by Ras and consequently inhibiting ERK1,2 activation 
(Schmitt & Stork, 2001; Schmitt & Stork, 2002). Further to this, an alternative PKA-
dependent inhibitory mechanism involves the induction of mitogen-activated 
protein kinase phosphatase 1 (MKP-1, also known as DUSP1). MKP-1 
dephosphorylates MAPKs (ERK, JNK and p38 MAPKs) on tyrosine and threonine 
residues. MKP-1 has been shown to be induced following cAMP elevation in a 
PKA-dependent manner. Thus, dephosphorylation of ERK1,2 by MKP-1 
represents another inhibitory mechanism (Burgun et al., 2000; Sewer & 
Waterman, 2003). In summary, a number of mechanisms have been ascribed to 
the inhibition or activation of ERK1,2 in a variety of cell types, highlighting the 
complexity of ERK1,2 regulation by cAMP. 
When examining the STAT3 pathway, a cAMP-mediated inhibition of sIL-6Rα/IL-
6– and leptin-induced STAT3 activation in HUVECs was observed. These results 
are in contrast to the findings by Sobota and co-workers (2008); demonstrating no 
inhibition of STAT3 activation in response to cAMP elevation in human dermal 
fibroblasts (Sobota et al., 2008). This may be due to different experimental 
conditions, since these investigators treated the cells with sIL-6Rα/IL-6 for up to 60 
minutes in the presence or absence of Fsk, whereas the present study pre-treated 
the cells with Fsk and rolipram (Roli) for 5 hours. Indeed, it could be postulated 
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that short-term effects of cAMP in HUVECs lead to the inhibition of ERK1,2 
activation via the phosphorylation of Raf1 by PKA (described above), whereas 
long-term effects of cAMP in HUVECs result in the inhibition of both ERK1,2 and 
STAT3 via a mechanism distinct from Raf1 phosphorylation and activation. 
Certainly, part of the basis of this current work was to discount the involvement of 
the well described PKA-Raf1 inhibitory mechanism in the cAMP-mediated 
inhibition observed in the present study. However, work carried out by Sengupta 
and co-workers (1996), showed that IL-6-induced STAT3 binding to a high affinity 
serum-inducible element (hSIE) oligonucleotode in human mononuclear cells was 
inhibited following only 60 minutes pre-incubation with 8-Br-cAMP (Sengupta et 
al., 1996). This therefore also suggests the presence of cell-type specific effects of 
cAMP and is supported by the present results showing that STAT3 activation in 
response to sIL-6Rα/IL-6 was only modestly inhibited by cAMP elevation in AS-Ms 
and leptin-induced STAT3 activation was not inhibited at all, despite using exactly 
the same experimental conditions. Furthermore, the effects of cAMP on sIL-
6Rα/IL-6- or leptin-induced ERK1,2 activation in AS-Ms could not be assessed as 
levels of ERK1,2 activation in response to both these cytokines were no greater 
than basal levels of ERK1,2 activation. It may be worth noting however that cAMP 
elevation substantially reduced “basal levels” of ERK1,2 in these cells, which has 
been demonstrated in other studies. For example, Wang and co-workers (2001) 
demonstrated inhibition of ERK1,2 phosphorylation in response to 8-CPT-cAMP, 
Fsk and isoproterenol when compared to basal levels of ERK1,2 phosphorylation 
in rat C6 glioma cells (Wang et al., 2001). Thus, although both cell types were 
endothelial in origin and both cell types were subjected to the same experimental 
conditions, each cell type responded differently to cAMP elevation on IL-6 and 
leptin signalling. It is well known that endothelial cells from different origins display 
variation with respect to their biochemical and immunological properties (Aird, 
2005). Therefore, the differences observed between these cell types may be 
attributable to the different origins of these cells. Of particular relevance, AS-Ms 
are derived from a cutaneous angisarcoma (Krump-Konvalinkova et al., 2003). As 
a cancerous cell line, high basal levels of ERK1,2 activation may be expected in 
these cells.  
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4.3.2 cAMP-mediated PKA-independent Inhibition of sIL-6Rα/IL-6-induced 
ERK1,2 and STAT3 Activation in HUVECs 
Further experiments focusing on the cAMP-mediated inhibition of sIL-6Rα/IL-6-
induced ERK1,2 and STAT3 activation in HUVECs demonstrated that this 
inhibition occurred via a mechanism independent of PKA. These results are 
supported by a number of studies demonstrating PKA-independent inhibitory 
effects of cAMP in endothelial cells. For example, cAMP elevation in HUVECs has 
been shown to reduce vascular permeability and enhance vascular endothelial 
(VE) cadherin-mediated adhesion via a cAMP/Epac/Rap1 pathway, which is 
independent of PKA (Cullere et al., 2005; Fukuhara et al., 2005). Conversely, 
Sobota and coworkers (2008) demonstrated a cAMP-mediated inhibition of sIL-
6Rα/IL-6-induced ERK1,2 activation via PKA-dependent phosphorylation and 
inhibition of Raf-1 (Sobota et al., 2008). Thus, results from the present study imply 
that the cAMP-mediated mechanism of inhibition is distinct from the well 
characterised PKA-dependent inhibition of Raf-1, often associated with cAMP-
mediated growth factor signalling inhibition. Furthermore, these results may also 
discount a role for MKP-1 in the inhibition of ERK1,2, since MKP-1 has been 
shown to be activated by PKA. However, MKP-1 is also induced by ERK1,2 in 
various cell types, in an inhibitory feedback manner (Brondello et al., 1997; 
Grumont et al., 1996). Previous studies from the Palmer lab and the present study 
(detailed later) have implied that activation of ERK1,2 is required to observe 
cAMP-mediated inhibition of IL-6 signalling. Thus, cAMP-mediated and ERK1,2-
dependent activation of MPK-1 could represent a mode of inhibition of sIL-6Rα/IL-
6-induced ERK1,2 activation. Additionally, the H89-insensitive inhibition of sIL-
6Rα/IL-6-induced STAT3 activation may also limit the involvement of SHP2 in the 
inhibition, since SHP2 has been shown to be positively regulated by PKA, leading 
to the stimulation of phosphatase activity (Rocchi et al., 2000). In summary, a 
PKA-independent inhibition of sIL-6Rα/IL-6-induced ERK1,2 and STAT3 activation 
has been observed in HUVECs, which could potentially discount the previously 
described PKA-dependent mechanisms of inhibition and may implicate the other 
major cAMP sensor; Epac. 
4.3.3 Epac-dependent & -independent Inhibition of sIL-6Rα/IL-6-induced 
STAT3 and ERK1,2 Activation, respectively, in HUVECs  
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The use of the Epac-selective cAMP analogue 8pCPT in this study showed that 
8pCPT could recapitulate the cAMP-mediated inhibition of sIL-6Rα/IL-6-induced 
STAT3 activation, but not ERK1,2 in HUVECs. Since HUVECs have been shown 
to express only Epac1 and not Epac2 (Fang & Olah, 2007), it may be postulated 
that an Epac1-mediated inhibitory mechanism was operational. However, this did 
not account for the inability of 8pCPT to recapitulate cAMP-mediated inhibition of 
sIL-6Rα/IL-6-induced ERK1,2 activation. Previous results from Chapter 3, together 
with the present Chapter’s results demonstrate a substantial amount of variation 
when using 8pCPT and this should be taken into account when making any 
conclusions. Indeed, varying results have been reported in the literature when 
using 8pCPT, in relation to ERK1,2 activation. As discussed later in the context of 
the present results, ERK1,2 activation appears to be necessary to observe cAMP-
mediated inhibition. Previous reports in the Palmer lab have demonstrated that 
8pCPT treatment in HUVECs could not activate ERK1,2 (data not published). This 
result is in agreement with other studies, which demonstrate Rap1 activation but 
not ERK1,2 activation in several cell lines, including CHO, OVCAR3, PC12, 
HEK293T and AtT20 (Enserink et al., 2002; Wang et al., 2006). Enserink et al. 
(2002) suggested that Epac-mediated Rap1 activation and cAMP-mediated 
ERK1,2 activation were independent processes. As such, Rap1 is incapable of 
activating ERK1,2. However, other studies have demonstrated that 8pCPT can 
activate ERK1,2 in HEK293 cells, N1E-115 neuroblastoma cells and HUVECs 
(Fang & Olah, 2007; Keiper et al., 2004). Furthermore, Wang et al. (2006) 
proposed that the inability of Rap1 to activate ERK1,2 was not due to a property of 
Rap1, but rather a property of Epac. These investigators suggested that Epac-
mediated ERK activation may be dependent on the localisation of Rap GEFs 
within the cell, and their ability to activate different pools of Rap1 (Wang et al., 
2006). Epac1 has been shown to have a distinct perinuclear expression pattern, 
whereas the Rap1 GEF C3G is cytoplasmic under basal conditions and becomes 
recruited to the plasma membrane upon activation (Qiao et al., 2002; Radha et al., 
2004). Rap1 activated by C3G is capable of activating ERK and this appears to be 
a consequence of its localisation. When the membrane targeting motif of Ki-Ras 
was fused to the C terminus of Epac1, Epac1 was relocated to the plasma 
membrane where it could activate ERK via a Rap1/BRaf mechanism (Wang et al., 
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2006). Thus, variability exists in terms of 8pCPT-Rap1 regulation of ERK1,2. The 
present results demonstrate that 8pCPT is capable of mimicking the Fsk and Roli-
mediated inhibition of sIL-6Rα/IL-6-induced STAT3 activation, but not capable of 
mimicking the Fsk and Roli-mediated inhibition of sIL-6Rα/IL-6-induced ERK1,2 
activation. This may suggest the involvement of two separate inhibitory 
mechanisms in HUVECs; an Epac1-dependent inhibition of sIL-6Rα/IL-6-induced 
STAT3 activation and an Epac1-independent inhibition of sIL-6Rα/IL-6-induced 
ERK1,2 activation. However, later experiments will disprove this assumption. A 
more likely explanation is experimental variation associated with this analogue. As 
previously mentioned in Chapter 3, 8pCPT could be getting degraded over the 5 
hour incubation period. Additionally, 8pCPT has been shown to have low 
membrane permeability. Indeed, recently a new Epac analogue has been 
developed (8-pCPT-2’-O-Me-cAMP-AM), which is more efficiently delivered into 
cells (Vliem et al., 2008). 
4.3.4 cAMP-mediated SOCS3-dependent & -independent Inhibition of sIL-
6Rα/IL-6-induced ERK1,2 and STAT3 Activation, and leptin-induced STAT3 
Activation, respectively, in HUVECs 
The PKA-independent inhibition of IL-6Rα/IL-6-stimulated ERK1,2 and STAT3 
activation following cAMP elevation, and potentially Epac1-dependent inhibition of 
IL-6Rα/IL-6-stimulated STAT3 activation in HUVECs, did not alter the levels of 
total ERK1,2 and STAT3 expression. From these observations it may be 
postulated that a post-receptor inhibitory mechanism was operational. In line with 
the working hypothesis and the involvement of SOCS3 in the inhibitory 
mechanism, previous results from the Palmer lab have shown that Fsk-mediated 
induction of SOCS3 is not inhibited by H89 in HUVECs (Sands et al., 2006). 
Additionally, expression of a constitutively active GTPase-deficient Val12Rap1a 
was shown to be capable of triggering SOCS3 accumulation in HUVECs (Sands et 
al., 2006). Further to this, depletion of Rap1a using specific siRNA targeting 
Rap1a in HUVECs substantially attenuated SOCS3 induction by Fsk and Roli. 
Furthermore, depletion of Epac1 using siRNA in HUVECs was shown to abolish 
SOCS3 induction following cAMP elevation (Sands et al., 2006). Lastly, over-
expression of RapGAP, which is known to increase the intrinsic GTPase activity of 
Rap1, was shown to severely attenuate the ability of Fsk and Roli, and 8-pCPT to 
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induce SOCS3 in HUVECs (Yarwood et al., 2008). Collectively, these results 
together with the results from Chapter 3, which show a trend of SOCS3 
accumulation following 8pCPT treatment in HUVECs and AS-Ms (Figure 3.13 & 
3.14) suggest an Epac1-mediated SOCS3 induction, which is independent of PKA. 
The possibility of SOCS3 involvement in the cAMP-mediated inhibition of IL-6 and 
leptin signalling was next investigated by using specific siRNA targeting SOCS3. 
These experiments demonstrated that SOCS3 is involved in the cAMP-mediated 
inhibition of sIL-6Rα/IL-6-induced ERK1,2 and STAT3 activation in HUVECs. 
However, a role for SOCS3 in the cAMP-mediated inhibition of leptin-induced 
STAT3 activation in HUVECs was not demonstrated. The SOCS3 binding sites on 
the leptin receptor have been identified as pTyr985 and pTyr1077. The affinity of 
SOCS3 binding to these sites has been shown to be much lower than for pTyr757 
on gp130. For example, pTyr985 has an 80-fold lower affinity for SOCS3, when 
compared to pTyr757 (De Souza et al., 2002). As an alternative to SOCS3, protein 
tyrosine phosphatase 1B (PTP1B) may be a strong candidate for the observed 
negative regulation of leptin signalling. Supporting this assumption is a study using 
PTP1B-deficient mice. These mice are hypersensitive to insulin and leptin, and are 
resistant to diet-induced obesity (Elchebly et al., 1999). A large body of evidence 
suggests that PTP1B targets leptin signaling mainly via JAK2 dephosphorylation 
and thus targets both the STAT and ERK1,2 pathways (Lavens et al., 2006). 
Interestingly, serine phosphorylation of PTP1B in response to cAMP analogues 
has been shown in HeLa cells (Brautigan & Pinault, 1993). Further to PTP1B, 
other SOCS members could be involved in the cAMP-mediated inhibition of leptin 
signalling. For example, SOCS7 has been shown to inhibit leptin-induced STAT3 
activation in HEK293T cells (Martens et al., 2005).  
4.3.5 cAMP-mediated SOCS3-independent Inhibition of sIL-6Rα/IL-6-induced 
ERK1,2 and STAT3 Activation in AS-Ms 
With regards to AS-Ms, depletion of SOCS3 in these cells demonstrated no 
involvement of SOCS3 in the cAMP-mediated inhibition of sIL-6Rα/IL-6-induced 
STAT3 and ERK1,2 activation. As mentioned previously, other inhibitory 
mechanism could be responsible for this inhibition, independent of SOCS3. For 
example, in addition to PTP1B and other SOCS members, SHP2 could possibly 
be involved. Previous work in the Palmer lab has shown that pre-treatment of 
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HUVECs with the tyrosine phosphatase inhibitor mpV does not alter the cAMP-
mediated inhibition of sIL-6Rα/IL-6-induced STAT3 activation (Sands et al., 2006). 
This argues against a role for SHP2 and other protein tyrosine phosphatases in 
the cAMP-mediated inhibition observed in HUVECs, but since this experiment was 
not performed in AS-Ms, SHP2 involvement could still be a possibility. Indeed, 
studies have shown that expression of catalytically inactive dominant negative 
SHP2 mutants results in increased gp130, JAK and STAT3 phosphorylation as 
well as gene induction (Lehmann et al., 2003; Symes et al., 1997). 
4.3.6 cAMP-mediated SOCS3-dependent Inhibition of sIL-6Rα/IL-6-induced 
ERK1,2 and STAT3 Activation in MEFs 
Further support for the involvement of SOCS3 in the cAMP-mediated inhibition of 
sIL-6Rα/IL-6 signalling in HUVECs was demonstrated when the inhibition of sIL-
6Rα/IL-6-induced ERK1,2 and STAT3 activation was shown to be severely 
attenuated in SOCS3-/- MEFs, while remaining intact in the SOCS3+/+ MEFs. 
These results strengthen the involvement of SOCS3 in the inhibitory mechanism 
and also show that the SOCS3-mediated inhibitory effects of cAMP on IL-6Rα/IL-6 
signalling were not limited to HUVECs and may be a feature common to various 
cell types. Indeed, previous work in the Palmer lab has shown that the 
cAMP/SOCS3 inhibitory pathway is also present in human aortic endothelial cells 
(HAECs), as observed by a cAMP-mediated inhibition of sIL-6Rα/IL-6-induced 
STAT3 activation and SOCS3 induction in these cells (Sands et al., 2006).  
4.3.7 PMA-stimulated ERK1,2 Activation in HUVECs – Insensitivity to cAMP 
Inhibitory Mechanism 
Further weight to the cAMP/SOCS3 pathway was added when examining the PMA 
effects in HUVECs. PMA, a direct protein kinase C (PKC) activator is known to 
intercept the ERK1,2 pathway at the level of Raf-1 (Kolch et al., 1993). This is 
supported by the findings that ERK activation following phorbol ester treatment 
does not require functional p21Ras, since a virus expressing dominant negative 
Asn17 mutant p21Ras in Rat-1 cells inhibits PDGF-mediated ERK2 activation, but 
not PMA-mediated ERK2 activation (de Vries-Smits et al., 1992). Furthermore, 
activation of p21Ras following PMA treatment could not be demonstrated under 
conditions in which insulin-induced p21Ras activation was readily observed 
(Medema et al., 1991). However, there is also evidence to suggest a Ras-
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dependent activation of ERK1,2 following PMA treatment. Interestingly, this Ras-
dependent activation of ERK1,2 in PMA-treated bovine pulmonary artery 
endothelial cells (BPAECs) was found to lead to endothelial barrier dysfunction 
(Verin et al., 2000). Further to a Raf-1-dependent and a Ras-dependent 
PMA/PKC-mediated ERK1,2 activation, other diacylglycerol/phorbol ester effectors 
have been identified. These include chimaerins, protein kinase D, RasGRPs, 
Munc13s and DAG kinase γ (Brose & Rosenmund, 2002). Of particular interest 
are the RasGRP effectors, since these comprise a family of 4 guanine nucleotide 
exchange proteins (GEFs) for Ras, all of which activate Ras in response to 
DAG/phorbol ester stimulation independent of PKC (Brose & Rosenmund, 2002). 
SOCS3 intercepts the ERK1,2 pathway at the level of the receptor, upstream of 
Raf-1 and Ras, while the well documented PKA/Raf-1 inhibitory pathway, 
mentioned previously, intercepts the ERK1,2 pathway at the level of Raf-1. In the 
present study, a cAMP-mediated inhibition of ERK1,2 activation following PMA 
stimulation in HUVECs could not be demonstrated. These results therefore 
suggest that the cAMP-mediated inhibitory effect observed in the present study 
does not appear to be intercepting the ERK1,2 pathway at the level of Ras or Raf-
1, since PMA-stimulated ERK1,2 activation is still intact. Thus, the well described 
PKA-mediated inhibitory mechanism at the level of Raf-1 may not be operating, 
making the cAMP/SOCS3 pathway a more likely inhibitory mechanism. 
Furthermore, cAMP-mediated inhibition of PMA-stimulated ERK1,2 activation 
could not be shown by pre-treating the cells with Fsk and Roli for shorter 
incubations. This is in contrast to other studies, which have demonstrated a cAMP-
mediated inhibition of PMA-stimulated ERK1,2 activation by pre-treating cells with 
cAMP-elevating agents for 5 minutes in adipocytes and CHO cells (Bradley et al., 
1993), 10 minutes in A14 cells (Burgering et al., 1993) and 15 minutes in MC3T3-
E1 osteoblasts (Siddhanti et al., 1995). Thus, the short-term effects of cAMP on 
PMA-stimulated ERK1,2 activation still do not support a role for the PKA/Raf-1 
pathway.  
4.3.8 cAMP-induced ERK1,2 Activation in HUVECs 
Interestingly, treating HUVECs with Fsk and Roli for a shorter length of time (15 
minutes) demonstrated activation of ERK1,2, whereas longer incubations (5 hours) 
showed no ERK1,2 activation. Additionally, this cAMP-mediated ERK1,2 activation 
was shown to be PKA-dependent. Previous results from the Palmer lab have 
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demonstrated that cAMP-mediated induction of SOCS3 in HUVECs is abolished 
by pre-treating the cells with the MEK inhibitor U0126. Furthermore, a selective 
JAK inhibitor was shown to have no effect on cAMP-mediated SOCS3 induction, 
but abolished SOCS3 induction in response to sIL-6Rα/IL-6 (Sands et al., 2006). 
Recently, Yarwood et al. (2008) suggested that the family of transcription factors 
termed CCAATT/enhancer binding proteins (CEBPs) link Epac activation to 
SOCS3 induction (Yarwood et al., 2008). These findings are in contrast to the 
cAMP-mediated PKA-dependent activation of ERK1,2 observed in the present 
study, but are consistent with the cAMP-mediated PKA-independent inhibition of 
sIL-6Rα/IL-6-induced ERK1,2 and STAT3 activation. Thus, the PKA-mediated 
stimulation of ERK1,2 may be distinct from the PKA-independent inhibitory 
mechanism. Intriguingly, further experiments demonstrated that ERK1,2 activation 
appears to be required for the cAMP-mediated inhibition of sIL-6Rα/IL-6-induced 
STAT3 activation, since the MEK inhibitor U0126 severely impaired STAT3 
inhibition. This result also suggests that the inhibitory effects of cAMP were not 
due to an inactivation of dual specificity ERK phosphatases, such as the 
aforementioned MKP-1. Of interest, ERK1,2 activation in response to Fsk and Roli 
could not be observed in AS-Ms. This could possibly explain earlier results 
wherein SOCS3 siRNA had no effect on the inhibition of sIL-6Rα/IL-6-stimulated 
ERK1,2 and STAT3 phosphorylation in AS-Ms. However, results from Chapter 3 
demonstrated SOCS3 induction in response to Fsk and Roli treatment in AS-Ms. 
Thus, although Fsk and Roli treatment triggers SOCS3 induction in these cells, the 
induction may be completely distinct from the cAMP-mediated inhibitory effects on 
sIL-6Rα/IL-6-stimulated ERK1,2 and STAT3 phosphorylation in AS-Ms. It is 
tempting to speculate that a strong stimulation of cAMP-mediated ERK1,2 
activation is required to observe cAMP/SOCS3 inhibition of IL-6 signalling in AS-
Ms.  
4.3.9 cAMP-mediated Epac1-dependent Inhibition of sIL-6Rα/IL-6-induced 
ERK1,2 and STAT3 activation in HUVECs 
As no pharmacological inhibitors of Epac currently exist, Epac siRNA is a powerful 
tool to determine the role of Epac in various processes, such as the regulation of 
EC permeability and the induction of SOCS3 (Kooistra et al., 2005; Sands et al., 
2006). In the present study, the depletion of Epac1 in HUVECs had the effect of 
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severely attenuating the cAMP-mediated inhibition of sIL-6Rα/IL-6-induced 
ERK1,2 and STAT3 activation. These results strongly implicate Epac1 in the 
cAMP-mediated inhibitory mechanism, which is consistent with other studies 
demonstrating Epac-mediated inhibitory effects in HUVECs, namely reduced 
vascular permeability and enhanced vascular endothelial (VE) cadherin-mediated 
cell-cell interactions. These effects were proposed to occur via a cAMP/Epac/Rap1 
pathway, which is independent of PKA (Cullere et al., 2005; Fukuhara et al., 
2005). These results are also consistent with the anti-inflammatory effects of 
cAMP in endothelial cells (Blease et al., 1998; Morandini et al., 1996; Pober et al., 
1993). Therefore, targeting the cAMP/Epac/Rap1 pathway could prove to be 
beneficial in terms of limiting a number of endothelial functions associated with 
endothelial dysfunction. In comparison, and as mentioned previously, findings from 
Sobota and co-workers (2008) demonstrated a PKA-dependent and Epac-
independent inhibition of sIL-6Rα/IL-6-induced ERK1,2 activation in human dermal 
fibroblasts (Sobota et al., 2008). It is interesting to note that the SOCS-mediated 
inhibitory mechanism observed in the present study targets gp130 and thus both 
the sIL-6Rα/IL-6-stimulated ERK1,2 and STAT3 pathways in response to cAMP 
elevation, whereas the PKA-dependent inhibitory mechanism observed in Sobota 
et al. (2008) targets Raf-1 in response to cAMP elevation and thus only the sIL-
6Rα/IL-6-stimulated ERK1,2 pathway.  
4.3.10 cAMP Selectivity - Compartmentalisation 
How and why cAMP selectively activates some pathways in some cells and other 
pathways in other cells is still unclear. This is particularly exemplified in the 
selective activation of ERK1,2 in some cells and the inhibition of ERK1,2 in other 
cells in response to cAMP as discussed earlier in this Chapter. This may be due to 
a number of reasons. For example, the signalling proteins that couple different 
pathways may be expressed in a cell type dependent manner. Alternatively, and of 
interest to the present study there is increasing evidence to support the 
compartmentalization of cAMP within the cell, which may only permit the selective 
activation of certain signaling pathways.  
Early models proposed that cAMP was distributed uniformly within cells, but it is 
now known that cAMP can also localise to discreet cellular compartments (Dodge-
Kafka et al., 2005; Netherton et al., 2007). This is in part achieved by the 
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association of PKA with A-kinase anchoring proteins (AKAPs). AKAPs are non-
enzymatic scaffolding proteins, which anchor PKA to specific subcellular structures 
(Michel & Scott, 2002). One of the first AKAPs to be described was AKAP75, 
originally identified as a contaminant in PKA type II preparations (Sarkar et al., 
1984). Since then, the family of AKAPs has increased to over 50 members. Of 
relevance to the present study, muscle-specific mAKAP signalling complexes 
identified in the heart, have been shown to comprise PKA, Epac1, PDE4D3 and 
ERK5. As mentioned previously in section 1.2.2 of the Introduction, this complex 
incorporates 2 cAMP-mediated pathways and 2 coupled cAMP-dependent 
feedback loops. Briefly, both PKA and Epac1 can become activated via ERK 
phosphorylation of PDE4D3 on Ser579 (Hoffmann et al., 1999), which suppresses 
phosphodiesterase activity leading to increased cAMP levels. Activated PKA can 
then phosphorylate PDE4D3 on Ser54 (Sette & Conti, 1996), which increases its 
affinity for cAMP and then decreases localised cAMP levels. Additionally, activated 
Epac1 can inhibit ERK5, thus preventing continued inactivation of PDE4D3 
(Dodge-Kafka et al., 2005) (Figure 4.1). This is in contrast to other studies as 
Epac- and PKA-integrated signalling is observed within the same signalling 
complex, whereas other studies have shown that PKA- and Epac-based 
complexes are distinct and cannot be found together (Netherton et al., 2007; 
Raymond et al., 2007). Furthermore, these conflicting studies also demonstrate 
that PDE3B and PDE4D are similarly non-overlapping, with PKA- or Epac-based 
signalling complexes containing either PDE3B or PDE4D but not both (Netherton 
et al., 2007; Raymond et al., 2007). Raymond and coworkers (2007) proposed that 
at least 3 signalling complexes were present in 293T cells; PDE3B-EPAC, 
PDE4D-EPAC and PDE4D-AKAP-PKA (Raymond et al., 2007). Of interest, further 
work by this group showed that the PDE3B-EPAC complex was also found in 
human aortic endothelial cells (HAECs) (Netherton et al., 2007). When examining 
the mAKAP signalling complex in rat neonatal ventriculocytes (RNVs), pre-
treatment with forskolin for 20 minutes resulted in a reduction in serum-dependent 
activation of mAKAP-associated ERK5, which could not be rescued by the PKA 
inhibitor H89 (Dodge-Kafka et al., 2005). Similar results were observed when 
using alternative PKA inhibitors, such as KT5720 and Rp-cAMPs, thereby 
implicating a PKA-independent mechanism of cAMP–mediated inhibition of ERK5 
(Dodge-Kafka et al., 2005). 8pCPT was used to assess whether Epac1 was 
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playing a role in mAKAP-associated ERK5 inhibition, and results showed that 
8pCPT treatment for 1hr recapitulated the inhibitory effect of forskolin on serum-
dependent activation of ERK5, thereby suggesting the involvement of Epac1, and 
not PKA, in mAKAP-associated ERK5 inhibition (Dodge-Kafka et al., 2005). 
Furthermore, the same group implicated Rap-1 in the inhibitory effect, since 
expression of a constitutively active RapGAP blocked cAMP–mediated inhibition of 
ERK5 (Dodge-Kafka et al., 2005). These results parallel the present results to a 
degree and may possibly suggest the presence of an analogous signalling 
complex in the present study. 
4.3.11 Possible Downstream Effects of ERK1,2 Activation 
Although the cAMP-mediated inhibitory mechanism was the main focus of the 
present study, it should be noted that in an attempt to investigate this inhibitory 
effect on ERK1,2 signalling further downstream, the transcriptional activity of the 
well characterised ERK-responsive transcription factor Elk-1 was shown to be 
unaffected by sIL-6Rα/IL-6 or leptin treatment in HUVECs (and AS-Ms). However, 
a trend of increased Elk-1 transcriptional activity following PMA treatment was 
observed in HUVECs (and AS-Ms). These findings were largely supported by the 
results from the nuclear extraction experiments, as ERK1,2 activation following 
sIL-6Rα/IL-6- or leptin treatment in the nuclear fractions of both HUVECs and AS-
Ms was substantially lower when compared to PMA-induced ERK1,2 activation in 
the nuclear fractions of both cell types. A possible explanation for these 
observations may involve the spatial regulation of MAPK and in particular the 
nucleocytoplasmic trafficking of ERK1,2. Sef (similar expression to fgf genes) is a 
transmembrane protein which has been shown to sequester activated 
MEK1,2/ERK1,2 complexes in the cytoplasm by preventing MEK1,2 dissociation. 
MEK1,2 dissociation is required for ERK1,2 translocation to the nucleus. Thus, Sef 
blocks ERK1,2 translocation, and does not appear to  affect the activity of ERK1,2 
in the cytoplasm (Kondoh et al., 2005). Of relevance to the present study, Elk-1 
transcriptional activity in response to FGF and EGF treatment in HEK293 cells and 
HeLa cells was shown to be inhibited following transfection with human Sef (hSef) 
constructs. In comparison, activation of p90 ribosomal S6 kinase 2 (RSK2) by 
FGF, a well known cytoplasmic ERK1,2 substrate was unaffected by hSef (Torii et 
al., 2004). In addition to Sef, another protein which has been shown to influence 
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ERK1,2 localisation is phosphoprotein enriched in astrocytes 15 kDa (PEA-15). 
PEA-15 has been shown to promote cytoplasmic localisation of ERK1,2 by binding 
to ERK1,2 and RSK2 and sequestering them both in the cytoplasm. PEA-15 is 
believed to act as a scaffold protein, enhancing ERK1,2 phosphorylation of RSK2. 
Lymphocytes from PEA-15 knock-out mice demonstrated diminished RSK2 activity 
in response to PMA, which is rescued by exogenous PEA-15 expression 
(Vaidyanathan et al., 2007). Thus, the possible involvement of Sef and/or PEA-15 
in sIL-6Rα/IL-6- or leptin-induced ERK1,2 activation could result in the preferential 
activation of cytoplasmic substrates, as opposed to nuclear substrates. Indeed, a 
study conducted in human bone marrow stromal cells showed that leptin induced 
apoptosis through the ERK1/2 cascade via activation of cytosolic phospholipase 
A2 (cPLA2) (Kim et al., 2003) In comparison to Sef and PEA-15 which both act to 
sequester ERK1,2 in the cytoplasm, the kinase suppressor of Ras (KRS) has been 
shown to inhibit Elk1 activity by promoting Elk-1 dephosphorylation via activation 
of the major Elk-1 phosphatase; phosphoprotein phosphatase 2B (PP2B, also 
known as calcineurin). EGF- and Ras-induced activation of Elk-1 in COS1 cells 
has been shown to be inhibited by KSR, whilst ERK1,2 activation is unaffected 
(Sugimoto et al., 1998). The involvement of KSR could possibly explain the lack of 
PMA-induced Elk-1 transcriptional activity despite observing a marked increase in 
ERK1,2 activation in the nuclear fractions following PMA treatment. However, 
further to the possible regulation of ERK1,2 and /or Elk-1 outlined above, 
consideration must also be given to experimental drawbacks such as low 
transfection efficiency. 
4.3.12 Mechanism of Inhibition - Summary 
In summary, and in relation to the inhibitory mechanism, results from this Chapter 
demonstrate a cAMP-mediated inhibition of sIL-6Rα/IL-6-stimulated ERK1,2 and 
STAT3 activation in HUVECs, which is independent of PKA. This cAMP-mediated 
inhibition was also shown to be Epac1- and SOCS3-dependent. Further to this, 
there appeared to be a requirement for ERK1,2 activation in the cAMP-mediated 
inhibition of sIL-6Rα/IL-6-stimulated STAT3 activation in HUVECs. In contrast to 
these findings, cAMP-mediated inhibition of leptin-stimulated STAT3 activation in 
HUVECs was shown to occur via a SOCS3- independent mechanism. The 
responses to cAMP elevation on sIL-6Rα/IL-6- and leptin-stimulated ERK1,2 
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activation in AS-Ms were variable, since basal levels of ERK1,2 activation were 
high. Moreover, the responses to cAMP elevation on sIL-6Rα/IL-6- and leptin-
stimulated STAT3 activation were either very modest or showed no effect, 
respectively. However, siRNA experiments demonstrated that SOCS3 was not 
involved in the cAMP-mediated inhibition of sIL-6Rα/IL-6-stimulated ERK1,2 and 
STAT3 activation in AS-Ms. Focusing on the results relevant to the working 
hypothesis of this study, the present results together with previous results from the 
Palmer lab and Yarwood et al. (2008) show an Epac1-mediated accumulation of 
GTP-bound Rap1a which is sufficient to induce SOCS3 expression possibly via 
the C/EBP family of transcription factors. SOCS3 accumulation subsequently 
leads to the inhibition of sIL-6Rα/IL-6-stimulated ERK1,2 and STAT3 activation in 
HUVECs. These inhibitory effects appear to be both ERK1,2-dependent and PKA-
independent.  
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Figure 4.1 mAKAP Complex in Cardiomyocytes  
 
Cytokines such as LIF activate ERK5, which phosphorylates PDE4D3 on Ser579, 
causing its inactivation. This leads to an increase in local cAMP levels and the 
subsequent activation of PKA and Epac1. Activated PKA phosphorylates PDE4D3 
on Ser54, which increases its affinity for cAMP and lowers the levels of cAMP. 
Additionally, activated Epac1 inhibits ERK5 via Rap1, thus preventing continued 
inactivation of PDE4D3. Therefore, both PKA and Epac1 mediate negative 
feedback of local cAMP levels within this multi-protein complex. 
(Taken from (Bos, 2006). 
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Figure 4.2 The Effect of cAMP elevating agents on ERK1,2 Phosphorylation 
by sIL-6Rα/IL-6 in HUVECs 
 
4 x 105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with PBS and treated for 5 hrs with or without 10µM forskolin 
(Fsk) and/or 10µM rolipram (Roli) in serum-free medium. Following 5 hrs, cells 
were treated with or without sIL-6Rα/IL-6 at a concentration of 25ng/ml/5ng/ml 
respectively for 30 minutes. The controls in this experiment included vehicle (V) 
treated cells, which were treated with ethanol, DMSO and PBS at the same 
volume and for the same length of time as Fsk, Roli and sIL-6Rα/IL-6 treatment 
respectively, and 1µM PMA treated cells (data not shown), a potent activator of 
ERK1,2 in endothelial cells. Following treatment, soluble cell extracts equalised for 
protein concentration were fractionated by SDS-PAGE for immunoblotting with the 
indicated antibodies. Quantitative analysis of phosphorylated ERK1,2 levels in 
HUVECs from three experiments is presented as mean values +/- standard error 
(***p<0.001 versus phosphorylated ERK1,2 levels in vehicle-treated cells, 
***p<0.001 versus phosphorylated ERK1,2 levels in sIL-6Rα/IL-6-treated alone 
cells). sIL-6Rα/IL-6-treated alone cells set at 100. Total ERK1,2 expression is also 
shown as a representative immunoblot to control for protein loading. [F=Fsk, 
R=Roli].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
167 
 
 
 
 
0
20
40
60
80
100
120
140
160
V IL-6 IL-6 + F IL-6 + R IL-6 + F/R F R F/R
E
R
K
1,
2 
Ph
os
ph
or
yl
at
io
n 
(s
IL
-6
R
/IL
-6
 s
et
 
at
 1
00
)
Treatment
*** ***
 
 
 
 
 
 
 
 
 
 
 
168 
 
Figure 4.3 The Effect of cAMP elevating agents on STAT3 Phosphorylation 
by sIL-6Rα/IL-6 in HUVECs 
 
4 x 105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with PBS and treated for 5 hrs with or without 10µM forskolin 
(Fsk) and/or 10µM rolipram (Roli) in serum-free medium. Following 5 hrs, cells 
were treated with or without sIL-6Rα/IL-6 at a concentration of 25ng/ml/5ng/ml 
respectively for 30 minutes. The controls in this experiment included vehicle (V) 
treated cells, which were treated with ethanol, DMSO and PBS at the same 
volume and for the same length of time as Fsk, Roli and sIL-6Rα/IL-6 treatment 
respectively. Following treatment, soluble cell extracts equalised for protein 
concentration were fractionated by SDS-PAGE for immunoblotting with the 
indicated antibodies. Quantitative analysis of phosphorylated STAT3 levels in 
HUVECs from three experiments is presented as mean values +/- standard error 
(***p<0.001 versus phosphorylated STAT3 levels in vehicle-treated cells, 
***p<0.001 versus phosphorylated STAT3 levels in sIL-6Rα/IL-6-treated alone 
cells). sIL-6Rα/IL-6-treated alone cells set at 100. Total STAT3 expression is also 
shown as a representative immunoblot to control for protein loading. [F=Fsk, 
R=Roli].  
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Figure 4.4 The Effect of cAMP elevating agents on STAT3 Phosphorylation 
by Leptin in HUVECs 
 
4 x 105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with PBS and treated for 5 hrs with or without 10µM forskolin 
(Fsk) and/or 10µM rolipram (Roli) in serum-free medium. Following 5 hrs, cells 
were treated with or without leptin at a concentration of 125ng/ml for 30 minutes. 
The controls in this experiment included vehicle (V) treated cells, which were 
treated with ethanol, DMSO and serum-free medium at the same volume and for 
the same length of time as Fsk, Roli and leptin treatment respectively. Following 
treatment, soluble cell extracts equalised for protein concentration were 
fractionated by SDS-PAGE for immunoblotting with the indicated antibodies. 
Quantitative analysis of phosphorylated STAT3 levels in HUVECs from three 
experiments is presented as mean values +/- standard error (***p<0.001 versus 
phosphorylated STAT3 levels in vehicle-treated cells, **p<0.01 / *p<0.05 versus 
phosphorylated STAT3 levels in leptin treated alone cells). Leptin-treated alone 
cells set at 100. Total STAT3 expression is also shown as a representative 
immunoblot to control for protein loading. [F=Fsk, R=Roli].  
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Figure 4.5 The Effect of cAMP elevating agents on ERK1,2 Phosphorylation 
by sIL-6Rα/IL-6 in AS-Ms 
 
4 x 105 AS-Ms / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with PBS and treated for 5 hrs with or without 10µM forskolin 
(Fsk) and/or 10µM rolipram (Roli) in serum-free medium. Following 5 hrs, cells 
were treated with or without sIL-6Rα/IL-6 at a concentration of 25ng/ml/5ng/ml 
respectively for 30 minutes. The controls in this experiment included vehicle (V) 
treated cells, which were treated with ethanol, DMSO and PBS at the same 
volume and for the same length of time as Fsk, Roli and sIL-6Rα/IL-6 treatment 
respectively, and 1µM PMA treated cells (data not shown), a potent activator of 
ERK1,2 in endothelial cells. Following treatment, soluble cell extracts equalised for 
protein concentration were fractionated by SDS-PAGE for immunoblotting with the 
indicated antibodies. Quantitative analysis of phosphorylated ERK1,2 levels in AS-
Ms from three experiments is presented as mean values +/- standard error 
(***p<0.001 versus phosphorylated ERK1,2 levels in sIL-6Rα/IL-6-treated alone 
cells). sIL-6Rα/IL-6-treated alone cells set at 100. Total ERK1,2 expression is also 
shown as a representative immunoblot to control for protein loading. [F=Fsk, 
R=Roli].  
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Figure 4.6 The Effect of cAMP elevating agents on STAT3 Phosphorylation 
by sIL-6Rα/IL-6 in AS-Ms 
 
4 x 105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with PBS and treated for 5 hrs with or without 10µM forskolin 
(Fsk) and/or 10µM rolipram (Roli) in serum-free medium. Following 5 hrs, cells 
were treated with or without sIL-6Rα/IL-6 at a concentration of 25ng/ml/5ng/ml 
respectively for 30 minutes. The controls in this experiment included vehicle (V) 
treated cells, which were treated with ethanol, DMSO and PBS at the same 
volume and for the same length of time as Fsk, Roli and sIL-6Rα/IL-6 treatment 
respectively. Following treatment, soluble cell extracts equalised for protein 
concentration were fractionated by SDS-PAGE for immunoblotting with the 
indicated antibodies. Quantitative analysis of phosphorylated STAT3 levels in AS-
Ms from three experiments is presented as mean values +/- standard error 
(**p<0.01 versus phosphorylated STAT3 levels in vehicle-treated cells, *p<0.05 
versus phosphorylated STAT3 levels in sIL-6Rα/IL-6-treated alone cells). sIL-
6Rα/IL-6-treated alone cells set at 100. Total STAT3 expression is also shown as 
a representative immunoblot to control for protein loading. [F=Fsk, R=Roli].  
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Figure 4.7 The Effect of cAMP elevating agents on ERK1,2 Phosphorylation 
by Leptin in AS-Ms 
 
4 x 105 AS-Ms / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with PBS and treated for 5 hrs with or without 10µM forskolin 
(Fsk) and/or 10µM rolipram (Roli) in serum-free medium. Following 5 hrs, cells 
were treated with or without leptin at a concentration of 125ng/ml for 30 minutes. 
The controls in this experiment included vehicle (V) treated cells, which were 
treated with ethanol, DMSO and serum-free medium at the same volume and for 
the same length of time as Fsk, Roli and leptin treatment respectively, and 1µM 
PMA treated cells (data not shown), a potent activator of ERK1,2 in endothelial 
cells. Following treatment, soluble cell extracts equalised for protein concentration 
were fractionated by SDS-PAGE for immunoblotting with the indicated antibodies. 
Quantitative analysis of phosphorylated ERK1,2 levels in AS-Ms from three 
experiments is presented as mean values +/- standard error (***p<0.001 versus 
phosphorylated ERK1,2 levels in leptin-treated alone cells). Leptin-treated alone 
cells set at 100. Total ERK1,2 expression is also shown as a representative 
immunoblot to control for protein loading. [F=Fsk, R=Roli].  
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Figure 4.8 The Effect of cAMP elevating agents on STAT3 Phosphorylation 
by Leptin in AS-Ms 
 
4 x 105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with PBS and treated for 5 hrs with or without 10µM forskolin 
(Fsk) and/or 10µM rolipram (Roli) in serum-free medium. Following 5 hrs, cells 
were treated with or without leptin at a concentration of 125ng/ml for 30 minutes. 
The controls in this experiment included vehicle (V) treated cells, which were 
treated with ethanol, DMSO and serum-free medium at the same volume and for 
the same length of time as Fsk, Roli and leptin treatment respectively. Following 
treatment, soluble cell extracts equalised for protein concentration were 
fractionated by SDS-PAGE for immunoblotting with the indicated antibodies. 
Quantitative analysis of phosphorylated STAT3 levels in AS-Ms from three 
experiments is presented as mean values +/- standard error (***p<0.001 versus 
phosphorylated STAT3 levels in vehicle-treated cells). Leptin-treated alone cells 
set at 100. Total STAT3 expression is also shown as a representative immunoblot 
to control for protein loading. [F=Fsk, R=Roli].  
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Figure 4.9 The Effect of sIL-6Rα/IL-6 and Leptin Treatment on the 
Transcriptional Activity of Elk1 in HUVECs and AS-Ms 
 
3 x 105 HUVECs/well and 3.5 x 105 AS-Ms/well were seeded into 6 well plates. 24 
hrs after seeding, medium was replaced with fresh medium and the cells were 
transfected with a trans-activator plasmid (Gal4-Elk-1) at 1µg/well, a luciferase 
reporter plasmid (Gal4-luc) at 1µg/well and a normalisation Renilla plasmid (pRL-
CMV) at 0.5µg/well. Cells were incubated overnight before another change of 
medium and left for a further 24 hrs. Following 24 hrs, cells were treated with or 
without 1µM U0126 for 30 minutes prior to treatment with sIL-6Rα/IL-6 
(25ng/ml/5ng/ml) or leptin (125ng/ml) for 6 hours. The controls in this experiment 
included vehicle (V) treated cells, which were transfected with all three constructs 
and 1µM PMA treated cells, a potent activator of ERK1,2 in endothelial cells. 
Following treatment, cell lysates were assayed for Firefly and Renilla luciferase 
activity, using a luminometer. The results are expressed as fold increase +/- 
standard error from 3 independent experiments performed in triplicate in HUVECs 
(a.) and AS-Ms (b.). Graph (c) shows luciferase activity from one biological 
replicate assayed in triplicate in HUVECs (*p<0.05 versus luciferase activity in 
vehicle-treated cells). [U1=U0126]. 
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Figure 4.10 The Effect of sIL-6Rα/IL-6 and Leptin Treatment on ERK1,2 and 
STAT3 Activation and Translocation to the Nucleus in HUVECs  
  
12x105 HUVECs were seeded into 10cm2 dishes. 24 hrs after seeding, cells were 
washed twice in PBS and serum starved for 4 hrs. Following 4 hrs, cells were 
treated with or without leptin (125ng/ml) or sIL-6Rα/IL-6 (25ng/ml/5ng/ml) for 30 
minutes. The controls in this experiment included vehicle (V) treated cells, which 
were treated with PBS and serum-free medium at the same volume and for the 
same length of time as sIL-6Rα/IL-6 and leptin treatment respectively and 1µM 
PMA, a potent activator of ERK1,2 in endothelial cells. Following treatment, cells 
were harvested in PBS. A series of centrifugation and washing steps were then 
undertaken, resulting in the isolation of nuclear and cytoplasmic cell fractions. Both 
fractions were equalised for protein concentration and fractionated by SDS-PAGE 
for immunoblotting with the indicated antibodies. SP1, a transcription factor and 
tubulin, a cytoskeleton protein, were both analysed to confirm the isolation of 
nuclear and cytosolic preparations respectively. Quantitative analysis of 
phosphorylated ERK1,2 and STAT3 levels in HUVECs from three experiments is 
presented as mean values +/- standard error (***p<0.001, *p<0.05 versus 
phosphorylated ERK1,2 levels in vehicle-treated cells and **p<0.01 versus 
phosphorylated STAT3 in vehicle-treated cells). Basal is set at 100.  
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Figure 4.11 The Effect of sIL-6Rα/IL-6 and Leptin Treatment on ERK1,2 and 
STAT3 Translocation to the Nucleus in AS-Ms  
 
12x105 AS-Ms were seeded into 10cm2 dishes. 24 hrs after seeding, cells were 
washed twice in PBS and serum starved for 4 hrs. Following 4 hrs, cells were 
treated with or without leptin (125ng/ml) or sIL-6Rα/IL-6 (25ng/ml/5ng/ml) for 30 
minutes. The controls in this experiment included vehicle (V) treated cells, which 
were treated with PBS and serum-free medium at the same volume and for the 
same length of time as sIL-6Rα/IL-6 and leptin treatment respectively and 1µM 
PMA, a potent activator of ERK1,2 in endothelial cells. Following treatment, cells 
were harvested in PBS. A series of centrifugation and washing steps were then 
undertaken, resulting in the isolation of nuclear and cytoplasmic cell fractions. Both 
fractions preparations were equalised for protein concentration and fractionated by 
SDS-PAGE for immunoblotting with the indicated antibodies. SP1, a transcription 
factor and tubulin, a cytoskeleton protein, were both analysed to confirm the 
isolation of nuclear and cytosolic preparations respectively. Quantitative analysis 
of phosphorylated ERK1,2 and STAT3 levels in AS-Ms from three experiments is 
presented as mean values +/- standard error (**p<0.01, *p<0.05 versus 
phosphorylated ERK1,2 and phosphorylated STAT3 levels in vehicle-treated 
cells). Basal is set at 100.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
185 
 
SP1
TUBULIN
Phospho-STAT3
Phospho-ERK 1, 2
NUCLEUS CYTOPLASM
0
100
200
300
400
500
600
700
800
900
1000
V IL-6 L
S
TA
T3
 P
ho
sp
ho
ry
la
tio
n 
(V
eh
ic
le
 
se
t a
t 1
00
)
Treatment
Nuclear 
Fraction
Cytoplasmic 
Fraction
**
*
0
500
1000
1500
2000
2500
V IL-6 L PMA
ER
K
1,
2 
P
ho
sp
ho
ry
la
tio
n 
(V
eh
ic
le
 s
et
 
at
 1
00
)
Treatment
Nuclear 
Fraction
Cytoplasmic 
Fraction
*
*
 
 
 
 
186 
 
Figure 4.12 The Effect of H89 on cAMP-mediated Inhibition of ERK1,2 
Phosphorylation and the Effect of 8pCPT on ERK Phosphorylation by sIL-
6Rα/IL-6 in HUVECs 
 
4 x 105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with PBS and treated for 30 minutes with or without 5µM H89 
prior to treatment with 10µM forskolin (Fsk) and 10µM rolipram (Roli) or 100µM 
8pCPT for 5 hrs in serum-free medium. Following 5 hrs, cells were treated with or 
without sIL-6Rα/IL-6 at a concentration of 25ng/ml/5ng/ml respectively for 30 
minutes. The controls in this experiment included vehicle (V) treated cells, which 
were treated with ethanol, DMSO and PBS at the same volume and for the same 
length of time as Fsk, Roli and sIL-6Rα/IL-6 treatment respectively, and 1µM PMA 
treated cells (data not shown), a potent activator of ERK1,2 in endothelial cells. 
Following treatment, soluble cell extracts equalised for protein concentration were 
fractionated by SDS-PAGE for immunoblotting with the indicated antibodies. 
Quantitative analysis of phosphorylated ERK1,2 levels in HUVECs from three 
experiments is presented as mean values +/- standard error (**p<0.01 versus 
phosphorylated ERK1,2 levels in vehicle-treated cells, **p<0.01 / *p<0.05 versus 
phosphorylated ERK1,2 levels in sIL-6Rα/IL-6-treated alone cells). sIL-6Rα/IL-6-
treated alone cells set at 100. Total ERK1,2 expression is also shown as a 
representative immunoblot to control for protein loading. [F=Fsk, R=Roli, 
8MC=8pCPT].  
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Figure 4.13 The Effect of H89 on cAMP-mediated Inhibition of STAT3 
Phosphorylation and the Effect of 8pCPT on STAT3 Phosphorylation by sIL-
6Rα/IL-6 in HUVECs 
 
4 x 105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with PBS and treated for 30 minutes with or without 5µM H89 
prior to treatment with 10µM forskolin (Fsk) and 10µM rolipram (Roli) or 100µM 
8pCPT for 5 hrs in serum-free medium. Following 5 hrs, cells were treated with or 
without sIL-6Rα/IL-6 at a concentration of 25ng/ml/5ng/ml respectively for 30 
minutes. The controls in this experiment included vehicle (V) treated cells, which 
were treated with ethanol, DMSO and PBS at the same volume and for the same 
length of time as Fsk, Roli and sIL-6Rα/IL-6 treatment respectively. Following 
treatment, soluble cell extracts equalised for protein concentration were 
fractionated by SDS-PAGE for immunoblotting with the indicated antibodies. 
Quantitative analysis of phosphorylated STAT3 levels in HUVECs from three 
experiments is presented as mean values +/- standard error (***p<0.001 versus 
phosphorylated STAT3 levels in vehicle-treated cells, ***p<0.001 / *p<0.05 versus 
phosphorylated STAT3 levels in sIL-6Rα/IL-6-treated alone cells). sIL-6Rα/IL-6-
treated alone cells set at 100. Total STAT3 expression is also shown as a 
representative immunoblot to control for protein loading. [F=Fsk, R=Roli, 
8MC=8pCPT].  
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Figure 4.14 The Effect of H89 on cAMP-mediated Inhibition of ERK1,2 
Phosphorylation and the Effect of 8pCPT on ERK Phosphorylation by sIL-
6Rα/IL-6 in AS-Ms 
 
4 x 105 AS-Ms / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with PBS and treated for 30 minutes with or without 5µM H89 
prior to treatment with 10µM forskolin (Fsk) and 10µM rolipram (Roli) or 100µM 
8pCPT for 5 hrs in serum-free medium. Following 5 hrs, cells were treated with or 
without sIL-6Rα/IL-6 at a concentration of 25ng/ml/5ng/ml respectively for 30 
minutes. The controls in this experiment included vehicle (V) treated cells, which 
were treated with ethanol, DMSO and PBS at the same volume and for the same 
length of time as Fsk, Roli and sIL-6Rα/IL-6 treatment respectively, and 1µM PMA 
treated cells (data not shown), a potent activator of ERK1,2 in endothelial cells. 
Following treatment, soluble cell extracts equalised for protein concentration were 
fractionated by SDS-PAGE for immunoblotting with the indicated antibodies. 
Quantitative analysis of phosphorylated ERK1,2 levels in AS-Ms from three 
experiments is presented as mean values +/- standard error (**p<0.01 versus 
phosphorylated ERK1,2 levels in sIL-6Rα/IL-6-treated alone cells). sIL-6Rα/IL-6-
treated alone cells set at 100. Total ERK1,2 expression is also shown as a 
representative immunoblot to control for protein loading. [F=Fsk, R=Roli, 
8MC=8pCPT].  
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Figure 4.15 The Effect of H89 on cAMP-mediated Inhibition of ERK1,2 
Phosphorylation and the Effect of 8pCPT on ERK Phosphorylation by Leptin 
in AS-Ms 
 
4 x 105 AS-Ms / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with PBS and treated for 30 minutes with or without 5µM H89 
prior to treatment with 10µM forskolin (Fsk) and 10µM rolipram (Roli) or 100µM 
8pCPT for 5 hrs in serum-free medium. Following 5 hrs, cells were treated with or 
without leptin at a concentration of 125ng/ml for 30 minutes. The controls in this 
experiment included vehicle (V) treated cells, which were treated with ethanol, 
DMSO and serum-free medium at the same volume and for the same length of 
time as Fsk, Roli and leptin treatment respectively, and 1µM PMA treated cells 
(data not shown), a potent activator of ERK1,2 in endothelial cells. Following 
treatment, soluble cell extracts equalised for protein concentration were 
fractionated by SDS-PAGE for immunoblotting with the indicated antibodies. 
Quantitative analysis of phosphorylated ERK1,2 levels in AS-Ms from three 
experiments is presented as mean values +/- standard error (***p<0.001 / **p<0.01 
versus phosphorylated ERK1,2 levels in leptin-treated alone cells). Leptin-treated 
alone cells set at 100. Total ERK1,2 expression is also shown as a representative 
immunoblot to control for protein loading. [F=Fsk, R=Roli, 8MC=8pCPT].  
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Figure 4.16 The Effect of Increasing Concentrations of SOCS3 siRNA on 
cAMP-mediated Induction of SOCS3 in HUVECs and AS-Ms 
 
2 x 105 AS-Ms / well and 2 x 105 HUVECs / well were seeded into 6 well plates. 24 
hrs after seeding, cells were washed twice with serum-free medium before adding 
1ml / well serum-free medium. Cells were then transfected with or without 10nM 
control siRNA and varying concentrations of SOCS3 siRNA, and incubated for 5 
hrs. After 5 hrs, 1ml / well medium was added to the cells for incubation overnight. 
The following day, the transfection procedure was repeated. On the fourth day, 
cells were washed twice with PBS and treated for 5 hrs with or without 10µM 
forskolin (Fsk) and 10µM rolipram (Roli) in serum-free medium. All wells were also 
treated with MG132 at a concentration of 6μM for 5 hrs. Following treatment, 
soluble cell extracts equalised for protein concentration were fractionated by SDS-
PAGE for immunoblotting with the indicated antibodies. The immunoblots show 
the expression of SOCS3 in HUVECs (a.) and AS-Ms (b.) from one experiment. 
The expression of the cytoskeleton protein, tubulin is also shown in both HUVECs 
and ASM-S to control for protein loading.  
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Figure 4.17 The Effect of SOCS3 siRNA on cAMP-mediated Induction of 
SOCS3 in HUVECs  
 
2 x 105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with serum-free medium before adding 1ml / well serum-free 
medium. Cells were then transfected with either 10nM control siRNA or 10nM 
SOCS3 siRNA and incubated for 5 hrs. After 5 hrs, 1ml / well medium was added 
to the cells for incubation overnight. The following day, the transfection procedure 
was repeated. On the fourth day, cells were washed twice with PBS and treated 
for 5 hrs with or without 10µM forskolin (Fsk) and 10µM rolipram (Roli) in serum-
free medium. Vehicle (V) treated cells were treated with ethanol and DMSO at the 
same volume and the same length of time as Fsk and Roli treatment respectively. 
All wells were also treated with MG132 at a concentration of 6μM for 5 hrs. 
Following treatment, soluble cell extracts equalised for protein concentration were 
fractionated by SDS-PAGE for immunoblotting with the indicated antibodies. 
Quantitative analysis of SOCS3 expression levels in HUVECs from three 
experiments is presented as mean values +/- standard error (***p<0.001 versus 
SOCS3 expression levels in vehicle-treated cells, *p<0.05 versus SOCS3 
expression levels in Fsk/Roli-treated cells). Basal is set at 100. The expression of 
the cytoskeleton protein, tubulin is also shown as a representative immunoblot to 
control for protein loading. [F=Fsk, R=Roli].  
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Figure 4.18 The Effect of SOCS3 siRNA on cAMP-mediated Inhibition of 
ERK1,2 Phosphorylation by sIL-6Rα/IL-6 in HUVECs 
 
2 x 105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with serum-free medium before adding 1ml / well serum-free 
medium. Cells were then transfected with either 10nM control siRNA or 10nM 
SOCS3 siRNA and incubated for 5 hrs. After 5 hrs, 1ml / well medium was added 
to the cells for incubation overnight. The following day, the transfection procedure 
was repeated. On the fourth day, cells were washed twice with PBS and treated 
for 5 hrs with or without 10µM forskolin (Fsk) and 10µM rolipram (Roli) in serum-
free medium. Following 5 hrs, cells were treated with or without sIL-6Rα/IL-6 at a 
concentration of 25ng/ml/5ng/ml respectively for 30 minutes. The controls in this 
experiment included vehicle (V) treated cells, which were treated with ethanol, 
DMSO and PBS at the same volume and for the same length of time as Fsk, Roli 
and sIL-6Rα/IL-6 treatment respectively and 1µM PMA treated cells (data not 
shown), a potent activator of ERK1,2 in endothelial cells. Following treatment, 
soluble cell extracts equalised for protein concentration were fractionated by SDS-
PAGE for immunoblotting with the indicated antibodies. Quantitative analysis of 
phosphorylated ERK1,2 levels in HUVECs from three experiments is presented as 
mean values +/- standard error (***p<0.001 / **p<0.01 versus phosphorylated 
ERK1,2 levels in vehicle-treated cells, ***p<0.001 versus phosphorylated ERK1,2 
levels in sIL-6Rα/IL-6-treated alone cells). sIL-6Rα/IL-6-treated alone cells set at 
100. Total ERK1,2 expression is also shown as a representative immunoblot to 
control for protein loading. [F=Fsk, R=Roli].  
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Figure 4.19 The Effect of SOCS3 siRNA on cAMP-mediated Inhibition of 
STAT3 Phosphorylation by sIL-6Rα/IL-6 in HUVECs 
 
2 x 105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with serum-free medium before adding 1ml / well serum-free 
medium. Cells were then transfected with either 10nM control siRNA or 10nM 
SOCS3 siRNA and incubated for 5 hrs. After 5 hrs, 1ml / well medium was added 
to the cells for incubation overnight. The following day, the transfection procedure 
was repeated. On the third day, cells were washed twice with PBS and treated for 
5 hrs with or without 10µM forskolin (Fsk) and 10µM rolipram (Roli) in serum-free 
medium. Following 5 hrs, cells were treated with or without sIL-6Rα/IL-6 at a 
concentration of 25ng/ml/5ng/ml respectively for 30 minutes. The controls in this 
experiment included vehicle (V) treated cells, which were treated with ethanol, 
DMSO and PBS at the same volume and for the same length of time as Fsk, Roli 
and sIL-6Rα/IL-6 treatment respectively. Following treatment, soluble cell extracts 
equalised for protein concentration were fractionated by SDS-PAGE for 
immunoblotting with the indicated antibodies. Quantitative analysis of 
phosphorylated STAT3 levels in HUVECs from three experiments is presented as 
mean values +/- standard error (***p<0.001 versus phosphorylated STAT3 levels 
in vehicle-treated cells, ***p<0.001 / **p<0.01 versus phosphorylated STAT3 levels 
in sIL-6Rα/IL-6-treated alone cells). sIL-6Rα/IL-6-treated alone cells set at 100. 
Total STAT3 expression is also shown as a representative immunoblot to control 
for protein loading. [F=Fsk, R=Roli].  
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Figure 4.20 The Effect of SOCS3 siRNA on cAMP-mediated Inhibition of 
STAT3 Phosphorylation by Leptin in HUVECs 
 
2 x 105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with serum-free medium before adding 1ml / well serum-free 
medium. Cells were then transfected with either 10nM control siRNA or 10nM 
SOCS3 siRNA and incubated for 5 hrs. After 5 hrs, 1ml / well medium was added 
to the cells for incubation overnight. The following day, the transfection procedure 
was repeated. On the third day, cells were washed twice with PBS and treated for 
5 hrs with or without 10µM forskolin (Fsk) and 10µM rolipram (Roli) in serum-free 
medium. Following 5 hrs, cells were treated with or without leptin at a 
concentration of 125ng/ml for 30 minutes. The controls in this experiment included 
vehicle (V) treated cells, which were treated with ethanol, DMSO and serum-free 
medium at the same volume and for the same length of time as Fsk, Roli and 
leptin treatment respectively. Following treatment, soluble cell extracts equalised 
for protein concentration were fractionated by SDS-PAGE for immunoblotting with 
the indicated antibodies. Quantitative analysis of phosphorylated STAT3 levels in 
HUVECs from four experiments is presented as mean values +/- standard error 
(***p<0.001 versus phosphorylated STAT3 levels in vehicle-treated cells, 
***p<0.001 versus phosphorylated STAT3 levels in leptin-treated alone cells). 
Leptin-treated alone cells set at 100. Total STAT3 expression is also shown as a 
representative immunoblot to control for protein loading. [F=Fsk, R=Roli].  
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Figure 4.21 The Effect of SOCS3 siRNA on cAMP-mediated Induction of 
SOCS3 in AS-Ms  
 
2 x 105 AS-Ms / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with serum-free medium before adding 1ml / well serum-free 
medium. Cells were then transfected with either 10nM control siRNA or 10nM 
SOCS3 siRNA and incubated for 5 hrs. After 5 hrs, 1ml / well medium was added 
to the cells for incubation overnight. The following day, the transfection procedure 
was repeated. On the fourth day, cells were washed twice with PBS and treated 
for 5 hrs with or without 10µM forskolin (Fsk) and 10µM rolipram (Roli) in serum-
free medium. Vehicle (V) treated cells were treated with ethanol and DMSO at the 
same volume and the same length of time as Fsk and Roli treatment respectively. 
All wells were also treated with MG132 at a concentration of 6μM for 5 hrs. 
Following treatment, soluble cell extracts equalised for protein concentration were 
fractionated by SDS-PAGE for immunoblotting with the indicated antibodies. The 
immunoblot shows the expression of SOCS3 in AS-Ms from one experiment. The 
expression of the cytoskeleton protein, tubulin is also shown as an immunoblot 
from 1 experiment to control for protein loading. [F=Fsk, R=Roli].  
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Figure 4.22 The Effect of SOCS3 siRNA on cAMP-mediated Inhibition of 
ERK1,2 Phosphorylation by sIL-6Rα/IL-6 in AS-Ms 
 
2 x 105 AS-Ms / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with serum-free medium before adding 1ml / well serum-free 
medium. Cells were then transfected with either 10nM control siRNA or 10nM 
SOCS3 siRNA and incubated for 5 hrs. After 5 hrs, 1ml / well medium was added 
to the cells for incubation overnight. The following day, the transfection procedure 
was repeated. On the third day, cells were washed twice with PBS and treated for 
5 hrs with or without 10µM forskolin (Fsk) and 10µM rolipram (Roli) in serum-free 
medium. Following 5 hrs, cells were treated with or without sIL-6Rα/IL-6 at a 
concentration of 25ng/ml/5ng/ml respectively for 30 minutes. The controls in this 
experiment included vehicle (V) treated cells, which were treated with ethanol, 
DMSO and PBS at the same volume and for the same length of time as Fsk, Roli 
and sIL-6Rα/IL-6 treatment respectively and 1µM PMA treated cells (data not 
shown), a potent activator of ERK1,2 in endothelial cells. Following treatment, 
soluble cell extracts equalised for protein concentration were fractionated by SDS-
PAGE for immunoblotting with the indicated antibodies. Quantitative analysis of 
phosphorylated ERK1,2 levels in AS-Ms from three experiments is presented as 
mean values +/- standard error (**p<0.01 versus phosphorylated ERK1,2 levels in 
vehicle-treated cells, ***p<0.001 / *p<0.05 versus phosphorylated ERK1,2 levels in 
sIL-6Rα/IL-6 -treated alone cells). sIL-6Rα/IL-6 -treated alone cells set at 100. 
Total ERK1,2 expression is also shown as a representative immunoblot to control 
for protein loading. [F=Fsk, R=Roli].  
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Figure 4.23 The Effect of SOCS3 siRNA on cAMP-mediated Inhibition of 
STAT3 Phosphorylation by sIL-6Rα/IL-6 in AS-Ms 
 
2 x 105 AS-Ms / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with serum-free medium before adding 1ml / well serum-free 
medium. Cells were then transfected with either 10nM control siRNA or 10nM 
SOCS3 siRNA and incubated for 5 hrs. After 5 hrs, 1ml / well medium was added 
to the cells for incubation overnight. The following day, the transfection procedure 
was repeated. On the third day, cells were washed twice with PBS and treated for 
5 hrs with or without 10µM forskolin (Fsk) and 10µM rolipram (Roli) in serum-free 
medium. Following 5 hrs, cells were treated with or without sIL-6Rα/IL-6 at a 
concentration of 25ng/ml/5ng/ml respectively for 30 minutes. The controls in this 
experiment included vehicle (V) treated cells, which were treated with ethanol, 
DMSO and PBS at the same volume and for the same length of time as Fsk, Roli 
and sIL-6Rα/IL-6 treatment respectively. Following treatment, soluble cell extracts 
equalised for protein concentration were fractionated by SDS-PAGE for 
immunoblotting with the indicated antibodies. Quantitative analysis of 
phosphorylated STAT3 levels in AS-Ms from three experiments is presented as 
mean values +/- standard error (***p<0.001 versus phosphorylated STAT3 levels 
in vehicle-treated cells, *p<0.05 versus phosphorylated STAT3 levels in sIL-
6Rα/IL-6 -treated alone cells). sIL-6Rα/IL-6 -treated alone cells set at 100. Total 
STAT3 expression is also shown as a representative immunoblot to control for 
protein loading. [F=Fsk, R=Roli].  
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Figure 4.24 The Effect of cAMP elevating agents on SOCS3 Induction in W/T 
and SOCS3-/- MEFs  
 
W/T and SOCS3-/- MEFs were seeded into 6 well plates and grown until 
confluent. 24 hrs after seeding, cells were washed twice with PBS and treated for 
5 hrs with or without 10µM forskolin (Fsk) and 10µM rolipram (Roli) in serum-free 
medium. Vehicle (V) treated cells were treated with ethanol and DMSO at the 
same volume and for the same length of time as Fsk and Roli treatment 
respectively. All wells were also treated with MG132 at a concentration of 6μM for 
5 hrs. Following treatment, soluble cell extracts equalised for protein concentration 
were fractionated by SDS-PAGE for immunoblotting with the indicated antibodies. 
Quantitative analysis of SOCS3 expression levels in W/T and SOCS3-/- MEFs 
from three experiments is presented as mean values +/- standard error 
(***p<0.001 versus SOCS3 expression levels in vehicle-treated cells). Basal is set 
at 100. The expression of the cytoskeleton protein, tubulin is also shown as a 
representative immunoblot to control for protein loading. [F=Fsk, R=Roli].  
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Figure 4.25 The Effect of cAMP elevating agents on ERK1,2 Phosphorylation 
by sIL-6Rα/IL-6 in W/T and SOCS3-/- MEFs  
 
W/T and SOCS3-/- MEFs were seeded into 6 well plates and grown until 
confluent. 24 hrs after seeding, cells were washed twice with PBS and treated for 
5 hrs with or without 10µM forskolin (Fsk) and 10µM rolipram (Roli) in serum-free 
medium. Following 5 hrs, cells were treated with or without sIL-6Rα/IL-6 at a 
concentration of 25ng/ml/5ng/ml respectively for 30 minutes. The controls in this 
experiment included vehicle (V) treated cells, which were treated with ethanol, 
DMSO and PBS at the same volume and for the same length of time as Fsk, Roli 
and sIL-6Rα/IL-6 treatment respectively, and 1µM PMA treated cells, a potent 
activator of ERK1,2 in endothelial cells (as observed in previous experiments in 
the Palmer lab). Following treatment, soluble cell extracts equalised for protein 
concentration were fractionated by SDS-PAGE for immunoblotting with the 
indicated antibodies. Quantitative analysis of phosphorylated ERK1,2 levels in W/T 
and SOCS3-/- MEFs from three experiments is presented as mean values +/- 
standard error (***p<0.001 versus phosphorylated ERK1,2 levels in vehicle-treated 
cells, ***p<0.001 versus phosphorylated ERK1,2 levels in sIL-6Rα/IL-6-treated 
alone cells). sIL-6Rα/IL-6-treated alone cells set at 100. Total ERK1,2 expression 
is also shown as a representative immunoblot to control for protein loading. 
[F=Fsk, R=Roli].  
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Figure 4.26 The Effect of cAMP elevating agents on STAT3 Phosphorylation 
by sIL-6Rα/IL-6 in W/T and SOCS3-/- MEFs  
 
W/T and SOCS3-/- MEFs were seeded into 6 well plates and grown until 
confluent. 24 hrs after seeding, cells were washed twice with PBS and treated for 
5 hrs with or without 10µM forskolin (Fsk) and 10µM rolipram (Roli) in serum-free 
medium. Following 5 hrs, cells were treated with or without sIL-6Rα/IL-6 at a 
concentration of 25ng/ml/5ng/ml respectively for 30 minutes. The controls in this 
experiment included vehicle (V) treated cells, which were treated with ethanol, 
DMSO and PBS at the same volume and for the same length of time as Fsk, Roli 
and sIL-6Rα/IL-6 treatment respectively. Following treatment, soluble cell extracts 
equalised for protein concentration were fractionated by SDS-PAGE for 
immunoblotting with the indicated antibodies. Quantitative analysis of 
phosphorylated STAT3 levels in W/T and SOCS3-/- MEFs from three experiments 
is presented as mean values +/- standard error (***p<0.001 versus phosphorylated 
STAT3 levels in vehicle-treated cells, *p<0.05 versus phosphorylated STAT3 
levels in sIL-6Rα/IL-6-treated alone cells). sIL-6Rα/IL-6-treated alone cells set at 
100. Total STAT3 expression is also shown as a representative immunoblot to 
control for protein loading. [F=Fsk, R=Roli].  
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Figure 4.27 The Effect of cAMP elevating agents (5 hr pre-treatment) in the 
presence and absence of H89 on ERK1,2 Phosphorylation by PMA in 
HUVECs  
 
4 x 105 HUVECs were seeded into 6 well plates. 24 hrs after seeding, cells were 
washed twice with PBS and treated for 30 minutes with or without 5µM H89 prior 
to treatment for 5 hrs with or without 10µM forskolin (Fsk) and 10µM rolipram (Roli) 
in serum-free medium. Following 5 hrs, cells were treated with or without 1 µM 
PMA for 5 minutes. The controls in this experiment included vehicle (V) treated 
cells, which were treated with ethanol and DMSO at the same volume and for the 
same length of time as Fsk, Roli and PMA treatment. Following treatment, soluble 
cell extracts equalised for protein concentration were fractionated by SDS-PAGE 
for immunoblotting with the indicated antibodies. Quantitative analysis of 
phosphorylated ERK levels in HUVECs from three experiments is presented as 
mean values +/- standard error (***p<0.001 / *p<0.05 versus phosphorylated ERK 
levels in vehicle-treated cells). Basal is set at 100. The expression of the 
cytoskeleton protein, tubulin is also shown as a representative immunoblot to 
control for protein loading. [F=Fsk, R=Roli].  
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Figure 4.28 The Effect of cAMP elevating agents (15 mins pre-treatment) in 
the presence and absence of H89 on ERK1,2 Phosphorylation by PMA in 
HUVECs  
 
4 x 105 HUVECs were seeded into 6 well plates. 24 hrs after seeding, cells were 
washed twice with PBS and treated for 30 minutes with or without 5µM H89 prior 
to treatment for 15 minutes with or without 10µM forskolin (Fsk) and 10µM rolipram 
(Roli) in serum-free medium. Following 15 minutes, cells were treated with or 
without 1 µM PMA for 5 minutes. The controls in this experiment included vehicle 
(V) treated cells, which were treated with ethanol and DMSO at the same volume 
and for the same length of time as Fsk, Roli and PMA treatment. Following 
treatment, soluble cell extracts equalised for protein concentration were 
fractionated by SDS-PAGE for immunoblotting with the indicated antibodies. 
Quantitative analysis of phosphorylated ERK levels in HUVECs from three 
experiments is presented as mean values +/- standard error (***p<0.001 / **p<0.01 
/ *p<0.05 versus phosphorylated ERK levels in vehicle-treated cells, **p<0.01 
versus phosphorylated ERK levels in PMA-treated alone cells, *p<0.05 versus 
phosphorylated ERK levels in Fsk- and Roli-treated alone cells). Basal is set at 
100. Total ERK1,2 expression is also shown as a representative immunoblot to 
control for protein loading. [F=Fsk, R=Roli].  
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Figure 4.29 The Effect of U0126 Treatment on cAMP-mediated Inhibition of 
ERK1,2 Phosphorylation by sIL-6Rα/IL-6 in HUVECs  
 
4 x 105 HUVECs were seeded into 6 well plates. 24 hrs after seeding, cells were 
washed twice with PBS and treated for 30 minutes with or without 1µM U0126 
prior to treatment for 5 hrs with or without 10µM forskolin (Fsk) and 10µM rolipram 
(Roli) in serum-free medium. Following 5 hrs, cells were treated with or without 
sIL-6Rα/IL-6 at a concentration of 25ng/ml/5ng/ml respectively for 30 minutes. The 
controls in this experiment included vehicle (V) treated cells, which were treated 
with ethanol, DMSO and PBS at the same volume and for the same length of time 
as Fsk, Roli and sIL-6Rα/IL-6 treatment respectively, and 1µM PMA treated cells, 
a potent activator of ERK1,2 in endothelial cells. Following treatment, soluble cell 
extracts equalised for protein concentration were fractionated by SDS-PAGE for 
immunoblotting with the indicated antibodies. Quantitative analysis of 
phosphorylated ERK levels in HUVECs from three experiments is presented as 
mean values +/- standard error (***p<0.001 / *p<0.05 versus phosphorylated ERK 
levels in vehicle-treated cells, *p<0.05 versus phosphorylated ERK levels in sIL-
6Rα/IL-6-treated alone cells). Basal is set at 100. Total ERK1,2 expression is also 
shown as a representative immunoblot to control for protein loading. [F=Fsk, 
R=Roli].  
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Figure 4.30 The Effect of U0126 Treatment on cAMP-mediated Inhibition of 
STAT3 Phosphorylation by sIL-6Rα/IL-6 in HUVECs  
 
4 x 105 HUVECs were seeded into 6 well plates. 24 hrs after seeding, cells were 
washed twice with PBS and treated for 30 minutes with or without 1µM U0126 
prior to treatment for 5 hrs with or without 10µM forskolin (Fsk) and 10µM rolipram 
(Roli) in serum-free medium. Following 5 hrs, cells were treated with or without 
sIL-6Rα/IL-6 at a concentration of 25ng/ml/5ng/ml respectively for 30 minutes. The 
controls in this experiment included vehicle (V) treated cells, which were treated 
with ethanol, DMSO and PBS at the same volume and for the same length of time 
as Fsk, Roli and sIL-6Rα/IL-6 treatment respectively. Following treatment, soluble 
cell extracts equalised for protein concentration were fractionated by SDS-PAGE 
for immunoblotting with the indicated antibodies. Quantitative analysis of 
phosphorylated STAT3 levels in HUVECs from three experiments is presented as 
mean values +/- standard error (***p<0.001 versus phosphorylated STAT3 levels 
in vehicle-treated cells, ***p<0.001 versus phosphorylated STAT3 levels in sIL-
6Rα/IL-6-treated alone cells). Basal is set at 100. Total STAT3 expression is also 
shown as a representative immunoblot to control for protein loading. [F=Fsk, 
R=Roli].  
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Figure 4.31 The Effect of cAMP elevating agents on ERK1,2 Phosphorylation 
in AS-Ms  
 
4 x 105 AS-Ms were seeded into 6 well plates. 24 hrs after seeding, cells were 
washed twice with PBS and treated for 30 minutes with or without 1µM U0126 
prior to treatment for 15 mins with or without 10µM forskolin (Fsk) and 10µM 
rolipram (Roli), in serum-free medium. The controls in this experiment included 
vehicle (V) treated cells, which were treated with ethanol and DMSO at the same 
volume and for the same length of time as Fsk and Roli treatment respectively. 
Following treatment, soluble cell extracts equalised for protein concentration were 
fractionated by SDS-PAGE for immunoblotting with the indicated antibodies. 
Quantitative analysis of phosphorylated ERK1,2 levels in AS-Ms from three 
experiments is presented as mean values +/- standard error (*p<0.05 versus 
phosphorylated ERK1,2 levels in vehicle-treated cells). Basal is set at 100. Total 
ERK1,2 expression is also shown as a representative immunoblot to control for 
protein loading. [F=Fsk, R=Roli].  
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Figure 4.32 The Effect of Epac siRNA on basal levels of Epac Expression in 
HUVECs  
 
2 x 105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with serum-free medium before adding 1ml / well serum-free 
medium. Cells were then transfected with either 20nM control siRNA or 20nM 
Epac siRNA and incubated for 5 hrs. After 5 hrs, 1ml / well medium was added to 
the cells for incubation overnight. The following day, the transfection procedure 
was repeated. On the fourth day, cells were washed twice with PBS and incubated 
for 5 hrs in serum-free medium. Following incubation, soluble cell extracts 
equalised for protein concentration were fractionated by SDS-PAGE for 
immunoblotting with the indicated antibodies. Quantitative analysis of Epac 
expression levels in HUVECs from four experiments is presented as mean values 
+/- standard error (***p<0.001 versus Epac expression levels in control siRNA-
treated cells). Control siRNA-treated cells set at 100. Total ERK1,2 expression is 
also shown as a representative immunoblot to control for protein loading.  
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Figure 4.33 The Effect of Epac siRNA on cAMP-mediated Inhibition of 
ERK1,2 Phosphorylation by sIL-6Rα/IL-6 in HUVECs 
 
2 x 105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with serum-free medium before adding 1ml / well serum-free 
medium. Cells were then transfected with either 20nM control siRNA or 20nM 
Epac siRNA and incubated for 5 hrs. After 5 hrs, 1ml / well medium was added to 
the cells for incubation overnight. The following day, the transfection procedure 
was repeated. On the fourth day, cells were washed twice with PBS and treated 
for 5 hrs with or without 10µM forskolin (Fsk) and 10µM rolipram (Roli) in serum-
free medium. Vehicle (V) treated cells were treated with ethanol and DMSO at the 
same volume and the same length of time as Fsk and Roli treatment respectively 
Following treatment, soluble cell extracts equalised for protein concentration were 
fractionated by SDS-PAGE for immunoblotting with the indicated antibodies. 
Quantitative analysis of phosphorylated ERK1,2 levels in HUVECs from five 
experiments is presented as mean values +/- standard error (***p<0.001 versus 
phosphorylated ERK1,2 levels in sIL-6Rα/IL-6 -treated alone cells, **p<0.01 / 
*p<0.05 versus phosphorylated ERK1,2 levels in vehicle-treated cells). sIL-6Rα/IL-
6-treated alone cells set at 100. Total ERK1,2 expression is also shown as a 
representative immunoblot to control for protein loading.  
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Figure 4.34 The Effect of Epac siRNA on cAMP-mediated Inhibition of STAT3 
Phosphorylation by sIL-6Rα/IL-6 in HUVECs 
 
2 x 105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells 
were washed twice with serum-free medium before adding 1ml / well serum-free 
medium. Cells were then transfected with either 20nM control siRNA or 20nM 
Epac siRNA and incubated for 5 hrs. After 5 hrs, 1ml / well medium was added to 
the cells for incubation overnight. The following day, the transfection procedure 
was repeated. On the fourth day, cells were washed twice with PBS and treated 
for 5 hrs with or without 10µM forskolin (Fsk) and 10µM rolipram (Roli) in serum-
free medium. Vehicle (V) treated cells were treated with ethanol and DMSO at the 
same volume and the same length of time as Fsk and Roli treatment respectively 
Following treatment, soluble cell extracts equalised for protein concentration were 
fractionated by SDS-PAGE for immunoblotting with the indicated antibodies. 
Quantitative analysis of phosphorylated STAT3 levels in HUVECs from four 
experiments is presented as mean values +/- standard error (***p<0.001 versus 
phosphorylated STAT3 levels in vehicle-treated cells and sIL-6Rα/IL-6 -treated 
alone cells, *p<0.05 versus phosphorylated STAT3 levels in sIL-6Rα/IL-6 -treated 
alone cells). sIL-6Rα/IL-6-treated alone cells set at 100. Total STAT3 expression is 
also shown as a representative immunoblot to control for protein loading.  
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Figure 4.35 HUVEC Morphology in Response to SOCS3 and Epac siRNA 
Treatment 
 
Light micrograph images of HUVECs treated with and without Epac siRNA (a) and 
SOCS3 siRNA (b) at day 4 of the transfection process. Images were captured 
using a Zeiss microscope (10 x objective lens) and manipulated using Axiovision 
software.  
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Summary 
An exhaustive number of studies have demonstrated the inhibitory effects of cAMP 
on a myriad of cell types and tissues. Significantly, elevation of cAMP has been 
associated with the inhibition of function of various inflammatory cell types, 
including macrophages, neutrophils, eosinophils, T cells and endothelial cells 
(Bulut et al., 1993; Dent et al., 1991; Fonteh et al., 1993; Nielson, 1987; Pober et 
al., 1993; Renz et al., 1988; Teixeira et al., 1997). Examples of these inhibitory 
effects include, the reduction of cytokines, such as TNFα, and nitric oxide release 
from macrophages (Bulut et al., 1993; Renz et al., 1988), the suppression of 
lysosomal enzymes, ROS and platelet-activating factor (PAF) from neutrophils 
(Fonteh et al., 1993; Nielson, 1987), the inhibition of eosinophil respiratory burst 
activity (Dent et al., 1991), the inhibition of cytotoxic T lymphocyte activation 
(Teixeira et al., 1997; Wisloff & Christoffersen, 1977), and importantly, the 
inhibition of TNFα-induced adhesion molecule expression in endothelial cells 
(Morandini et al., 1996; Pober et al., 1993). Furthermore, studies have also shown 
a cAMP-mediated reduction in endothelial cell permeability (Cullere et al., 2005; 
Fukuhara et al., 2005; Suttorp et al., 1993), and suppression of transendothelial 
leukocyte migration (Lidington et al., 1996; Lorenowicz et al., 2007).  
PDE4 inhibitors have been extensively studied in various animal models of 
inflammatory disease (reviewed in Teixeira et al., 1997). All of these studies have 
demonstrated suppression of inflammation and disease activity following treatment 
with PDE4 inhibitors (Teixeira et al., 1997). Clinically, PDE4 inhibitors have been 
in development since the early 1980s, with asthma and chronic obstructive 
pulmonary disease (COPD) constituting the predominant disease indications. 
However, not one of these PDE4 inhibitors has yet reached the market. This is 
due to lack of efficacy and/or dose-limiting adverse effects, such as nausea, 
abdominal pain, vomiting and diarrhea (Giembycz, 2008). An example of one such 
PDE4 inhibitor is rolipram, which has been used throughout the course of the 
current study. This was terminated during clinical development due to its side 
effects of nausea and gastrointestinal disturbances (Boswell-Smith et al., 2006). It 
is believed that the inhibition of PDE4D in particular, in non-target tissues, is 
responsible for the emetic effects. Since PDE4 is encoded by four genes (A-D), 
selective sub-type inhibitors could potentially overcome the side effects. Indeed, 
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selective ablation of PDE4B in mouse macrophages has been shown to 
substantially reduce LPS-stimulated TNFα release, whereas PDE4A and PDE4D-
null macrophages displayed no reduction in LPS-stimulated TNFα release. 
Furthermore, PDE4B null mice were partially protected from LPS-induced shock 
(Jin et al., 2005). In addition to sub-type specific inhibitors, slow–releasing 
formulations have been developed to reduce systemic exposure. For example, 
pentoxifylline is a slow-releasing non-selective PDE inhibitor, which has been used 
to treat peripheral vascular disease and cerebrovascular disease (Ward & 
Clissold, 1987). 
With regards to the clinical implications of inhibiting cytokine signalling, a 
humanised anti-IL-6R monoclonal antibody so-called tocilizumab has been used in 
the treatment of rheumatoid arthritis (RA) with strong therapeutic effects 
(Nakahara & Nishimoto, 2006). Tocilizumab has also been used in Crohn’s 
disease and Castleman's disease with promising results (Ito et al., 2004; Nakahara 
& Nishimoto, 2006). Interestingly, a phase III study is currently recruiting 
participants to investigate the effect of tocilizumab on lipids, arterial stiffness and 
markers of atherogenic risk in patients with moderate to severe active rheumatoid 
arthritis (www.clinicaltrials.gov). Therapeutically, the inhibition of leptin signalling is 
more complex. Human leptin deficiency is associated with morbid obesity. Despite 
this obesity, no risk factors for cardiovascular disease, such as hypertension and 
impairment in lipid metabolism have been observed (Ozata et al., 1999). This 
supports the presence of selective resistance in obese (non-leptin deficient) 
individuals, wherein these individuals display central but not peripheral resistance 
to leptin, as discussed in Section 1.3.6, Chapter 1 Introduction. For example, 
ob/ob mice on an atherogenic diet are protected from atherosclerosis, despite 
displaying obesity, diabetes, and hyperlipidemia (Schafer et al., 2004). Indeed, 
leptin has been shown to promote atherosclerosis and thrombus formation in 
atherosclerotic-prone apoE-deficient mice, despite a reduction in adipose tissue 
mass and fasting insulin levels (Bodary et al., 2005). Therefore, hyperleptinemia 
may be the contributory factor that leads to the cardiovascular morbidity 
associated with obesity. Inhibiting leptin signalling may represent a promising 
strategy for limiting the progression of atherosclerosis in hyperleptinemic obese 
individuals.  
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Thus, the inhibition of IL-6 signalling has demonstrated clinically beneficial effects 
on inflammatory diseases, such as RA and Crohn’s disease. Furthermore, human 
epidemiological studies have shown that leptin is associated with the development 
of cardiovascular disease (Ciccone et al., 2001; Wannamethee et al., 2007; Wolk 
et al., 2004). In addition, research has shown that both cytokines can modulate EC 
function, for example, by upregulating adhesion molecules such as VCAM-1 and 
ICAM-1, increasing MCP-1 and endothelin-1 expression, and inducing oxidative 
stress (Modur et al., 1997; Quehenberger et al., 2002; Romano et al., 1997; 
Yamagishi et al., 2001). As such, it would be of interest to further investigate ways 
in which these signalling pathways can be negatively regulated. As mentioned 
previously, cAMP is considered a crucial immunomodulator. Although the anti-
inflammatory effects of cAMP have been well described, the molecular 
mechanisms underlying these effects are less known. In relation to endothelial 
cells, cAMP has been shown to limit vascular permeability and enhance 
endothelial barrier function via a cAMP/Epac/Rap1 pathway (Cullere et al., 2005; 
Fukuhara et al., 2005). This is of particular relevance to the present study as 
results have suggested an Epac1-dependent cAMP-mediated inhibition of IL-6/sIL-
6α-stimulated ERK1,2 and STAT3 activation in HUVECs. Furthermore, the present 
results demonstrate the involvement of SOCS3 in the observed inhibition. 
Therefore, an Epac1- and SOCS3-dependent inhibitory pathway has been 
identified and represents a novel inhibitory pathway, distinct from the PKA-Raf1 
pathway which has been well described for the cAMP-mediated inhibition of 
growth factor signalling. This novel pathway is important in terms of expanding our 
knowledge of endogenous protective signalling pathways that can potentially be 
exploited for therapeutic benefit. Interestingly, intracellular delivery of SOCS3 has 
been shown to greatly attenuate the acute inflammation observed following 
administration of staphylococcal enterotoxin B (SEB) and lipopolysaccaride (LPS) 
in mice. A cell-penetrating form of SOCS3 (CP-SOCS3) has been developed, 
which has a membrane-translocating motif (MTM) derived from the hydrophobic 
signal sequence of fibroblast growth factor 4, attached to either the N-terminal or 
C-terminal end. CP-SOCS3 administered to mice challenged with SEB or LPS via 
intraperitoneal injection revealed that CP-SOCS3 increased survival and 
suppressed inflammatory cytokines, such as TNFα and IL-6 (Jo et al., 2005). In a 
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similar study, liposome-mediated gene delivery of SOCS3 in a lethal endotoxic 
shock mouse model was shown to increase survival and greatly reduce the serum 
level of TNFα from peritoneal macrophages (Fang et al., 2005). 
In contrast, a role for SOCS3 in the cAMP-mediated inhibition of leptin-stimulated 
STAT3 activation in HUVECs could not be demonstrated. As an alternative to 
SOCS3; SHP2, PTPB1 and other SOCS members may be responsible for the 
observed inhibition (as discussed in Chapter 4 Discussion). These results are in 
contrast to studies using mice with a neuronal deletion of SOCS3, which 
demonstrated prolonged activation of STAT3 in response to leptin. Moreover, 
SOCS3 deficient mice exhibited greater body weight loss when compared to their 
wild-type littermates and were also resistant to high fat diet-induced weight gain 
and hyperleptinemia, and retained insulin sensitivity (Mori et al., 2004). Although 
SOCS3 has been implicated in the negative regulation of leptin signalling, a large 
body of research has also implicated PTPB1 in this inhibition, which is discussed 
in Chapter 4 Discussion. Interestingly, PTP1B has been shown to target the insulin 
receptor as well as JAK2, contributing towards insulin resistance in addition to 
leptin resistance (Lavens et al., 2006). Inhibitors of PTP1B are currently under 
investigation for the treatment of obesity and type 2 diabetes (Hooft van 
Huijsduijnen et al., 2002). Indeed, further research will need to be carried out to 
confirm the involvement of PTPB1 in cAMP-mediated inhibition of leptin signalling 
in HUVECs observed in the present study, for example, by using siRNA knock 
down or over expression approaches. Of note, SOCS3 has also been shown to 
target insulin signalling via ubiquitin-mediated degradation of IRS1 and IRS2 in 
HEK293 cells (Rui et al., 2002). As IRS1 and IRS2 represent alternative SOCS 
binding partners, it may be of interest to determine whether or not the 
Epac1/SOCS3 pathway observed in the present study also regulates the SOCS3-
mediated degradation of IRS1 and IRS2.  
Consistent with the SOCS3-independent cAMP-mediated inhibition of leptin-
stimulated STAT3 activation in HUVECs, experiments conducted in AS-Ms 
demonstrated no involvement of SOCS3 in the cAMP-mediated inhibition of sIL-
6Rα/IL-6-induced STAT3 and ERK1,2 activation. As previously mentioned, other 
inhibitory mechanisms independent of SOCS3 may be responsible for the 
observed inhibition, such as SHP2. Indeed, studies have shown that expression of 
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catalytically inactive dominant negative SHP2 mutants results in increased gp130, 
JAK and STAT3 phosphorylation as well as gene induction (Lehmann et al., 2003; 
Symes et al., 1997). Further studies in AS-Ms could investigate the involvement of 
SHP2 and other possible inhibitory molecules in this inhibitory mechanism. 
Despite observing different responses in HUVECs and AS-Ms, AS-Ms may still 
represent a useful and tractable cell type to study in the context of endothelial 
inflammation. Indeed, it is likely that different inhibitory molecules are involved in 
the regulation of IL-6 and leptin signalling in different cell types, and studying AS-
Ms as well as HUVECs would provide a greater understanding of all of these 
inhibitory mechanisms.  
With repect to the SOCS3- and Epac1-dependent inhibition of IL-6/sIL-6α-
stimulated ERK1,2 and STAT3 activation in HUVECs, further results from this 
study demonstrated a requirement for ERK1,2 activation in the inhibition of STAT3 
activation. These results tie in well with recent findings from work carried out by 
Yarwood et al. (2008). These investigators have suggested that the C/EBP family 
of transcription factors link Epac1 activation to SOCS3 induction and since the 
C/EBP proteins have been shown to be substrates for ERK and RSK proteins 
(Ramji & Foka, 2002), an Epac1/ERK/C/EBP/SOCS3 pathway leading to the 
inhibition of IL-6/sIL-6α-stimulated STAT3 activation could be a possibility. 
However, this remains to be determined. 
In conclusion, a potentially new pathway has been identified which inhibits 
cytokine receptor activation of ERK1,2 and STAT3 in endothelial cells. 
Additionally, the AS-M cell line has been further characterised in the context of 
cytokine and cAMP signalling. Overall, results from this study could contribute 
towards the identification of new molecular targets for the therapeutic treatment of 
chronic inflammatory diseases, such as atherosclersosis, and further examination 
of AS-Ms could uncover potentially new mechanisms of inhibition, or increase our 
knowledge of existing inhibitory mechanisms. 
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